Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 140
Encontrada(s) 2 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of adherence to individual quality-of-care indicators on the prognosis of bloodstream infection due to Staphylococcus aureus, a prospective observational multicentre cohort

  • Escrihuela-Vidal, Francesc|||0000-0003-3652-3121
  • Kaasch, Achim J.
  • Von Cube, Maja
  • Rieg, Siegbert
  • Kern, Winfried V.
  • Seifert, Harald
  • Song, Kyoung-Ho
  • Liao, Chun-Hsing
  • Tilley, Robert
  • Gott, Hannah
  • Scarborough, Mathew|||0000-0002-0455-0785
  • Gordon, Claire
  • Llewelyn, Martin J.
  • Kuehl, Richard
  • Morata, Laura|||0000-0001-5795-0814
  • Soriano Viladomiu, Alex|||0000-0002-9374-0811
  • Edgeworth, Jonathan
  • De Gopegui, Enrique Ruiz
  • Nsutebu, Emmanuel
  • Cisneros, José Miguel|||0000-0001-5001-672X
  • Fowler, Vance G.
  • Thwaites, Guy
  • López-Contreras, Joaquín|||0000-0002-3166-4016
  • Barlow, Gavin
  • Ternavasio-De La Vega, Hugo Guillermo
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • López Cortés, Luis Eduardo|||0000-0002-9347-527X
To analyse the adherence and impact of quality-of-care indicators (QCIs) in the management of Staphylococcus aureus bloodstream infection in a prospective and multicentre cohort. Analysis of the prospective, multicentre international S. Aureus Collaboration cohort of S. Aureus bloodstream infection cases observed between January 2013 and April 2015. Multivariable analysis was performed to evaluate the impact of adherence to QCIs on 90-day mortality. A total of 1784 cases were included. Overall, 90-day mortality was 29.9% and mean follow-up period was 118 days. Adherence was 67% (n = 1180/1762) for follow-up blood cultures, 31% (n = 416/1342) for early focus control, 77.6% (n = 546/704) for performance of echocardiography, 75.5% (n = 1348/1784) for adequacy of targeted antimicrobial therapy, 88.6% (n = 851/960) for adequacy of treatment duration in non-complicated bloodstream infections and 61.2% (n = 366/598) in complicated bloodstream infections. Full bundle adherence was 18.4% (n = 328/1784). After controlling for immortal time bias and potential confounders, focus control (adjusted hazard ratio = 0.76; 95% CI, 0.59-0.99; p 0.038) and adequate targeted antimicrobial therapy (adjusted hazard ratio = 0.75; 95% CI, 0.61-0.91; p 0.004) were associated with low 90-day mortality. Adherence to QCIs in S. Aureus bloodstream infection did not reach expected rates. Apart from the benefits of application as a bundle, focus control and adequate targeted therapy were independently associated with low mortality.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals, the COMBACTE-NET ARTHR-IS multi-centre study

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad|||0000-0001-6410-013X
  • Mur, Isabel|||0000-0001-7660-8483
  • Tedeschi, Sara|||0000-0001-9546-2811
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Murillo Rubio, Oscar|||0000-0001-5776-8422
  • Soldevila-Boixader, Laura|||0000-0003-0649-3785
  • Scarborough, Mathew|||0000-0002-0455-0785
  • Scarborough, Claire
  • Kluytmans, Jan A. J. W.
  • Ferrari, Matteo Carlo
  • Pletz, Mathias|||0000-0001-8157-2753
  • McNamara, Iain R.
  • Escudero Sánchez, Rosa|||0000-0001-5736-8111
  • Arvieux, Cedric
  • Batailler, Cécile
  • Dauchy, Frédéric Antoine
  • Liu, Waiyan
  • Lora-Tamayo, Jaime
  • Praena-Segovia, Julia|||0000-0001-8138-0874
  • Ustianowski, Andrew P.
  • Cinconze, Elisa
  • Pellegrini, Michele|||0000-0001-8505-9260
  • Bagnoli, Fabio
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Del-Toro-López, Maria Dolores
The aim of this study was to estimate the incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infections (SA-PJI) after primary hip and knee arthroplasty in European centres. This study was conducted in patients who underwent primary hip and knee arthroplasty in 19 European hospitals between 2014 and 2016. The global incidence of PJI and SA-PJI was calculated. The associated disease burden was measured indirectly as infection-related mortality plus loss of function. For healthcare utilization, number and duration of hospitalizations, number and type of surgical procedures, duration of antibiotic treatments, and number of outpatient visits were collected. Subgroup and regression analyses were used to evaluate the impact of SA-PJI on healthcare utilization, controlling for confounding variables. The incidence of PJI caused by any micro-organism was 1.41%, and 0.40% for SA-PJI. Among SA-PJI, 20.7% were due to MRSA with substantial regional differences, and were more frequent in partial hip arthroplasty (PHA). Related deaths and loss of function occurred in 7.0% and 10.2% of SA-PJI cases, respectively, and were higher in patients with PHA. Compared with patients without PJI, patients with SA-PJI had a mean of 1.4 more readmissions, 25.1 more days of hospitalization, underwent 1.8 more surgical procedures, and had 5.4 more outpatient visits, controlling for confounding variables. Healthcare utilization was higher in patients who failed surgical treatment of SA-PJI. This study confirmed that the SA-PJI burden is high, especially in PHA, and provided a solid basis for planning interventions to prevent SA-PJI.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of viral detection in patients with community-acquired pneumonia, An observational cohort study, Impacto de la detección viral en pacientes con neumonía comunitaria

  • Sellarès-Nadal, Júlia|||0000-0002-0209-6494
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Velasquez, Fernando
  • Martin-Gomez, M. Teresa|||0000-0001-8119-8749
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Romero-Herrera, Daniel
  • Eremiev, Simeón|||0000-0002-5494-183X
  • Bosch-Nicolau, Pau|||0000-0002-7435-1829
  • Rodriguez-Pardo, Dolors|||0000-0001-6781-5405
  • Len, Oscar|||0000-0002-1819-3141
  • Falcó, Vicenç|||0000-0001-9626-0023
Purpose: The presence of a respiratory virus in patients with community-acquired pneumonia (CAP) may have an impact on the bacterial etiology and clinical presentation. In this study we aimed to assess the role of viral infection in the bacterial etiology and outcomes of patients with CAP. Methods: We performed a retrospective study of all adults hospitalized with CAP between November 2017 and October 2018. Patients were classified according to the presence of viral infection. An unvaried and a multivaried analysis were performed to identify variables associated with viral infection and clinical outcomes. Results: Overall 590 patients were included. A microorganism was documented in 375 cases (63.5%). A viral infection was demonstrated in 118 (20%). The main pathogens were Streptococcus pneumoniae (35.8%), Staphylococcus aureus (2.9%) and influenza virus (10.8%). A trend to a higher rate of S. aureus (p = 0.06) in patients with viral infection was observed. Patients with viral infection had more often bilateral consolidation patterns (17.8% vs 10.8%, p = 0.04), respiratory failure (59.3% vs 42.8%, p = 0.001), ICU admission (17.8% vs 7%, p = 0.001) and invasive mechanical ventilation (9.3% vs 2.8%, p = 0.003). Risk factors for respiratory failure were chronic lung disease, age >65 years, positive blood cultures and viral infection. Influenza, virus but no other respiratory viruses, was associated with respiratory failure (OR, 3.72; 95% CI, 2.06-6.73). Conclusions: Our study reinforces the idea that co-viral infection has an impact in the clinical presentation of CAP causing a more severe clinical picture. This impact seems to be mainly due to influenza virus infection., Objetivos: La presencia de virus respiratorios en pacientes con neumonía adquirida en la comunidad (NAC) puede tener un impacto en la etiología bacteriana y en la presentación clínica. El objetivo de este estudio fue evaluar el papel de la infección viral en la etiología bacteriana y la evolución de los pacientes con NAC. Métodos: Realizamos un estudio retrospectivo de todos los adultos hospitalizados con diagnóstico de NAC entre noviembre de 2017 y octubre de 2018. Los pacientes fueron clasificados según la presencia de infección viral. Se realizó un análisis univariado y multivariado para identificar variables asociadas con la infección viral y la evolución clínica. Resultados: En total se incluyeron 590 pacientes. Se documentó el microorganismo en 375 casos (63,5%). Se demostró una infección viral en 118 (20%). Los principales patógenos fueron S. pneumoniae (35,8%), S. aureus (2,9%) y virus de la influenza (10,8%). Se observó una tendencia a una mayor tasa de S. aureus (p = 0,06) en pacientes con infección viral. Los pacientes con infección viral tenían con mayor frecuencia patrones de consolidación bilateral (17,8% vs 10,8%; p = 0,04), insuficiencia respiratoria (59,3% vs 42,8%; p = 0,001), ingreso en UCI (17,8% vs 7%; p = 0,001) y necesidad de ventilación mecánica invasiva (9,3% vs 2,8%; p = 0,003). Los factores de riesgo para insuficiencia respiratoria fueron enfermedad pulmonar crónica, edad >65 años, hemocultivos positivos e infección viral. El virus de la influenza, pero ningún otro virus respiratorio, se asoció con insuficiencia respiratoria (OR: 3,72; IC 95%: 2,06-6,73). Conclusiones: Nuestro estudio refuerza la idea de que la infección viral tiene un impacto en la presentación clínica de la NAC provocando un cuadro clínico más grave. Este impacto parece deberse principalmente a la infección por el virus de la influenza.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk factors and clinical impact of multidrug resistance in healthcare-associated bacteraemic urinary tract infections, a post-hoc analysis of a multicentre prospective cohort in Spain

  • Gómez-Zorrilla, S.
  • Becerra Aparicio, Federico|||0000-0002-0948-0958
  • Sendra, Elena|||0000-0002-4374-2173
  • Zamorano, L.
  • Grau, I.
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Fariñas, M.C.
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, M.R.
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Morte-Romea, E.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • López Montesinos, I.
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Ponz, Ricardo|||0009-0007-9027-3326
  • Cotarelo, M.|||0000-0002-7017-0369
  • Cantón, R.
  • Oliver, Antonio|||0000-0001-9327-1894
  • Ruiz-Garbajosa, P.
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
The global burden associated with antimicrobial resistance is of increasing concern. Aim: To evaluate risk factors associated with multidrug-resistant (MDR) infection and its clinical impact in a cohort of patients with healthcare-associated bacteraemic urinary tract infections (BUTIs). Methods: This was a prospective, multicentre, post-hoc analysis of patients with healthcare-associated-BUTI (ITUBRAS-2). The primary outcome was MDR profile. Secondary outcomes were clinical response (at 48-72 h and at hospital discharge) and length of hospital stay from onset of BUTI. Logistic regression was used to evaluate variables associated with MDR profile and clinical response. Length of hospital stay was evaluated using multivariate median regression. Findings: In all, 443 episodes were included, of which 271 (61.17%) were classified as expressing an MDR profile. In univariate analysis, MDR profile was associated with E. coli episodes (odds ratio (OR): 3.13; 95% confidence interval (CI): 2.11-4.69, P < 0.001) and the extensively drug-resistant (XDR) pattern with P. aeruginosa aetiology (7.84; 2.37-25.95; P = 0.001). MDR was independently associated with prior use of fluoroquinolones (adjusted OR: 2.43; 95% CI: 1.25-4.69), cephalosporins (2.14; 1.35-3.41), and imipenem or meropenem (2.08; 1.03-4.20) but not with prior ertapenem. In terms of outcomes, MDR profile was not associated with lower frequency of clinical cure, but was associated with longer hospital stay. Conclusion: MDR profile was independently associated with prior use of fluoroquinolones, cephalosporins, imipenem, and meropenem, but not with prior ertapenem. MDR-BUTI episodes were not associated with worse clinical cure, although they were independently associated with longer duration of hospital stay.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Whole Genome Sequencing Analysis of Klebsiella pneumoniae Isolates from Health Care-Associated Bacteremia of Urinary Origin in Spain, Findings from the Multicenter ITUBRAS-2 Cohort Study

  • Becerra Aparicio, Federico|||0000-0002-0948-0958
  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • Hernández García, Marta
  • Xanthopoulou, K.|||0000-0001-8591-8184
  • Gijón, Desiré
  • Siverio Pares, Ana Cristina
  • Berbel, Dàmaris|||0000-0002-3689-3360
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Rivera, Alba|||0000-0002-9709-6162
  • de Malet, A.
  • Xercavins, M.|||0000-0003-1463-6344
  • Ruiz De Gopegui, E.
  • Canoura-Fernández, L.
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Seral, C.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Cotarelo, M.|||0000-0002-7017-0369
  • Ponz, Ricardo|||0009-0007-9027-3326
  • Higgins, P.G.
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, A.
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
  • Ruiz-Garbajosa, P.
  • Montesinos, I.L.
  • Merino, I.
  • de Gopegui, E.R.
  • López-Causapé, C.
  • Grau, I.
  • Sabé, N.
  • Shaw, E.
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Sendra, E.
  • Rubio, V.
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Badía, C.
  • Calvo, E.
  • Fariñas, M.C.
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, M.R.
  • Morte-Romea, E.
  • Paño-Pardo, J.R.
  • Carmona-Torre, F.
  • Quintano, F.T.
  • Sánchez Carrillo, Carlos
  • Cortarelo, M.
Background: The objective of this study was to assess the microbiological and clinical features of Klebsiella pneumoniae health care-associated bacteremia of urinary origin (HCA-BUO) in Spain, with a focus on third-generation cephalosporin-(3GCR-Kp) and carbapenem-resistant K pneumoniae (CR-Kp) isolates. Methods: A total of 96 (21.4%, 96/449) K pneumoniae blood isolates were prospectively collected from patients with HCA-BUO (n = 443) from 12 tertiary care hospitals in Spain (2017-2019). Antimicrobial susceptibility was determined (standard broth microdilution), and extended-spectrum β-lactamase, AmpC, and carbapenemase production was screened. A subset of 55 K pneumoniae isolates was analyzed by whole genome sequencing (Illumina) to determine population structure, resistome, and virulome. Additionally, 13 of these isolates were subjected to long-read sequencing (Nanopore) for plasmid characterization. Patients' baseline and clinical characteristics were reviewed. Results: 3GCR-Kp prevalence was 43.8% (42/96), mostly associated with extended-spectrum β-lactamase production (34/96, 35.4%; mainly CTX-M-15, 32/34, 94.1%) and the dissemination of sequence type (ST)-307 (15/34, 44.1%) and other globally spread multidrug-resistant high-risk clones. CR-Kp prevalence was 9.4% (9/96); all isolates belonged to different STs and were mostly associated with carbapenemase production (6/9, 66.7%; mainly OXA-48-like, n = 3). Additionally, 3GCR-Kp and CR-Kp isolates showed higher content of other antibiotic resistance genes. Altogether, these episodes were associated with prior antibiotic use and receipt of inadequate empirical treatment. Conclusions: There is a high prevalence of 3GCR and CR-Kp causing HCA-BUO in Spain, mainly driven by the dissemination of ST307/CTX-M-15 and other globally spread multidrug-resistant high-risk clones, challenging the selection of empirical and targeted treatments for these infections.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

  • Palacios-Baena, Z.R.
  • Calvo-Montes, J.
  • Martínez-Martínez, L.
  • Cantón, R.
  • Pitart, Cristina|||0000-0002-3083-7915
  • Bou, German|||0000-0001-8837-0062
  • Pascual, Á.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Alemán, Araceli
  • Rivera, A.
  • Pintado, Vicente
  • Ruiz-Garbajosa, P.
  • Gracia-Ahufinger, I.
  • Quintano, F.T.
  • Clavijo, E.
  • Arias, M.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Lecuona, M.
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Salamanca-Rivera, Elena
  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Pérez-Vázquez, María
  • Ruiz-Carrascoso, Guillermo
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Mulet, Xavier
  • González-López, Juanjo|||0000-0003-2419-5909
  • Sivianes, Fran
  • Delgado-Valverde, Mercedes
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Canut-Blasco, Andrés
  • Jorge Arribas García
  • Ayestarán, Ignacio
  • Gutiérrez, David
  • Gijón, Desirèe
  • Roca, Ignasi|||0000-0002-1800-1576
  • Nuvials, Xavier|||0000-0002-6648-2394
  • Viñado, Belén|||0000-0001-6212-5886
  • González, Mónica
  • Suberviola Canas, Borja
  • Maria Elicier Cano García
  • Tinajas, Almudena
  • García Bravo, Moises
  • de Tuesta Díaz, Jose Luis
  • Vidal-García, Matxalen
  • Gomáriz Díaz, María
  • Pérez del Molino Bernal, Mª Luisa
  • Coira Nieto, Amparo
  • Rodríguez Tarazona, Raquel Elisa
  • Arenal Andrés, Noelia
  • Paz Vidal, Mª Isabel
  • Rey-Cao, Sonia
  • Martínez Lamas, Lucía
  • Cabezas Fernández, Mª Teresa
  • Cabeza, Mª Isabel
  • Roldán, Carolina
  • Liébana, Carmen
  • Galán Sánchez, Fátima
  • GarcíaSánchez, Federico Juan Manuel
  • Chueca, Natalia|||0000-0002-3420-3290
  • Mora, Laura
  • Martí Salas, Carmina
  • Quesada, Dolores
  • Casabella Pernas, Antonio|||0000-0002-2534-3689
  • Sanchez, Nerea
  • Aldea Mansilla, Carmen
  • Rodríguez Escudero, M. José
  • Huertas, María
  • Gaitán Durán, Jorge
  • Esparcia Rodríguez, Oscar
  • Sainz de Baranda, Caridad
  • Riquelme Bravo, Eva
  • Hernando, Susana
  • Sánchez Arroyo, Rafael
  • Iglesias Nuñez, Nuria
  • Villa, Jennifer
  • Clapés Sanchez, Ester
  • Gimeno, Adelina
  • López Soria, Leyre
  • Barrios Andrés, Jose Luis
  • García Garrote, Fernando
  • Palop, Begoña
  • Valverde Troya, Miriam
  • García-Gonzàlez, Merce
  • Belles, Alba
  • Azcona, José Manuel
  • López-Calleja, Ana Isabel
  • Pérez Moreno, Mar Olga|||0000-0002-4216-4965
  • Fernández Natal, Isabel
  • Garduno Eseverri, Eugenio
  • Sánchez Benito, Rosario
  • de la Iglesia, Pedro
  • Illescas, Soledad
  • Garcia Agudo, Lidia
  • Frasquet, Juan
  • Leiva, José
  • Giner, Salvador
  • López-Urrutia Lorente, Luis
  • Perez Arellano, Jose Luis
  • del Rosario, Cristobal
  • Ortega Lafont, Pilar
  • Martínez Ramírez, Mariela
Background: Community-acquired (CA) and healthcare-associated (HCA) infections caused by carbapenemase-producing Enterobacterales (CPE) are not well characterized. The objective was to provide detailed information about the clinical and molecular epidemiological features of nosocomial, HCA and CA infections caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) and Escherichia coli (CP-Ec). Methods: A prospective cohort study was performed in 59 Spanish hospitals from February to March 2019, including the first 10 consecutive patients from whom CP-Kp or CP-Ec were isolated. Patients were stratified according to acquisition type. A multivariate analysis was performed to identify the impact of acquisition type in 30-day mortality. Results: Overall, 386 patients were included (363 [94%] with CP-Kp and 23 [6%] CP-Ec); in 296 patients (76.3%), the CPE was causing an infection. Acquisition was CA in 31 (8.0%) patients, HCA in 183 (47.4%) and nosocomial in 172 (48.3%). Among patients with a HCA acquisition, 100 (54.6%) had been previously admitted to hospital and 71 (38.8%) were nursing home residents. Urinary tract infections accounted for 19/23 (82.6%), 89/130 (68.5%) and 42/143 (29.4%) of CA, HCA and nosocomial infections, respectively. Overall, 68 infections (23%) were bacteremia (8.7%, 17.7% and 30.1% of CA, HCA and nosocomial, respectively). Mortality in infections was 28% (13%, 14.6% and 42.7% of CA, HCA and nosocomial, respectively). Nosocomial bloodstream infections were associated with increased odds for mortality (adjusted OR, 4.00; 95%CI 1.21-13.19). Conclusions: HCA and CA infections caused by CPE are frequent and clinically significant. This information may be useful for a better understanding of the epidemiology of CPE.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Host-dependent editing of SARS-CoV-2 in COVID-19 patients

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Piñana, Maria|||0000-0002-4766-2613
  • Campos, Carolina|||0000-0002-0132-7027
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Andrés, Cristina|||0000-0002-3200-0895
  • Abril, Josep Francesc|||0000-0001-7793-589X
  • Codina, María Gema|||0000-0002-5313-5086
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Sulleiro, Elena|||0000-0002-9783-6060
  • Joseph-Munné, Joan
  • Saubi, Narcis|||0000-0001-5493-1044
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Martin, Mari Carmen|||0000-0003-1327-8813
  • Castillo, Carla
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
A common trait among RNA viruses is their high capability to acquire genetic variability due to viral and host mechanisms. Next-generation sequencing (NGS) analysis enables the deep study of the viral quasispecies in samples from infected individuals. In this study, the viral quasispecies complexity and single nucleotide polymorphisms of the SARS-CoV-2 spike gene of coronavirus disease 2019 (COVID-19) patients with mild or severe disease were investigated using next-generation sequencing (Illumina platform). SARS-CoV-2 spike variability was higher in patients with long-lasting infection. Most substitutions found were present at frequencies lower than 1%, and had an A → G or T → C pattern, consistent with variants caused by adenosine deaminase acting on RNA-1 (ADAR1). ADAR1 affected a small fraction of replicating genomes, but produced multiple, mainly non-synonymous mutations. ADAR1 editing during replication rather than the RNA-dependent RNA polymerase (nsp12) was the predominant mechanism generating SARS-CoV-2 genetic variability. However, the mutations produced are not fixed in the infected human population, suggesting that ADAR1 may have an antiviral role, whereas nsp12-induced mutations occurring in patients with high viremia and persistent infection are the main source of new SARS-CoV-2 variants.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Modeling the Number of People Infected With SARS-COV-2 From Wastewater Viral Load in Northwest Spain

  • Vallejo, J. A.
  • Trigo Tasende, Noelia
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • López-Oriona, Ángel
  • Barbeito, Inés
  • Vaamonde, Manuel
  • Tarrío-Saavedra, Javier
  • Reif López, Rubén
  • Ladra, Susana
  • Rodiño-Janeiro, Bruno Kotska
  • Nasser-Ali, Mohammed
  • Cid, Ángeles
  • Veiga, María Carmen
  • Acevedo, Antón
  • Lamora, Carlos
  • Bou, Germán
  • Cao, Ricardo
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] The quantification of the SARS-CoV-2 RNA load in wastewater has emerged as a useful tool to monitor COVID–19 outbreaks in the community. This approach was implemented in the metropolitan area of A Coruña (NW Spain), where wastewater from a treatment plant was analyzed to track the epidemic dynamics in a population of 369,098 inhabitants. Viral load detected in the wastewater and the epidemiological data from A Coruña health system served as main sources for statistical models developing. Regression models described here allowed us to estimate the number of infected people (R2 = 0.9), including symptomatic and asymptomatic individuals. These models have helped to understand the real magnitude of the epidemic in a population at any given time and have been used as an effective early warning tool for predicting outbreaks in A Coruña municipality. The methodology of the present work could be used to develop a similar wastewater-based epidemiological model to track the evolution of the COVID–19 epidemic anywhere in the world where centralized water-based sanitation systems exist., This work was supported by EDAR Bens S.A., A Coruña, Spain [grant references INV04020, INV12120 and INV05921 to MP], the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 funded by the ISCIII, Spain - General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant numbers PI15/00860 to GB, PI17/01482 and PI20/00413 to MP], the GAIN, Xunta de Galicia, Spain [grant number IN607A 2016/22 to GB, ED431C-2016/015 and ED431C-2020/14 to RC, ED431C 2017/58 to SL, ED431G 2019/01 to RC and SL, and ED431C 2017/66 to MCV], MINECO, Spain [grant number MTM2017-82724-R to RC], Ministerio de Ciencia e Innovación, Spain [grant number PID2020-113578RB-100 to RC], and the Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/006 to GB]. The work was also supported by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 - Research and Innovation Framework Programme under grant agreement no 871029. SR-F was financially supported by REIPI RD16/0016/006, KC-P by IN607A 2016/22 and the Spanish Association against Cancer (AECC) and JAV by IN607A 2016/22. Funding for open access charge: Universidade da Coruña/CISUG, EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2017/58, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; ED431C 2017/66
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Antiviral and Antiproliferative Potential of Marine Organisms from the Yucatan Peninsula, Mexico

  • Pech-Puch, Dawrin
  • Berastegui-Cabrera, Judith
  • Pérez Povedano, Mar Anabel
  • Villegas-Hernández, Harold
  • Guillén-Hernández, Sergio
  • Cautain, Bastien
  • Reyes, Fernando
  • Pachón, Jerónimo
  • Gómez, Patricia
  • Rodríguez, Jaime
  • Jiménez, Carlos
  • Sánchez Céspedes, Javier
[Abstract] Viral infections are one of the main human health problems in recent decades and the cancer remains one of the most lethal diseases worldwide. The development of new antiviral drugs for the treatment of human adenovirus (HAdV) infections continues to be a challenging goal for medicinal chemistry. There is no specific antiviral drug approved to treat infections caused by HAdV so far and the off-label treatments currently available show great variability in their effectiveness. In relation to cancer, most of the available drugs are designed to act on specific targets by altering the activity of involved transporters and genes. Taking into account the high antiviral and antiproliferative activity against tumor cell lines displayed by some marine natural products reported in the literature, sixty five marine organisms were selected: 51 sponges (Porifera), 13 ascidians (Chordata), and 1 gorgonian (Cnidaria), collected from Yucatan Peninsula, Mexico, to evaluate their antiviral activity against human adenovirus type 5 (HAdV5) and their anticancer properties against five human tumor cell lines, namely human lung carcinoma (A549), human skin melanoma (A2058), hepatocyte carcinoma (HepG2), breast adenocarcinoma (MCF7), and pancreas carcinoma (MiaPaca-2). Eleven extracts displayed anti-HAdV activity being the organic extracts of Dysidea sp., Agelas citrina, Chondrilla sp., Spongia tubulifera, and Monanchora arbuscula the five most active ones. On the other hand, 24 extracts showed antiproliferative activity against at least one tumor cell line, being the extracts of the ascidian Eudistoma amanitum and the sponge Haliclona (Rhizoniera) curacaoensis the most active ones. This work constitutes the first wide antiviral and antiproliferative screening report of extracts from the marine sponges, ascidians, and a gorgonian collected from the Yucatan Peninsula, Mexico., This work was supported by Grants RTI2018-093634-B-C22 and RTC-2016-4611-1 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, both co-funded by the FEDER Programme from the European Union, BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). The study was also funded by projects GRC2018/039 and Agrupación Estratégica CICA-INIBIC ED431E 2018/03 (Consejería de Educación, Universidad y Formación Profesional de la Junta de Galicia) from the Xunta de Galicia (autonomous government of the region). DP-P received a fellowship from the program National Council of Science and Technology (CONACYT) of Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan (Mexico). Also supported by Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009) – co-financed by “A way to achieve Europe” ERDF, the Instituto de Salud Carlos III, Proyectos de Desarrollo Tecnológico en Salud (DTS17/00130 and PI18/01191), and the Spanish Adenovirus Network (AdenoNet, BIO2015/68990-REDT). JS-C is a researcher belonging to the program “Nicolás Monardes” (C-0059-2018), Servicio Andaluz de Salud, Junta de Andalucía, Spain. The antiproliferative studies were financed with internal funds from Fundación MEDINA, Xunta de Galicia; 0474_BLUEBIOLAB_1_E, Xunta de Galicia; GRC2018/039, Xunta de Galicia; ED431E 2018/03, Junta de Andalucía; C-0059-2018
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Carbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter junii Conferred by Acquisition of blaOXA-24/40 and Genetic Characterization of the Transmission Mechanism between Acinetobacter Genomic Species

  • Lasarte-Monterrubio, Cristina
  • Guijarro, Paula
  • Bellés, Alba
  • Vázquez-Ucha, Juan Carlos
  • Arca-Suárez, Jorge
  • Fernández-Lozano, Carlos
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Carbapenem resistance is increasing among Gram-negative bacteria, including the genus Acinetobacter. This study aimed to characterize, for the first time, the development of carbapenem resistance in clinical isolates of Acinetobacter junii and Acinetobacter nosocomialis conferred by the acquisition of a plasmid-borne blaOXA-24/40 gene and also to characterize the dissemination of this gene between species of Acinetobacter. Carbapenem-resistant A. nosocomialis HUAV-AN66 and A. junii HUAV-AJ77 strains were isolated in the Arnau de Vilanova Hospital (Spain). The genomes were sequenced, and in silico analysis were performed to characterize the genetic environment and the OXA-24/40 transmission mechanism. Antibiotic MICs were determined, and horizontal transfer assays were conducted to evaluate interspecies transmission of OXA-24/40. Carbapenems MICs obtained were ≥64 mg/L for HUAV-AN66 and HUAV-AJ77. Genome analysis revealed the presence in both strains of a new plasmid, designated pHUAV/OXA-24/40, harboring the carbapenem-resistance gene blaOXA-24/40 and flanked by sequences XerC/XerD. pHUAV/OXA-24/40 was successfully transferred from A. nosocomialis and A. junii to a carbapenem-susceptible A. baumannii strain, thus conferring carbapenem resistance. A second plasmid (pHUAV/AMG-R) was identified in both clinical isolates for the successful horizontal transfer of pHUAV/OXA-24/40. blaOXA-24/40-carrying plasmids of the GR12 group and showing high identity with pHUAV/OXA-24/40 were identified in at least 8 Acinetobacter species. In conclusion the carbapenemase OXA-24/40 is described for the first time in A. nosocomialis and A. junii. In both isolates the blaOXA-24/40 gene was located in the GR12 pHUAV/OXA-24/40 plasmid. GR12 plasmids are implicated in the dissemination and spread of carbapenem resistance among Acinetobacter species. IMPORTANCE Acinetobacter baumannii is one of the most relevant pathogens in terms of antibiotic resistance. The main resistance mechanisms are the carbapenem-hydrolyzing class D β-lactamases (CHDLs), especially OXA-23 and OXA-24/40. In addition to A. baumannii, there are other species within the genus Acinetobacter, which in general exhibit much lower resistance rates. In this work we characterize for the first time two clinical isolates of Acinetobacter nosocomialis and Acinetobacter junii, isolated in the same hospital, carrying the carbapenemase OXA-24/40 and displaying high resistance rates to carbapenems. By means of bioinformatics analysis we have also been able to characterize the mechanism by which this carbapenemase is horizontally transferred interspecies of Acinetobacter spp. The dissemination of carbapenemase OXA-24/40 between non-baumannii Acinetobacter species is concerning since it prevents the use of most β-lactam antibiotics in the fight against these resistant isolates., This work was supported by Projects PI17/01482 and PI20/01212 awarded to A.B. and PI18/00501 to G.B., all within in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII - General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINF (CIBER de Enfermedades Infecciosas). The study was also funded by project IN607A 2020/05 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) awarded to G.B. and IN607D 2021/12 awarded to A.B. This work was also supported by Planes Nacionales de I+D+i2008 to 2011/2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectiosus Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. J.A.-S.was financially supported by the Rio Hortega program (ISCIII, CM19/00219), J.C.V.-U. was financially supported by the pFIS program (ISCIII, PI17/01482), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and P.G.-S. was financially supported by IN607A 2020/05 Grant (Xunta de Galicia), Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Wastewater early warning system for SARS-CoV-2 outbreaks and variants in a Coruña, Spain

  • Trigo Tasende, Noelia
  • Vallejo, J. A.
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • Vaamonde, Manuel
  • López-Oriona, Ángel
  • Barbeito, Inés
  • Nasser-Ali, Mohammed
  • Reif López, Rubén
  • Rodiño-Janeiro, Bruno Kotska
  • Fernández-Álvarez, Elisa
  • Iglesias Corrás, Iago
  • Tarrío-Saavedra, Javier
  • Tomás, Laura
  • Gallego-García, Pilar
  • Posada, David
  • Bou, Germán
  • López-de-Ullibarri, Ignacio
  • Cao, Ricardo
  • Susana, Ladra
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract]: Wastewater-based epidemiology has been widely used as a cost-effective method for tracking the COVID-19 pandemic at the community level. Here we describe COVIDBENS, a wastewater surveillance program running from June 2020 to March 2022 in the wastewater treatment plant of Bens in A Coruña (Spain). The main goal of this work was to provide an effective early warning tool based in wastewater epidemiology to help in decision-making at both the social and public health levels. RT-qPCR procedures and Illumina sequencing were used to weekly monitor the viral load and to detect SARS-CoV-2 mutations in wastewater, respectively. In addition, own statistical models were applied to estimate the real number of infected people and the frequency of each emerging variant circulating in the community, which considerable improved the surveillance strategy. Our analysis detected 6 viral load waves in A Coruña with concentrations between 103 and 106 SARS-CoV-2 RNA copies/L. Our system was able to anticipate community outbreaks during the pandemic with 8-36 days in advance with respect to clinical reports and, to detect the emergence of new SARS-CoV-2 variants in A Coruña such as Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529 and BA.2) in wastewater with 42, 30, and 27 days, respectively, before the health system did. Data generated here helped local authorities and health managers to give a faster and more efficient response to the pandemic situation, and also allowed important industrial companies to adapt their production to each situation. The wastewater-based epidemiology program developed in our metropolitan area of A Coruña (Spain) during the SARS-CoV-2 pandemic served as a powerful early warning system combining statistical models with mutations and viral load monitoring in wastewater over time., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Funding for open access charge: Universidade da Coruña/CISUG. This work was supported by EDAR Bens S.A., A Coruña, Spain [grant references INV04020, INV12120, INV05921, and INV148721 to MP], by the National Plan for Scientific Research, Development and Technological Innovation funded by the Institute of Health Carlos III (ISCIII), Spain—General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant references PI15/00860 to GB, PI17/01482, and PI20/00413 to MP], by the Galician Innovation Agency (GAIN) (Xunta de Galicia, Spain) [grant references IN607A 2016/22 to GB, ED431C-2016/015 and ED431C-2020/14 to RC, ED431C 2021/53 to SL and ED431G 2019/01 and COV20/00604 to RC and SL, by Ministry of Economic Affairs and Digital Transformation (MINECO), Spain [grant references MTM2017-82724-R to RC], by the Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0006 to GB], by the “Innova Saúde” Program, (INNOVAMICROLAB project) co-founded by the Galician Healthcare Service (SERGAS) and the Spanish Ministry of Science and Innovation, and by the Spanish Network of Research in Infectious Diseases (CIBERINFEC, ISCIII), and by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 871029. SR-F was financially supported by REIPI RD16/0016/006, KC-P by IN607A 2016/22 and the Spanish Association against Cancer (AECC) and JAV by IN607A 2016/22. DP was funded by grant EPICOVIGAL FONDO SUPERA-COVID19 from Banco Santander-CSIC-CRUE, Spain, and grant CT850A-2 from (Health Knowledge Agency) ACIS SERGAS from the Consellería de Sanidade of Xunta de Galicia, Spain., EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, EDAR Bens S.A.; INV148721, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; COV20/00604
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Towards the early detection of β-lactamase-producing Enterobacteriaceae by MALDI-TOF MS analysis

  • Oviaño, Marina
  • Gómara, Marta
  • Barba, María José
  • Revillo, María José
  • Barbeyto, Luis Pedro
  • Bou, Germán
[Abstract] Objectives: Development of a novel MALDI-TOF MS-based method for the rapid detection of ESBL-producing Enterobacteriaceae. Methods: The method was evaluated in terms of sensitivity, specificity and turnaround time regarding the antibiotic used (cefotaxime, ceftazidime, ceftriaxone, cefpodoxime or cefepime) and the performance of the automated MBT STAR-BL software (Bruker Daltonik GmbH, Germany) relative to qualitative interpretation of spectra for detecting β-lactamase resistance by MALDI-TOF MS (Bruker Daltonik) in a collection of 11 isogenic Escherichia coli control strains expressing different β-lactamases. Finally, for clinical validation, β-lactamase activity was determined under previously evaluated conditions in 100 clinical isolates previously characterized by PCR and sequencing. Results: Clinical validation of the assay showed 100% sensitivity and specificity for detecting β-lactam resistance in 30 min by measuring hydrolysis of ceftriaxone (0.50 mg/mL) with the automated MBT STAR-BL software. Regarding the antibiotics evaluated, ceftriaxone yielded 70% more positive results than cefotaxime, 80% more than ceftazidime and 20% more than cefpodoxime, with 100% specificity. Cefepime revealed 100% sensitivity, but only 27% specificity. For the same incubation time, the automated software yielded on average 41% more positive results in relation to detecting resistance than qualitative interpretation of spectra. Conclusions: Our clinical validation of the method proved it to be highly reliable, simple to perform and time saving, transforming β-lactam resistance detection by MALDI-TOF MS into a ready-to-use technique in clinical laboratories., This work was supported by a grant from the Fondo de Investigación Sanitaria (grant number PI15/00860 to G. B.); Plan Nacional de I + D and Instituto de Salud Carlos III (ISCIII), Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0006) co-financed by European Development Regional Fund ‘A Way to Achieve Europe’ ERDF. M. O. is financially supported by the Río Hortega Programme of the ISCIII (CM15/00155). Sociedad Española de Enfermedades Infecciosas y Microbiología Clinica (SEIMC) supported relocation of M. G. to allow this work to be carried out.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

An improved matrix-assisted laser desorption ionization-time of flight mass spectrometry data analysis pipeline for the identification of carbapenemase-producing Klebsiella pneumoniae

  • Gato, Eva
  • Constanso-Conde, Ignacio
  • Candela, Ana
  • Galán, Fátima
  • Rodiño-Janeiro, Bruno Kotska
  • Arroyo, Manuel J.
  • Méndez, Gema
  • Mancera, Luis
  • Alioto, Tyler S.
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Rodríguez-Sánchez, Belén
  • Bou, Germán
  • Oviaño, Marina
[Abstract] The increasing emergence of carbapenemase-producing Klebsiella pneumoniae (CPK) isolates is a global health alarm. Rapid methods that require minimum sample preparation and rapid data analysis are urgently required. Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has recently been used by clinical laboratories for identification of antibiotic-resistant bacteria; however, discrepancies have arisen regarding biological and technical issues. The aim of this study was to standardize an operating procedure and data analysis for identification of CPK by MALDI-TOF MS. To evaluate this approach, a series of 162 K. pneumoniae isolates (112 CPK and 50 non-CPK) were processed in the MALDI BioTyper system (Bruker Daltonik, Germany) following a standard operating procedure. The study was conducted in two stages; the first is denominated the "reproducibility stage" and the second "CPK identification." The first stage was designed to evaluate the biological and technical variation associated with the entire analysis of CPK and the second stage to assess the final accuracy of MALDI-TOF MS for the identification of CPK. Therefore, we present an improved MALDI-TOF MS data analysis pipeline using neural network analysis implemented in Clover MS Data Analysis Software (Clover Biosoft, Spain) that is designed to reduce variability, guarantee interlaboratory reproducibility, and maximize the information selected from the bacterial proteome. Using the random forest (RF) algorithm, 100% of CPK isolates were correctly identified when all the peaks in the spectra were selected as input features and total ion current (TIC) normalization was applied. Thus, we have demonstrated that real-time direct tracking of CPK is possible using MALDI-TOF MS., This work was supported by funding awarded to M.O. through the Competitive Research Call 2019 of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). The research was also funded by the Fondo de Investigación Sanitaria through grants no. PI15/00860 and PI18/00860 to G.B., integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII) and by the Spanish Network of Research in Infectious Diseases (REIPI), grant no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the ISCIII, General Subdirection of Assessment and Promotion of the Research, European Regional Development Fund (FEDER) A Way of Making Europe. M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006) and E.G. by the research call 2019 of the SEIMC.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii

  • Vázquez-Ucha, Juan Carlos
  • Maneiro Rey, María
  • Martínez Guitián, Marta
  • Buynak, John
  • Bethel, Christopher R.
  • Bonomo, Robert
  • Bou, Germán
  • Poza, Margarita
  • González-Bello, Concepción
  • Beceiro Casas, Alejandro
[Abstract] The number of infections caused by Gram-negative pathogens carrying carbapenemases is increasing, and the group of carbapenem-hydrolyzing class D β-lactamases (CHDLs) is especially problematic. Several clinically important CHDLs have been identified in Acinetobacter baumannii, including OXA-23, OXA-24/40, OXA-58, OXA-143, OXA-235, and the chromosomally encoded OXA-51. The selection and dissemination of carbapenem-resistant A. baumannii strains constitutes a serious global threat. Carbapenems have been successfully utilized as last-resort antibiotics for the treatment of multidrug-resistant A. baumannii infections. However, the spread of OXA carbapenemases is compromising the continued use of these antimicrobials. In response to this clinical issue, it is necessary and urgent to design and develop new specific inhibitors with efficacy against these enzymes. The aim of this work was to characterize the inhibitory activity of LN-1-255 (a 6-alkylidene-2-substituted penicillin sulfone) and compare it to that of two established inhibitors (avibactam and tazobactam) against the most relevant enzymes of each group of class D carbapenemases in A. baumannii. The β-lactamase inhibitor LN-1-255 demonstrated excellent microbiological synergy and inhibition kinetics parameters against all tested CHDLs and a significantly higher activity than tazobactam and avibactam. A combination of carbapenems and LN-1-255 was effective against A. baumannii class D carbapenemases. Docking assays confirmed the affinity of LN-1-255 for the active site of these enzymes. LN-1-255 represents a potential new β-lactamase inhibitor that may have a significant role in eradicating infections caused by A. baumannii isolates carrying CHDLs., This work was financially supported by Planes Nacionales de I+D+i 2008-2011/2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014 and REIPI RD16/0016/006), cofinanced by the European Development Regional Fund “A Way to Achieve Europe” and the operative program Intelligent Growth 2014-2020. This work was also supported by the Galician Innovation Agency (IN607A 2016/22) and the ISCIII-General Subdirection of Assessment and Promotion of the Research (PI15/00860 to G.B. and PI14/00059 to M.P. and A.B.). This study was also supported by the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), the Xunta de Galicia (Centro Singular de Investigación de Galicia Accreditation 2016-2019, EDG431G/09), and the European Union (European Regional Development Fund-ERDF) to C.G.-B. J.C.V.-U. and A.B. were financially supported by the Miguel Servet Programme ISCIII-FEDER (CP13/00226). M.M. thanks the Spanish Ministry of Science and Innovation for her FPU fellowship. M.M.G. was financially supported by the grant “Clara Roy” from the Spanish Society of Clinical Microbiology and Infectious Diseases. Research reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI100560, R01AI063517, and R01AI072219 (to R.A.B.) and T32-GM-7250 to Case Western Reserve University, MLW. This study was supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, award number 1I01BX001974, to R.A.B., and by the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development and the Geriatric Research Education and Clinical Center VISN 10 to R.A.B., Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; EDG431G/09, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI100560, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI063517, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI072219, Case Western Reserve University; T32-GM-7250, Cleveland Department of Veterans Affairs; 1I01BX001974, VA Office of Research and Development and the Geriatric Research Education and Clinical Center; VISN 10
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: the SUPERIOR multicentre study

  • García-Fernández, Sergio
  • García-Castillo, María
  • Bou, Germán
  • García Calvo-Montes, Jorge
  • Cercenado, Emilia
  • Delgado-Valverde, Mercedes
  • Pitart, Cristina
  • Mulet, Xavier
  • Tormo, Nuria
  • López-Mendoza, Diego
  • Díaz-Regañón, Jazmín
  • Cantón, Rafael
Multicenter study, [Abstract] Patients in intensive care units (ICUs) present a high risk of developing an infection caused by multidrug-resistant bacteria. Consequently, new antimicrobials and combinations are required. In this study, the activity of ceftolozane/tazobactam (C/T) was evaluated against Enterobacterales (n = 400) and Pseudomonas aeruginosa (n = 80) clinical isolates collected from patients in Spanish ICUs with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Overall susceptibility to C/T in P. aeruginosa isolates by infection type was 95.7% in cUTI (MIC50/90, 1/4 mg/L) and 85.3% in cIAI (MIC50/90, 1/64 mg/L). Activity against P. aeruginosa was maintained regardless of its resistance pattern, confirming that C/T is one of the best antipseudomonal agents along with colistin and amikacin. Susceptibility to C/T in Enterobacterales by infection type was 79.5/81.9% and 89.3/92.3% (EUCAST/CLSI) in cIAI and cUTI isolates, respectively. Activity was excellent against wild-type organisms, with 100% susceptible and inhibited at MIC ≤1 mg/L. Nevertheless, C/T susceptibility decreased against extended-spectrum β-lactamase (ESBL)-producing isolates: Escherichia coli (80.4/84.8% susceptible by EUCAST/CLSI) and Klebsiella pneumoniae (59.1/77.3% susceptible by EUCAST/CLSI). No activity of C/T was observed in carbapenemase-producing isolates. The in vitro activity of C/T observed in this surveillance study suggests that this agent can be considered as a therapeutic option for cUTI and cIAI due to Enterobacterales and P. aeruginosa in ICU patients, particularly when carbapenemase-producing isolates are not involved., This study was funded by MSD Spain and was supported by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases [RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0010 and REIPI RD16/0016/0011], co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (ERDF), Operative program Intelligent Growth 2014–2020. SG-F is supported by a research contract from Instituto de Salud Carlos III, Spain [Rio Hortega program, ref. CM17/00033].
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification

  • Gato, Eva
  • Guijarro-Sánchez, Paula
  • Alonso-García, Isaac
  • Pedraza-Merino, Rosa
  • Conde, Adrián
  • Lence, Emilio
  • Rumbo-Feal, Soraya
  • Peña-Escolano, Andrea
  • Lasarte-Monterrubio, Cristina
  • Blanco Martín, Tania
  • Fernández González, Ana
  • Fernández-López, María del Carmen
  • Maceiras, Romina
  • Martínez Guitián, Marta
  • Vázquez-Ucha, Juan Carlos
  • Martínez-Martínez, Luis
  • González-Bello, Concepción
  • Arca-Suárez, Jorge
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Objectives: In order to inform and anticipate potential strategies aimed at combating KPC-producing Klebsiella pneumoniae infections, we analysed imipenem/relebactam and ceftazidime/avibactam single-step mutant frequencies, resistance development trajectories, differentially selected resistance mechanisms and their associated fitness cost using four representative high-risk K. pneumoniae clones. Methods: Mutant frequencies and mutant preventive concentrations were determined using agar plates containing incremental concentrations of β-lactam/β-lactamase inhibitor. Resistance dynamics were determined through incubation for 7 days in 10 mL MH tubes containing incremental concentrations of each antibiotic combination up to their 64 × baseline MIC. Two colonies per strain from each experiment were characterized by antimicrobial susceptibility testing, whole genome sequencing and competitive growth assays (to determine in vitro fitness). KPC variants associated with imipenem/relebactam resistance were characterized by cloning and biochemical experiments, atomic models and molecular dynamics simulation studies. Results: Imipenem/relebactam prevented the emergence of single-step resistance mutants at lower concentrations than ceftazidime/avibactam. In three of the four strains evaluated, imipenem/relebactam resistance development emerged more rapidly, and in the ST512/KPC-3 clone reached higher levels compared to baseline MICs than for ceftazidime/avibactam. Lineages evolved in the presence of ceftazidime/avibactam showed KPC substitutions associated with high-level ceftazidime/avibactam resistance, increased imipenem/relebactam susceptibility and low fitness costs. Lineages that evolved in the presence of imipenem/relebactam showed OmpK36 disruption, KPC modifications (S106L, N132S, L167R) and strain-specific substitutions associated with imipenem/relebactam resistance and high fitness costs. Imipenem/relebactam-selected KPC derivatives demonstrated enhanced relebactam resistance through important changes affecting relebactam recognition and positioning. Conclusions: Our findings anticipate potential resistance mechanisms affecting imipenem/relebactam during treatment of KPC-producing K. pneumoniae infections., This work was supported by MSD through the Investigator Initiated Studies Program, which provided financial support (to G.B.) and relebactam. This work was also supported by the Fondo de Investigación Sanitaria (grant numbers PI17/01482 and PI20/01212 for A.B. and PI18/00501 and PI21/00704 for G.B.) integrated in the Plan Nacional de I1D and funded by the Instituto de Salud Carlos III (ISCIII), CIBERINFEC (CIBER de Enfermedades Infecciosas). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0004 and no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research—European Regional Development Fund (FEDER) ‘A way of making Europe.’ The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12, A.B. and IN607A 2016/22, G.B.). PGS was financially supported by IN606A-2021/021. I.A.-G was financially supported by the Rio Hortega program (ISCIII, CM21/00076). J.C.V.-U. was financially supported by the ISCIII project FI18/00315. C.L.-M. was financially supported by IN606A-2019/ 029. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026). Financial support from the Spanish Agency of Research (PID2019-105512RB-I00/AEI/10.13039/501100011033, CG-B), the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation 2019–2022 (ED431G 2019/03), CG-B], and the European Regional Development Fund (ERDF) is gratefully acknowledged. AC acknowledges Banco Santander for his fellowship. We are also grateful to the Centro de Supercomputación de Galicia (CESGA) for use of the Finis Terrae computer., Xunta de Galicia; IN607D2021/12, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; IN606A-2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

In-Depth Analysis of the Role of the Acinetobactin Cluster in the Virulence of Acinetobacter baumannii

  • Conde-Pérez, Kelly
  • Vázquez-Ucha, Juan Carlos
  • Álvarez-Fraga, Laura
  • Ageitos, Lucía
  • Rumbo-Feal, Soraya
  • Martínez Guitián, Marta
  • Trigo Tasende, Noelia
  • Rodríguez, Jaime
  • Bou, Germán
  • Jiménez, Carlos
  • Beceiro Casas, Alejandro
  • Poza, Margarita
[Abstract] Acinetobacter baumannii is a multidrug-resistant pathogen that represents a serious threat to global health. A. baumannii possesses a wide range of virulence factors that contribute to the bacterial pathogenicity. Among them, the siderophore acinetobactin is one of the most important, being essential for the development of the infection. In this study we performed an in-depth analysis of the acinetobactin cluster in the strain A. baumannii ATCC 17978. For this purpose, nineteen individual isogenic mutant strains were generated, and further phenotypical analysis were performed. Individual mutants lacking the biosynthetic genes entA, basG, basC, basD, and basB showed a significant loss in virulence, due to the disruption in the acinetobactin production. Similarly, the gene bauA, coding for the acinetobactin receptor, was also found to be crucial for the bacterial pathogenesis. In addition, the analysis of the ΔbasJ/ΔfbsB double mutant strain demonstrated the high level of genetic redundancy between siderophores where the role of specific genes of the acinetobactin cluster can be fulfilled by their fimsbactin redundant genes. Overall, this study highlights the essential role of entA, basG, basC, basD, basB and bauA in the pathogenicity of A. baumannii and provides potential therapeutic targets for the design of new antivirulence agents against this microorganism., This work was funded by Projects PI15/00860 awarded to GB and PI17/01482 to AB and MP, all within in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by project IN607A 2016/22 (GAIN- Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB. This work was also supported by Planes Nacionales de I + D + i 2008–2011/2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. This work was also supported by Grant RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, co-funded by the FEDER Programme from the European Union and Xunta de Galicia for the support of Grant ED431E 2018/03 for CICA-INIBIC strategic and the initiative “Seed Projects 2019–2020.” JV-U was financially supported by the ISCIII project FI18/00315, LÁ-F by the ISCIII project PI14/00059 and the IN606B-2018/011, MM-G was financially supported by the Grant Clara Roy (SEIMC, Spanish Society of Clinical Microbiology and Infectious Diseases), KC-P by IN607A 2016/22 and AECC (Asociación Española Contra el Cáncer) predoctoral fellowship and LA by Xunta de Galicia co-funded with the European Social Fund (FSE) of the European Union (ED481A-2019/081), Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606B-2018/011, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED481A-2019/081
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Rapid determination of resistance to antibiotic inhibitors of protein synthesis in Staphylococcus aureus through in situ evaluation of DNase activity

  • Otero, Fátima
  • Santiso, Rebeca
  • López, Isidoro
  • Touzón, Inés
  • Gosálvez, Jaime
  • Bou, Germán
  • Fernández, José Luis
[Abstract] A rapid assay was designed for the detection of resistant strains of Staphylococcus aureus to antibiotic inhibitors of protein synthesis. The assay was based on the fact that a brief cell wall digestion with lysostaphin resulted in fragmentation of the chromosomal DNA by releasing the characteristic DNase stored in the cell wall. DNase activity was ascertained by visualization of the DNA fragments released from the isolated nucleoids. Lysostaphin-released DNase activity was found to be influenced by ribosomal protein synthesis. Inhibition of protein synthesis resulted in the prevention of lysostaphin-DNase induced DNA fragmentation when susceptible clinical strains were incubated with erythromycin, azithromycin, or doxycycline for 2 hr before enzymatic treatment. However, in nonsusceptible strains where protein synthesis was unsuccessfully inhibited, this suppression of lysostaphin-DNase was not, or only very slightly, evident. This assay was highly efficient, identifying resistance to erythromycin and azithromycin with 88-90.9% sensitivity and 100% specificity and with 100% sensitivity and specificity to gentamicin and doxycycline, within a 2 hr and 45 min period., The authors are grateful to Prof. Michael E. Kjelland for revision of the article. This work was supported by the Fondo de Investigaciones Sanitarias (PI14/01346) and REIPI, Spanish Network for Research in Infectious Diseases (Instituto de Salud Carlos III, RD16/0016/0006). This work was also funded by IMI sixth call COMBACTE New Drugs 4 Bad Bugs (ND4BB).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing

  • Arca-Suárez, Jorge
  • Rodiño-Janeiro, Bruno Kotska
  • Pérez Gómez, Astrid
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Cruz, Fernando
  • Gómez-Garrido, Jéssica
  • Alioto, Tyler S.
  • Álvarez-Tejado, Miguel
  • Gut, Marta
  • Gut, Ivo
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • Bou, Germán
Comparative study, [Abstract] The emergence of 16S rRNA methyltransferases (RMTs) in Gram-negative pathogens bearing other clinically relevant resistance mechanisms, such as carbapenemase-producing Enterobacterales (CPE), is becoming an alarming concern. We investigated the prevalence, antimicrobial susceptibility, resistance mechanisms, molecular epidemiology and genetic support of RMTs in CPE isolates from Spain. This study included a collection of 468 CPE isolates recovered during 2018 from 32 participating Spanish hospitals. MICs were determined using the broth microdilution method, the agar dilution method (fosfomycin) or MIC gradient strips (plazomicin). All isolates were subjected to hybrid whole-genome sequencing (WGS). Sequence types (STs), core genome phylogenetic relatedness, horizontally acquired resistance mechanisms, plasmid analysis and the genetic environment of RMTs were determined in silico from WGS data in all RMT-positive isolates. Among the 468 CPE isolates evaluated, 24 isolates (5.1%) recovered from nine different hospitals spanning five Spanish regions showed resistance to all aminoglycosides and were positive for an RMT (21 RmtF, 2 ArmA and 1 RmtC). All RMT-producers showed high-level resistance to all aminoglycosides, including plazomicin, and in most cases exhibited an extensively drug-resistant susceptibility profile. The RMT-positive isolates showed low genetic diversity and were global clones of Klebsiella pneumoniae (ST147, ST101, ST395) and Enterobacter cloacae (ST93) bearing blaOXA-48, blaNDM-1 or blaVIM-1 carbapenemase genes. RMTs were harboured in five different multidrug resistance plasmids and linked to efficient mobile genetic elements. Our findings highlight that RMTs are emerging among clinical CPE isolates from Spain and their spread should be monitored to preserve the future clinical utility of aminoglycosides and plazomicin., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI15/00860 and PI18/00501 to GB and P17/01482 to AB. MG and IG acknowledge the support of the MEIC through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and co-financing with the European Regional Development Fund [MINECO/FEDER, BIO2015-71792-P]. MG and IG also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d'Empresa i Coneixement and the CERCA Programme. Support was also provided by Planes Nacionales de I+D+i 2013–2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/006] co-financed by the European Regional Development Fund ‘A Way to Achieve Europe’, and the operative Intelligent Growth program 2014–2020. JAS was financially supported by the Fundacion Profesor Novoa Santos through a Post-especialización grant and by the Rio Hortega program [ISCIII-SERGAS, CM19/00219]. MO was financially supported by the Juan Rodés program [ISCIII-SERGAS, JR18/00006]. JCVU was financially supported by the pFIS program [ISCIII, PI17/01482].
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS

  • Hernández-García, Marta
  • García-Castillo, María
  • García-Fernández, Sergio
  • Melo-Cristino, José
  • Pinto, Margarida Feijó
  • Gonçalves, Elsa
  • Alves, Valquíria
  • Vieira, Ana Raquel
  • Ramalheira, Elmano
  • Sancho, Luísa
  • Diogo, José
  • Ferreira, Rui
  • Silva, Tania
  • Chaves, Catarina
  • Bou, Germán
  • Cercenado, Emilia
  • Delgado-Valverde, Mercedes
  • Oliver, Antonio
  • Pitart, Cristina
  • Rodríguez-Lozano, Jesús
  • Tormo, Nuria
  • Romano, Joao
  • Pássaro, Leonor
  • Paixao, Laura
  • López-Mendoza, Diego
  • Díaz-Regañón, Jazmín
  • Cantón, Rafael
[Abstract] Objectives: To analyse the epidemiology, the resistome and the virulome of ceftolozane/tazobactam-susceptible or -resistant Pseudomonas aeruginosa clinical isolates recovered from surveillance studies in Portugal (STEP, 2017-18) and Spain (SUPERIOR, 2016-17). Methods: P. aeruginosa isolates were recovered from intra-abdominal, urinary tract and lower respiratory tract infections in ICU patients admitted to 11 Portuguese and 8 Spanish hospitals. MICs were determined (ISO-standard broth microdilution, EUCAST 2020 breakpoints). A subset of 28 ceftolozane/tazobactam-resistant P. aeruginosa isolates were analysed and compared with 28 ceftolozane/tazobactam-susceptible P. aeruginosa strains by WGS. Results: Clonal complex (CC) 235 (27%) and CC175 (18%) were the most frequent, followed by CC244 (13%), CC348 (9%), CC253 (5%) and CC309 (5%). Inter-hospital clonal dissemination was observed, limited to a geographical region (CC235, CC244, CC348 and CC253 in Portugal and CC175 and CC309 in Spain). Carbapenemases were detected in 25 isolates (45%): GES-13 (13/25); VIM type (10/25) [VIM-2 (4/10), VIM-20 (3/10), VIM-1 (2/10) and VIM-36 (1/10)]; and KPC-3 (2/25). GES-13-CC235 (13/15) and VIM type-CC175 (5/10) associations were observed. Interestingly, KPC-3 and VIM-36 producers showed ceftolozane/tazobactam-susceptible phenotypes. However, ceftolozane/tazobactam resistance was significantly associated with GES-13 and VIM-type carbapenemase production. Six non-carbapenemase producers also displayed ceftolozane/tazobactam resistance, three of them showing known ceftolozane/tazobactam resistance-associated mutations in the PBP3 gene, ftsI (R504C and F533L). Overall, an extensive virulome was identified in all P. aeruginosa isolates, particularly in carbapenemase-producing strains. Conclusions: GES-13-CC235 and VIM type-CC175 were the most frequent MDR/XDR P. aeruginosa clones causing infections in Portuguese and Spanish ICU patients, respectively. Ceftolozane/tazobactam resistance was mainly due to carbapenemase production, although mutations in PBP-encoding genes may additionally be involved., The study was funded by MSD Portugal (protocol VP6918) and MSD Spain (protocol MSD-CEF-2016-01). This study was also supported by Plan Nacional de I + D + i 2013–16 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases [RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0010 and REIPI RD16/0016/0011], co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (EDRF), Operative Program Intelligent Growth 2014–20. M.H.-G. is supported by a research contract from a European Project [IMI-JU-9–2013, Ref. iABC - 115721–2].
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Enhanced antibacterial activity of repurposed Mitomycin C and Imipenem in combination with the lytic phage vB_KpnM-VAC13 against clinical isolates of Klebsiella pneumoniae

  • Pacios Santamaría, Olga
  • Fernández-García, Laura
  • Bleriot Rial, Inés
  • Blasco, Lucía
  • González-Bardanca, Mónica
  • Zamora López, María José
  • Fernández-Cuenca, Felipe
  • Oteo, Jesús
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Domingo-Calap, Pilar
  • Bou, Germán
  • Tomás, María
[Abstract] Klebsiella pneumoniae is an opportunistic Gram-negative pathogen that employs different strategies (resistance and persistence) to counteract antibiotic treatments. This study aimed to search for new means of combatting imipenem-resistant and persister strains of K. pneumoniae by repurposing the anticancer drug mitomycin C as an antimicrobial agent and by combining the drug and the conventional antibiotic imipenem with the lytic phage vB_KpnM-VAC13. Several clinical K. pneumoniae isolates were characterized, and an imipenem-resistant isolate (harboring OXA-245 β-lactamase) and a persister isolate were selected for study. The mitomycin C and imipenem MICs for both isolates were determined by the broth microdilution method. Time-kill curve data were obtained by optical density at 600 nm (OD600) measurement and CFU enumeration in the presence of each drug alone and with the phage. The frequency of occurrence of mutants resistant to each drug and the combinations was also calculated, and the efficacy of the combination treatments was evaluated using an in vivo infection model (Galleria mellonella). The lytic phage vB_KpnM-VAC13 and mitomycin C had synergistic effects on imipenem-resistant and persister isolates, both in vitro and in vivo. The phage-imipenem combination successfully killed the persisters but not the imipenem-resistant isolate harboring OXA-245 β-lactamase. Interestingly, the combinations decreased the emergence of in vitro resistant mutants of both isolates. Combinations of the lytic phage vB_KpnM-VAC13 with mitomycin C and imipenem were effective against the persister K. pneumoniae isolate. The lytic phage-mitomycin C combination was also effective against imipenem-resistant K. pneumoniae strains harboring OXA-245 β-lactamase., This study was funded by grants PI16/01163 and PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research–European Regional Development Fund and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI; RD16/0016/0001, RD16/0016/0006, and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC; http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Program (SERGAS and ISCIII). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López were financially supported by grants IN606A-2020/035 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia), and P. Domingo-Calap was financially supported by the ESCMID Research Grant 20200063.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the rapid detection of antimicrobial resistance mechanisms and beyond

  • Oviaño, Marina
  • Bou, Germán
Review, [Abstract] Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has been successfully applied in recent years for first-line identification of pathogens in clinical microbiology because it is simple to use, rapid, and accurate and has economic benefits in hospital management. The range of clinical applications of MALDI-TOF MS for bacterial isolates is increasing constantly, from species identification to the two most promising applications in the near future: detection of antimicrobial resistance and strain typing for epidemiological studies. The aim of this review is to outline the contribution of previous MALDI-TOF MS studies in relation to detection of antimicrobial resistance and to discuss potential future challenges in this field. Three main approaches are ready (or almost ready) for clinical use, including the detection of antibiotic modifications due to the enzymatic activity of bacteria, the detection of antimicrobial resistance by analysis of the peak patterns of bacteria or mass peak profiles, and the detection of resistance by semiquantification of bacterial growth in the presence of a given antibiotic. This review provides an expert guide for MALDI-TOF MS users to new approaches in the field of antimicrobial resistance detection, especially possible applications as a routine diagnostic tool in microbiology laboratories., This work was supported by the Fondo de Investigación Sanitaria (grant PI15/00860 to G.B.), integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII). The results of this work have been funded by the Spanish Network of Research in Infectious Diseases (REIPI) (grant RD16/0016/0006), integrated in the National Plan for Scientific Research, Development, and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) A Way of Making Europe.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Multiplex real-time PCR-shortTUB assay for detection of the mycobacterium tuberculosis complex in smear-negative clinical samples with low mycobacterial loads

  • Alcaide, Fernando
  • Trastoy, Rocío
  • Moure, Raquel
  • González-Bardanca, Mónica
  • Ambroa, Antón
  • Zamora López, María José
  • Bleriot Rial, Inés
  • Blasco, Lucía
  • Fernández-García, Laura
  • Tato, Marta
  • Bou, Germán
  • Tomás, María
Comparative study, [Abstract] Tuberculosis (TB) remains a major health problem worldwide. Control of TB requires rapid, accurate diagnosis of active disease. However, extrapulmonary TB is very difficult to diagnose because the clinical specimens have very low bacterial loads. Several molecular methods involving direct detection of the Mycobacterium tuberculosis complex (MTBC) have emerged in recent years. Real-time PCR amplification simultaneously combines the amplification and detection of candidate sequences by using fluorescent probes (mainly TaqMan or Molecular Beacons) in automated systems. The multiplex real-time PCR-short assay is performed using locked nucleic acid (LNA) probes (length, 8 to 9 nucleotides) in combination with CodUNG to detect multiple pathogens in clinical samples. In this study, we evaluated the performance of this novel multiplex assay for detecting the MTBC in comparison with that of the conventional culture-based method. The multiplex real-time PCR-shortTUB assay targets two genes, whiB3 (redox-responsive transcriptional regulator) and pstS1 (phosphate-specific transporter), yielding limits of detection (LOD) of 10 copies and 100 copies, respectively, and amplification efficiencies of 92% and 99.7%, respectively. A total of 94 extrapulmonary samples and pulmonary samples with low mycobacterial loads (all smear negative; 75 MTBC culture positive) were analyzed using the test, yielding an overall sensitivity of 88% and a specificity of 95%. For pleural fluid and tissues/biopsy specimens, the sensitivity was 83% and 85%, respectively. In summary, this technique could be implemented in routine clinical microbiology testing to reduce the overall turnaround time for MTBC detection and may therefore be a useful tool for the diagnosis of extrapulmonary tuberculosis and diagnosis using pulmonary samples with low mycobacterial loads., This study was funded by grant PI16/01163 awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research–European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER, the Spanish Network for Research in Infectious Diseases (REIPI; grants REIPI RD16/0016/0006 and RD16/0016/0011), the Study Group on Mechanisms of Action and Resistance to Antimicrobials-GEMARA and Mycobacterial Infections Study Group–GEIM (SEIMC; http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Program (SERGAS and ISCIII).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain

  • Vázquez-Ucha, Juan Carlos
  • Alonso-García, Isaac
  • Guijarro-Sánchez, Paula
  • Lasarte-Monterrubio, Cristina
  • Álvarez-Fraga, Laura
  • Cendón-Esteve, Arnau
  • Outeda, Michelle
  • Maceiras, Romina
  • Peña-Escolano, Andrea
  • Martínez Guitián, Marta
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
Multicenter study, [Abstract] Metallo-β-lactamase (MBL)-producing Enterobacterales are of particular concern because they are widely disseminated and difficult to treat, being resistant to almost all β-lactam antibiotics. Aztreonam is not hydrolysed by MBLs but is labile to serine β-lactamases (SBLs), which are usually co-produced by MBL-producing Enterobacterales. This study investigated the activity of aztreonam in combination with novel β-lactamase inhibitors (BLIs) against a national multi-centre study collection of strains co-producing MBLs and SBLs. Fifty-five clinical isolates co-producing MBLs (41 VIM producers, 10 NDM producers and 4 IMP producers) and SBLs were selected, and whole-genome sequencing (WGS) was performed. The minimum inhibitory concentration (MIC) values of aztreonam, aztreonam/avibactam, aztreonam/relebactam, aztreonam/zidebactam, aztreonam/taniborbactam, aztreonam/vaborbactam and aztreonam/enmetazobactam were determined. β-lactam/BLI resistance mechanisms were analysed by WGS. All BLIs decreased the MIC values of aztreonam for strains that were not susceptible to aztreonam. Aztreonam/zidebactam (MIC ≤1 mg/L for 96.4% of isolates), aztreonam/avibactam (MIC ≤1 mg/L for 92.7% of isolates) and aztreonam/taniborbactam (MIC ≤1 mg/L for 87.3 % of isolates) were the most active combinations. For other aztreonam/BLI combinations, 50-70% of the isolates yielded MIC values ≤1 mg/L. WGS data revealed that mutations in PBP3, defective OmpE35/OmpK35 porins, and the presence of extended-spectrum β-lactamases and class C β-lactamases were some of the resistance mechanisms involved in reduced susceptibility to aztreonam/BLIs. Combinations of aztreonam with new BLIs show promising activity against Enterobacterales co-producing MBLs and SBLs, particularly aztreonam/zidebactam, aztreonam/avibactam and aztreonam/taniborbactam. The present results show that these novel drugs may represent innovative therapeutic strategies by their use in yet-unexplored combinations as solutions for difficult-to-treat infections., This study was funded by Instituto de Salud Carlos III (ISCIII) through Projects N° Exp PI20/01212 and PI18/00501, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2017-2020, and co-funded by European Union – European Regional Development Fund ‘A way to make Europe’. The work was also supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB21/13/00055), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. In addition, the study was funded by Project IN607A 2020/05 (Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB, and Project IN607D 2021/12 awarded to AB. The work was also supported by Planes Nacionales de I+D+i 2017-2020 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006), co-financed by European Development Regional Fund ‘A way to achieve Europe’ and operative programme Intelligent Growth 2014-2020. JA-S was financially supported by the Juan Rodés programme (ISCIII, JR21/00026), JCV-U was financially supported by IN606B-2022/009 (Xunta de Galicia), CL-M was financially supported by IN606A-2019/029 (Xunta de Galicia) and PI20/01212 (ISCIII), and PG-S was financially supported by IN606A 2021/021 (Xunta de Galicia). AC and MO were financially supported by IN607D 2021/12. IA-G was financially supported by the Río Hortega programme (ISCIII, CM21/00076). LA-F was financially supported by IN606B- 2018/011 (Xunta de Galicia). MM-G was financially supported by RSU.UDC.M505 (Ministerio de Universidades)., Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A-2019/029, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; IN606B- 2018/011, Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Occurrence of the p019 gene in the blaKPC-harboring plasmids: adverse clinical impact for direct tracking of KPC-producing Klebsiella pneumoniae by matrix-assisted laser desorption ionization-time of flight mass spectrometry

  • Gato, Eva
  • Constanso-Conde, Ignacio
  • Rodiño-Janeiro, Bruno Kotska
  • Guijarro-Sánchez, Paula
  • Alioto, Tyler S.
  • Arroyo, Manuel J.
  • Méndez, Gema
  • Mancera, Luis
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Bou, Germán
  • Oviaño, Marina
[Abstract] Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has recently been used for the direct detection of KPC-producing isolates by analysis of the 11,109 Da mass peak representing the P019 protein. In this study, we evaluate the presence of the 11,109 Da mass peak in a collection of 435 unduplicated Klebsiella pneumoniae clinical isolates. The prevalence of the P019 peak in the blaKPC K. pneumoniae isolates was 49.2% (32/65). The 11,109 Da mass peak was not observed in any of the other carbapenemase (319) or noncarbapenemase producers (116). Computational analysis of the presence of the p019 gene was performed in the aforementioned carbapenemase-producing K. pneumoniae isolates fully characterized by whole-genome sequencing (WGS) and in a further collection of 1,649 K. pneumoniae genomes included in EuSCAPE. Herein, we have demonstrated that the p019 gene is not exclusively linked to the pKpQil plasmid but that it is present in the following plasmids: IncFIB(K)/IncFII(K)/ColRNAI, IncFIB(pQil), IncFIB(pQil)/ColRNAI, IncFIB(pQil)/IncFII(K), IncFIB(K)/IncFII(K), and IncX3. In addition, we have proven the independent movement of the Tn4401 and the ISKpn31, of which the p019 gene is a component. The absence of the p019 gene was obvious in Col440I, Col(pHAD28), IncFIB(K)/IncX3/IncFII(K), and IncFIB(K)/IncFII(K) plasmids. In addition, we also observed another plasmid in which neither Tn4401 nor ISKpn31 was found, IncP6. In the EuSCAPE, the occurrence of p019 varied from 0% to 100% among the different geographical locations. The adverse clinical impact of the diminished prevalence of the p019 gene within the plasmid encoding KPC-producing Klebsiella pneumoniae puts forward the need for reconsideration when applying this technique in a clinical setting., This study was supported by funding awarded to M.O. throughout the competitive research call 2019 of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). The research was also funded by the Fondo de Investigación Sanitaria (grant numbers PI15/00860, PI18/00860 to G.B.) integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII) and by the Spanish Network of Research in Infectious Diseases (REIPI), number RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation2013 to 2016 and funded by the ISCIII- General Subdirection of Assessment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe.” M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006) and E.G. was financially supported by the research call 2019 of the SEIMC. Clover Biosoft has received funding from the European Union’s Horizon H2020 research and innovation program under grant agreement number 868365.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

In vitro activity of Cefepime-Taniborbactam against Carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain

  • Hernández-García, Marta
  • García-Castillo, María
  • Ruiz-Garbajosa, Patricia
  • Bou, Germán
  • Siller, María
  • Pitart, Cristina
  • Gracia-Ahufinger, Irene
  • Mulet, Xavier
  • Pascual, Álvaro
  • Tormo, Nuria
  • Cantón, Rafael
[Abstract] Novel β-lactam-β-lactamase inhibitor combinations currently approved for clinical use are poorly active against metallo-β-lactamase (MBL)-producing strains. We evaluated the in vitro activity of cefepime-taniborbactam (FTB [formerly cefepime-VNRX-5133]) and comparator agents against carbapenemase-producing Enterobacterales (n = 247) and carbapenem-resistant Pseudomonas species (n = 170) clinical isolates prospectively collected from different clinical origins in patients admitted to 8 Spanish hospitals. FTB was the most active agent in both Enterobacterales (97.6% MICFTB, ≤8/4 mg/L) and Pseudomonas (67.1% MICFTB, ≤8/4 mg/L) populations. The MICFTB was >8 mg/L in 6/247 (2.4%) Enterobacterales isolates (3 KPC-producing Klebsiella pneumoniae isolates, 1 VIM-producing Enterobacter cloacae isolate, 1 IMP-producing E. cloacae isolate, and 1 NDM-producing Escherichia coli isolate) and in 56/170 (32.9%) Pseudomonas isolates, 19 of them carbapenemase producers (15 producers of VIM, 2 of GES, 1 of GES+VIM, and 1 of GES+KPC). Against the Enterobacterales isolates with meropenem MICs of >2 mg/L (138/247), FTB was the most active agent against both serine-β-lactamases (107/138) and MBL producers (31/138) (97.2 and 93.5% MICFTB, ≤8/4 mg/L, respectively), whereas the activity of comparators was reduced, particularly against the MBL producers (ceftazidime-avibactam, 94.4 and 12.9%, meropenem-vaborbactam, 85.0 and 64.5%, imipenem-relebactam, 76.6 and 9.7%, ceftolozane-tazobactam, 1.9 and 0%, and piperacillin-tazobactam, 0 and 0%, respectively). Among the meropenem-resistant Pseudomonas isolates (163/170; MIC, >2 mg/L), the activities of FTB against serine-β-lactamase (35/163) and MBL (43/163) producers were 88.6 and 65.1%, respectively, whereas the susceptibilities of comparators were as follows: ceftazidime-avibactam, 88.5 and 16.0%, meropenem-vaborbactam, 8.5 and 7.0%, imipenem-relebactam, 2.9 and 2.3%, ceftolozane-tazobactam, 0 and 2.3%, and piperacillin-tazobactam, 0 and 0%, respectively. Microbiological results suggest FTB as a potential therapeutic option in patients infected with carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas isolates, including MBL producers., This project was sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract no. HHSO100201900007C. This study was also supported by Plan Nacional de I+D + i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008, RD16/0016/0010, and REIPI RD16/0016/0011), cofinanced by the European Development Regional Fund “A Way to Achieve Europe” (ERDF), operative program Intelligent Growth 2014–2020 and CIBER en Enfermedades Infecciosas (CIBERINF) (CB21/13/00084).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

The Role of PemIK (PemK/PemI) Type II TA System from Klebsiella pneumoniae Clinical Strains in Lytic Phage Infection

  • Bleriot Rial, Inés
  • Blasco, Lucía
  • Pacios Santamaría, Olga
  • Fernández-García, Laura
  • Ambroa, Antón
  • López Díaz, María
  • Ortiz-Cartagena, Concha
  • Fernández-Cuenca, Felipe
  • Oteo, Jesús
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Domingo-Calap, Pilar
  • Wood, Thomas K.
  • Tomás, María
[Abstract] Since their discovery, toxin-antitoxin (TA) systems have captivated the attention of many scientists. Recent studies have demonstrated that TA systems play a key role in phage inhibition. The aim of the present study was to investigate the role of the PemIK (PemK/PemI) type II TA system in phage inhibition by its intrinsic expression in clinical strains of Klebsiella pneumoniae carrying the lncL plasmid, which harbours the carbapenemase OXA-48 and the PemK/PemI TA system. Furthermore, induced expression of the system in an IPTG-inducible plasmid in a reference strain of K. pneumoniae ATCC10031 was also studied. The results showed that induced expression of the whole TA system did not inhibit phage infection, whereas overexpression of the pemK toxin prevented early infection. To investigate the molecular mechanism involved in the PemK toxin-mediated inhibition of phage infection, assays measuring metabolic activity and viability were performed, revealing that overexpression of the PemK toxin led to dormancy of the bacteria. Thus, we demonstrate that the PemK/PemI TA system plays a role in phage infection and that the action of the free toxin induces a dormant state in the cells, resulting in inhibition of phage infections., This study was funded by grant PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research—European Regional Development Fund "A way of Making Europe" and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0006 and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López was financially supported by a grant IN606A-2020/035 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia) and M. Gonzalez-Bardanca was financially supported by the Rio Hortega program (ISCIII, CM20/00198), Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2018/008
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Increased antimicrobial resistance in a novel CMY-54 AmpC-type enzyme with a GluLeu217-218 insertion in the Ω-loop

  • Pérez-Llarena, Francisco J.
  • Vázquez-Ucha, Juan Carlos
  • Kerff, Frédéric
  • Zamorano, Laura
  • Miró, Elisenda
  • Póvoa Cabral, María
  • Fleites, Ana
  • Lantero, Marta
  • Martínez-Martínez, Luis
  • Oliver, Antonio
  • Galleni, Moreno
  • Navarro, Ferrán
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] During a Spanish surveillance study, a natural variant of a CMY-type β-lactamase related to CMY-2 with a GluLeu217-218 insertion in the Ω-loop (designated CMY-54) was found to increase the minimum inhibitory concentractions to β-lactams in a clinical strain of Escherichia coli. The aim of this study was to characterize CMY-54 by genetic, microbiological, and biochemical analysis. The blaCMY-54 gene is encoded by a plasmid of around 100 kb that hybridizes with K and FIB probes. The genetic context of blaCMY-54 and blaCMY-2 genes was found to be very similar. E. coli expressing CMY-54 under isogenic conditions showed a clear fourfold to eightfold increase in MICs to penicillins, cefotaxime, ceftazidime, and aztreonam compared with CMY-2. The catalytic efficiencies of pure CMY-2 and CMY-54 proteins correlated with their microbiological parameters. CMY-2 protein was more resistant to thermal denaturation than CMY-54, indicating that the Ω-loop of CMY-54 may be wider and more relaxed and probably enables better accommodation of these antimicrobials. Otherwise, the higher stabilization of CMY-2 may induce a slight reduction of the dynamics of this enzyme and primarily affect the hydrolysis of some of the bulkiest antibiotics. In summary, the GluLeu217-218 insertion observed in CMY-54 compared to CMY-2 produces a β-lactamase with a distinctive catalytic efficacy for β-lactam antimicrobials likely caused by an increased flexibility slightly affecting the active site shape, highlighting the relevance of single mutations on the hydrolytic spectrum in class C β-lactamases., This work was funded by the European Community, FP7, ID:278232 (MagicBullet) and by the Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0006) – cofinanced by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020. Additional funding was provided by the Fondo de Investigación Sanitaria (grants PI12/00552, PI14/00059, and PI15/00860) and by the ISCIII: CP13/00226. F.K. is a research associate from the FRS-FNRS (Belgium).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)

  • Hernández-García, Marta
  • García-Castillo, María
  • Melo-Cristino, José
  • Pinto, Margarida Feijó
  • Gonçalves, Elsa
  • Alves, Valquíria
  • Vieira, Ana Raquel
  • Ramalheira, Elmano
  • Sancho, Luísa
  • Diogo, José
  • Ferreira, Rui
  • Cruz, Hugo
  • Chaves, Catarina
  • Bou, Germán
  • Cercenado, Emilia
  • Delgado-Valverde, Mercedes
  • Oliver, Antonio
  • Pitart, Cristina
  • Rodríguez-Lozano, Jesús
  • Tormo, Nuria
  • Díaz-Regañón, Jazmín
  • Pássaro, Leonor
  • Duarte, Joana
  • Cantón, Rafael
[Abstract] Objectives: To study the in vitro activity of imipenem/relebactam and comparators and the imipenem/relebactam resistance mechanisms in a Pseudomonas aeruginosa collection from Portugal (STEP, 2017-18) and Spain (SUPERIOR, 2016-17) surveillance studies. Methods: P. aeruginosa isolates (n = 474) were prospectively recovered from complicated urinary tract (cUTI), complicated intra-abdominal (cIAI) and lower respiratory tract (LRTI) infections in 11 Portuguese and 8 Spanish ICUs. MICs were determined (ISO broth microdilution). All imipenem/relebactam-resistant P. aeruginosa isolates (n = 30) and a subset of imipenem/relebactam-susceptible strains (n = 32) were characterized by WGS. Results: Imipenem/relebactam (93.7% susceptible), ceftazidime/avibactam (93.5% susceptible) and ceftolozane/tazobactam (93.2% susceptible) displayed comparable activity. The imipenem/relebactam resistance rate was 6.3% (Portugal 5.8%; Spain 8.9%). Relebactam restored imipenem susceptibility to 76.9% (103/134) of imipenem-resistant isolates, including MDR (82.1%; 32/39), XDR (68.8%; 53/77) and difficult-to-treat (DTR) isolates (67.2%; 45/67). Among sequenced strains, differences in population structure were detected depending on the country: clonal complex (CC)175 and CC309 in Spain and CC235, CC244, CC348 and CC253 in Portugal. Different carbapenemase gene distributions were also found: VIM-20 (n = 3), VIM-1 (n = 2), VIM-2 (n = 1) and VIM-36 (n = 1) in Spain and GES-13 (n = 13), VIM-2 (n = 3) and KPC-3 (n = 2) in Portugal. GES-13-CC235 (n = 13) and VIM type-CC175 (n = 5) associations were predominant in Portugal and Spain, respectively. Imipenem/relebactam showed activity against KPC-3 strains (2/2), but was inactive against all GES-13 producers and most of the VIM producers (8/10). Mutations in genes affecting porin inactivation, efflux pump overexpression and LPS modification might also be involved in imipenem/relebactam resistance. Conclusions: Microbiological results reinforce imipenem/relebactam as a potential option to treat cUTI, cIAI and LRTI caused by MDR/XDR P. aeruginosa isolates, except for GES-13 and VIM producers., The study was funded by MSD Portugal (protocol VP6918) and MSD Spain (protocol MSD-CEF-2016-01). This study was also supported by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0010 and REIPI RD16/0016/0011), co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (ERDF), Operative program Intelligent Growth 2014–2020 and CIBER de Enfermedades Infecciosas (CIBERINFEC) (CB21/13/00084), Instituto de Salud Carlos III, Madrid, Spain.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii

  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Maneiro Rey, María
  • Conde-Pérez, Kelly
  • Álvarez-Fraga, Laura
  • Torrens Ribot, Gabriel
  • Oliver, Antonio
  • Buynak, John
  • Bonomo, Robert
  • Bou, Germán
  • González-Bello, Concepción
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] The carbapenem-hydrolyzing class D β-lactamases (CHDLs) are the main mechanism of carbapenem resistance in Acinetobacter baumannii. CHDLs are not effectively inactivated by clinically available β-lactam-type inhibitors. We have previously described the in vitro efficacy of the inhibitor LN-1-255 in combination with carbapenems. The aim of this study was to compare the efficacy of LN-1-255 with that of imipenem in murine pneumonia using A. baumannii strains carrying their most extended carbapenemases, OXA-23 and OXA-24/40. The blaOXA-23 and blaOXA-24/40 genes were cloned into the carbapenem-susceptible A. baumannii ATCC 17978 strain. Clinical isolates Ab1 and JC12/04, producing the enzymes OXA-23 and OXA-24/40, respectively, were used in the study. Pharmacokinetic (PK) parameters were determined. An experimental pneumonia model was used to evaluate the efficacy of the combined imipenem–LN-1-255 therapy. MICs of imipenem decreased between 32- and 128-fold in the presence of LN-1-255. Intramuscular treatment with imipenem–LN-1-255 (30/50 mg/kg) decreased the bacterial burden by (i) 4 and 1.7 log10 CFU/g lung in the infection with the ATCC 17978-OXA-23 and Ab1 strains, respectively, and by (ii) 2.5 and 4.5 log10 CFU/g lung in the infection produced by the ATCC 17978-OXA-24/40 and the JC12/04 strains, respectively. In all assays, combined therapy offered higher protection against pneumonia than that provided by monotherapy. No toxicity was observed in treated mice. Imipenem treatment combined with LN-1-255 treatment significantly reduced the severity of infection by carbapenem-resistant A. baumannii strains carrying CHDLs. Preclinical assays demonstrated the potential of LN-1-255 and imipenem therapy as a new antibacterial treatment., This work has been funded by projects PI15/00860 to G.B., CP13/00226 to A.B., and P14/00059 and PI17/01482 to M.P. and A.B., all of which were integrated into the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe,” The study was also funded by project IN607A 2016/22 (Consellería de Cultura, Educación e Ordenación Universitaria) to G.B. This study was also funded by the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), Xunta de Galicia (Centro Singular de Investigación de Galicia accreditation 2016 to 2019, ED431G/09), and by the European Regional Development Fund (ERDF) to C.G.-B. This work was also supported by Planes Nacionales de I+D+i 2008-2011/2013-2016 and by Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006), cofinanced by the European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. Also, this study was supported in part by funds from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (USA) under award numbers R01AI063517, R01AI072219, and R01AI100560, by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program award 1I01BX001974, and by the Geriatric Research Education and Clinical Center VISN 10 to R.A.B. J.D.B. acknowledges support from the National Institutes of Allergy and Infectious Diseases under award number R15AI142699. J.C.V.-U. was financially supported by the Miguel Servet Programme (CP13/00226; ISCIII, Spain) and by Consellería de Cultura, Educación e Ordenación Universitaria (IN607A 2016/22), and M.M.-G. was financially supported by a Clara Roy grant (Spanish Society of Clinical Microbiology and Infectious Diseases [SEIMC])., Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431G/09, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI063517, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI072219, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI100560, Estados Unidos. National Institutes of Allergy and Infectious Diseases; R15AI142699
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Assessment of activity and resistance mechanisms to cefepime in combination with the novel β-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing enterobacterales

  • Vázquez-Ucha, Juan Carlos
  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Oviaño, Marina
  • Álvarez-Fraga, Laura
  • Alonso-García, Isaac
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
Multicenter study, [Abstract] The global distribution of carbapenemases such as KPC, OXA-48, and metallo-β-lactamases (MBLs) gives cause for concern, as these enzymes are not inhibited by classical β-lactamase inhibitors (BLIs). The current development of new inhibitors is one of the most promising highlights for the treatment of multidrug-resistant bacteria. The activity of cefepime in combination with the novel BLIs zidebactam, taniborbactam, and enmetazobactam was studied in a collection of 400 carbapenemase-producing Enterobacterales (CPE). The genomes were fully sequenced and potential mechanisms of resistance to cefepime/BLI combinations were characterized. Cefepime resistance in the whole set of isolates was 79.5% (MIC50/90 64/≥128mg/L). The cefepime/zidebactam and cefepime/taniborbactam combinations showed the highest activity (MIC50/90 ≤0.5/1 and ≤0.5/2 mg/L, respectively). Cefepime/zidebactam displayed high activity, regardless of the carbapenemase or extended-spectrum β-lactamase (ESBL) considered (99% of isolates displayed MIC ≤2 mg/L). Cefepime/taniborbactam displayed excellent activity against OXA-48- and KPC-producing Enterobacterales and lower activity against MBL-producing isolates (four strains yielded MICs ≥16 mg/L: 2 NDM producers with an insertion in PBP3, one VIM-1 producer with nonfunctional OmpK35, and one IMP-8 producer). Cefepime/enmetazobactam displayed the lowest activity (MIC50/90 1/≥128 mg/L), with MICs ≥16 mg/L for 49 MBL producers, 40 OXA-48 producers (13 with amino acid changes in OmpK35/36, 4 in PBPs and 11 in RamR) and 25 KPC producers (most with an insertion in OmpK36). These results confirm the therapeutic potential of the new β-lactamase inhibitors, shedding light on the activity of cefepime and BLIs against CPE and resistance mechanisms. The cefepime/zidebactam and cefepime/taniborbactam combinations are particularly highlighted as promising alternatives to penicillin-based inhibitors for the treatment of CPE., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI17/01482 and PI20/01212 for A.B. and PI18/00501 for G.B. integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III, ISCIII).CIBERINF (CIBER de Enfermedades Infecciosas). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), N° RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research–European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12, A.B. and IN607A 2016/22, G.B.).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales

  • Vázquez-Ucha, Juan Carlos
  • Seoane-Estévez, Alejandro
  • Rodiño-Janeiro, Bruno Kotska
  • González-Bardanca, Mónica
  • Conde-Pérez, Kelly
  • Martínez Guitián, Marta
  • Álvarez-Fraga, Laura
  • Arca-Suárez, Jorge
  • Lasarte-Monterrubio, Cristina
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Background: Imipenem/relebactam is a novel carbapenem/β-lactamase inhibitor combination, developed to act against carbapenemase-producing Enterobacterales (CPE). Objectives: To assess the in vitro activity of imipenem/relebactam against a Spanish nationwide collection of CPE by testing the susceptibility of these isolates to 16 widely used antimicrobials and to determine the underlying β-lactam resistance mechanisms involved and the molecular epidemiology of carbapenemases in Spain. Materials and methods: Clinical CPE isolates (n = 401) collected for 2 months from 24 hospitals in Spain were tested. MIC50, MIC90 and susceptibility/resistance rates were interpreted in accordance with the EUCAST guidelines. β-Lactam resistance mechanisms and molecular epidemiology were characterized by WGS. Results: For all isolates, high rates of susceptibility to colistin (86.5%; MIC50/90 = 0.12/8 mg/L), imipenem/relebactam (85.8%; MIC50/90 = 0.5/4 mg/L) and ceftazidime/avibactam (83.8%, MIC50/90 = 1/≥256 mg/L) were observed. The subgroups of isolates producing OXA-48-like (n = 305, 75.1%) and KPC-like enzymes (n = 44, 10.8%) were highly susceptible to ceftazidime/avibactam (97.7%, MIC50/90 = 1/2 mg/L) and imipenem/relebactam (100.0%, MIC50/90 = ≤0.25/1 mg/L), respectively. The most widely disseminated high-risk clones of carbapenemase-producing Klebsiella pneumoniae across Spain were found to be ST11, ST147, ST392 and ST15 (mostly associated with OXA-48) and ST258/512 (in all cases producing KPC). Conclusions: Imipenem/relebactam, colistin and ceftazidime/avibactam were the most active antimicrobials against all CPEs. Imipenem/relebactam is a valuable addition to the antimicrobial arsenal used in the fight against CPE, particularly against KPC-producing isolates, which in all cases were susceptible to this combination., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI15/00860, PI18/00860 to G.B. and PI17/01482, PI20/01212 to A.B.) integrated in the Plan Nacional de I + D and funded by the Instituto de Salud Carlos III (ISCIII). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII—General Subdirection of Assessment and Promotion of the Research—European Regional Development Fund (FEDER) ‘A way of making Europe’.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections

  • Alonso-García, Isaac
  • Vázquez-Ucha, Juan Carlos
  • Lasarte-Monterrubio, Cristina
  • González-Mayo, Elena
  • Lada-Salvador, Paula
  • Vela-Fernández, Ramón
  • Aja-Macaya, Pablo
  • Guijarro-Sánchez, Paula
  • Rumbo-Feal, Soraya
  • Muíño-Andrade, María José
  • Fernández González, Ana
  • Martínez Guitián, Marta
  • Beceiro Casas, Alejandro
  • Rodríguez-Iglesias, Manuel
  • Oliver, Antonio
  • Arca-Suárez, Jorge
  • Galán-Sánchez, Fátima
  • Bou, Germán
[Abstract] Objectives: To describe and characterize the emergence of resistance to ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam in a patient receiving ceftazidime/avibactam treatment for an MDR Pseudomonas aeruginosa CNS infection. Methods: One baseline (PA1) and two post-exposure (PA2 and PA3) isolates obtained before and during treatment of a nosocomial P. aeruginosa meningoventriculitis were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. The impact on β-lactam resistance of mutations in blaPDC and mexR was determined through cloning experiments and complementation assays. Results: Isolate PA1 showed baseline resistance mutations in DacB (I354A) and OprD (N142fs) conferring resistance to conventional antipseudomonals but susceptibility to ceftazidime/avibactam, ceftolozane/tazobactam and imipenem/relebactam. Post-exposure isolates showed two divergent ceftazidime/avibactam-resistant phenotypes associated with distinctive mutations affecting the intrinsic P PDC β-lactamase (S254Ins) (PA2: ceftolozane/tazobactam and ceftazidime/avibactam-resistant) or MexAB-OprM negative regulator MexR in combination with modification of PBP3 (PA3: ceftazidime/avibactam and imipenem/relebactam-relebactam-resistant). Cloning experiments demonstrated the role of PDC modification in resistance to ceftolozane/tazobactam and ceftazidime/avibactam. Complementation with a functional copy of the mexR gene in isolate PA3 restored imipenem/relebactam susceptibility. Conclusions: We demonstrated how P. aeruginosa may simultaneously develop resistance and compromise the activity of new β-lactam/β-lactamase inhibitor combinations when exposed to ceftazidime/avibactam through selection of mutations leading to PDC modification and up-regulation of MexAB-OprM-mediated efflux., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI22/01212 for J.A.-S., PI17/01482 and PI20/01212 for A.B., PI21/00017 for A.O., and PI18/00501 and PI21/00704 for G.B. integrated in the Plan Nacional de I1D and funded by the Instituto de Salud Carlos III, ISCIII). This research was also funded by CIBERINFEC, no. CB21/13/00055 and no. CB21/13/00099 (CIBER de Enfermedades Infecciosas), and by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0004 and no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research–European Regional Development Fund (FEDER) ‘A way of making Europe’. The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12 to A.B. and IN607A 2016/22 to G.B.). I.A.-G was financially supported by the Rio Hortega programme (ISCIII, CM21/00076). J.C.V.-U. was financially supported by the ISCIII project FI18/00315. C.L.-M. was financially supported by IN606A-2019/029. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026)., Xunta de Galicia; IN607D2021/12, Xunta de Galicia; IN607A 2016/22
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Syzygium aromaticum (clove) and Thymus zygis (thyme) essential oils increase susceptibility to colistin in the nosocomial pathogens Acinetobacter baumannii and Klebsiella pneumoniae

  • Poza, Margarita
  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Conde-Pérez, Kelly
  • Arca-Suárez, Jorge
  • Álvarez-Fraga, Laura
  • Pérez Gómez, Astrid
  • Crecente-Campo, José
  • Alonso, María J.
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] The discovery of new antibiotics that are effective against Acinetobacter baumannii and Enterobacteralesis a research priority. Several essential oils (EOs) have displayed some antimicrobial activity and could potentially act as antibiotic adjuvants. Research in this area aims to develop new therapeutic alternatives to treat infections caused by these pathogens. MICs of different EOs were determined against A. baumannii and Klebsiella pneumoniae. Combined disk diffusion tests and checkerboard assays were used to study the synergy between the EOs and antibiotics. The fractional inhibitory concentration index (FICindex) was calculated in order to categorize the interaction. Time-kill assays were also performed. The EOs that displayed the highest levels of antimicrobial activity were clove (Syzygium aromaticum L.) and thyme (Thymus zygis L.). Combined disk diffusion tests and checkerboard assays revealed synergy between these EOs and colistin. Addition of either clove or thyme EO decreased the MIC of colistin by 8- to 64-fold and 8- to 128-fold in the colistin-resistant A. baumannii and K. pneumoniae strains, respectively (FICindex ≤ 0.5, synergy). MICs were also reduced in the colistin-susceptible strains. Time-kill assays also indicated the strong activity of the combined therapy. In summary, the use of clove or thyme EO in combination with colistin could improve the efficacy of the antibiotic and significantly reduce the concentrations needed to inhibit growth of A. baumannii and K. pneumoniae., Funding: This study was funded by projects IN607A 2016/22 (GAIN), PI15/00860, PI18/00501 and REIPI RD16/0016/006 (co-financed by the European Development Regional Fund "A way to achieve Europe" and the operative Intelligent Growth program 2014-2020) awarded to GB, PI14/00059 and PI17/01482 awarded to AB and MP (Instituto de Salud Carlos III). JCVU was financially supported the pFIS Programme (FI18/00315, ISCIII), MMG by a Clara Roy grant (SEIMC), KCP by IN607A 2016/22 (GAIN), CLM by IN606A-2019/029 (GAIN) and JAS by the Rio Hortega program (CM19/00219, ISCIII) and the FPNS (post-specialization grant). Acknowledgements: We thank Dr J.D. Boyce for the kind gift of ATCC19606ΔlpxC. We also thank Dr S. Pournaras for the kind gift of AB248 and AB249.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Mechanisms of bacterial tolerance and persistence in the gastrointestinal and respiratory environments

  • Trastoy, Rocío
  • Manso, Tamara
  • Fernández-García, Laura
  • Blasco, Lucía
  • Ambroa, Antón
  • Pérez del Molino, María Luisa
  • Bou, Germán
  • García-Contreras, Rodolfo
  • Wood, Thomas K.
  • Tomás, María
Review, [Abstract] Pathogens that infect the gastrointestinal and respiratory tracts are subjected to intense pressure due to the environmental conditions of the surroundings. This pressure has led to the development of mechanisms of bacterial tolerance or persistence which enable microorganisms to survive in these locations. In this review, we analyze the general stress response (RpoS mediated), reactive oxygen species (ROS) tolerance, energy metabolism, drug efflux pumps, SOS response, quorum sensing (QS) bacterial communication, (p)ppGpp signaling, and toxin-antitoxin (TA) systems of pathogens, such as Escherichia coli, Salmonella spp., Vibrio spp., Helicobacter spp., Campylobacter jejuni, Enterococcus spp., Shigella spp., Yersinia spp., and Clostridium difficile, all of which inhabit the gastrointestinal tract. The following respiratory tract pathogens are also considered: Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, Burkholderia cenocepacia, and Mycobacterium tuberculosis Knowledge of the molecular mechanisms regulating the bacterial tolerance and persistence phenotypes is essential in the fight against multiresistant pathogens, as it will enable the identification of new targets for developing innovative anti-infective treatments., This study was funded by grants PI13/02390 and PI16/01163, awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate of Evaluation and Promotion of Research-European Regional Development Fund “A Way of Making Europe” and the Instituto de Salud Carlos III FEDER, Spanish Network for Research in Infectious Diseases (REIPI) (grants RD16/0016/0001 and RD16/0016/0006), as well as the Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA; SEIMC). M. Tomás was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). R. Trastoy and L. Fernández-García were financially supported by a postspeciality from the Fundación Novo Santos (CHUAC-SERGAS, Galicia, Spain) and a predoctoral fellowship from the Xunta de Galicia (GAIN, Axencia de Innovación), respectively.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Phenotypic and Genomic Comparison of Klebsiella pneumoniae Lytic Phages: vB_KpnM-VAC66 and vB_KpnM-VAC13

  • Pacios Santamaría, Olga
  • Fernández-García, Laura
  • Bleriot Rial, Inés
  • Blasco, Lucía
  • Ambroa, Antón
  • López Díaz, María
  • Ortiz-Cartagena, Concha
  • Fernández-Cuenca, Felipe
  • Oteo, Jesús
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Domingo-Calap, Pilar
  • Tomás, María
[Abstract] Klebsiella pneumoniae is a human pathogen that worsens the prognosis of many immunocompromised patients. Here, we annotated and compared the genomes of two lytic phages that infect clinical strains of K. pneumoniae (vB_KpnM-VAC13 and vB_KpnM-VAC66) and phenotypically characterized vB_KpnM-VAC66 (time of adsorption of 12 min, burst size of 31.49 ± 0.61 PFU/infected cell, and a host range of 20.8% of the tested strains). Transmission electronic microscopy showed that vB_KpnM-VAC66 belongs to the Myoviridae family. The genomic analysis of the phage vB_KpnM-VAC66 revealed that its genome encoded 289 proteins. When compared to the genome of vB_KpnM-VAC13, they showed a nucleotide similarity of 97.56%, with a 93% of query cover, and the phylogenetic study performed with other Tevenvirinae phages showed a close common ancestor. However, there were 21 coding sequences which differed. Interestingly, the main differences were that vB_KpnM-VAC66 encoded 10 more homing endonucleases than vB_KpnM-VAC13, and that the nucleotidic and amino-acid sequences of the L-shaped tail fiber protein were highly dissimilar, leading to different three-dimensional protein predictions. Both phages differed significantly in their host range. These viruses may be useful in the development of alternative therapies to antibiotics or as a co-therapy increasing its antimicrobial potential, especially when addressing multidrug resistant (MDR) pathogens., This study was funded by grants PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research—European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0006 and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/ accessed on 1 February 2021) and project PID2020-112835RA-I00 funded by MCIN/AEI /10.13039/501100011033, and project SEJIGENT/2021/014 funded by Conselleria d’Innovació, Universitats, Ciència i Societat Digital (Generalitat Valenciana). M. Tomás was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). O. Pacios, L. Fernández-García and M. López were financially supported by the grants IN606A-2020/035, IN606B-2021/013 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). P. Domingo-Calap was financially supported by a Ramón y Cajal contract RYC2019-028015-I funded by MCIN/AEI /10.13039/501100011033, ESF Invest in your future, Generalitat Valenciana; SEJIGENT/2021/014, Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2021/013, Xunta de Galicia; IN606B-2018/008
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Engineering and evaluation of a live-attenuated vaccine candidate with enhanced Type 1 fimbriae expression to optimize protection against Salmonella Typhimurium

  • García, Patricia
  • Rodríguez-Coello, Arianna
  • García-Pose, Andrea
  • Fernández-López, María del Carmen
  • Muras, Andrea
  • Moscoso, Miriam
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Background:Salmonella Typhimurium is a major zoonotic pathogen, in which type 1 fimbriae play a crucial role in intestinal colonization and immune modulation. This study aimed to improve the protective immunity of a previously developed growth-deficient strain-a double auxotroph for D-glutamate and D-alanine-by engineering the inducible expression of type 1 fimbriae. Methods: PtetA-driven expression of the fim operon was achieved by λ-Red mutagenesis. fimA expression was quantified by qRT-PCR, and fimbriation visualized by transmission electron microscopy. Adhesive properties were evaluated through FimH sequence analysis, yeast agglutination, mannose-binding/inhibition assays, and HT-29 cell adherence. BALB/c mice were immunized orogastrically with IRTA ΔΔΔ or IRTA ΔΔΔ PtetA::fim. Safety and immunogenicity were assessed by clinical monitoring, bacterial load, fecal shedding, ELISA tests, and adhesion/blocking assays using fecal extracts. Protection was evaluated after challenging with wild-type and heterologous strains. Results: IRTA ΔΔΔ PtetA::fim showed robust fimA expression, dense fimbrial coverage, a marked mannose-sensitive adhesive phenotype and enhanced HT-29 attachment. Fimbrial overexpression did not alter intestinal colonization or translocation to mesenteric lymph nodes (mLNs). Immunization elicited a mixed IgG1/IgG2a, significantly increased IgA and IgG against type 1 fimbriae-expressing Salmonella, and enhanced the ability of fecal extracts to inhibit the adherence of wild-type strains. Upon challenge (IRTA wild-type/20220258), IRTA ΔΔΔ PtetA::fim reduced infection burden in the cecum (-1.46/1.47-log), large intestine (-1.35/2.17-log), mLNs (-1.32/0.98-log) and systemic organs more effectively than IRTA ΔΔΔ. Conclusions: Inducible expression of type 1 fimbriae enhances mucosal immunity and protection, supporting their inclusion in next-generation Salmonella vaccines. Future work should assess cross-protection and optimize FimH-mediated targeting for mucosal delivery., This study was supported by a grant from SERGAS (The Galician Healthcare Service) (Programs “InnovaSaude” and “InnovaMicrolab”), the Spanish Network for Research in Infectious Diseases (RD16/0016/0006), CIBER-Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (CB21/13/00055), project PI18/00501, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (ERDF/ESF, “A way to make Europe”/”Investing in your future”) and PI21/00704, funded by ISCIII and co-funded by the European Union, awarded to GB. This research was also supported by Projects PI20/01212 and PI23/00851 awarded to A.B., funded by ISCIII and co-funded by the European Union, and by project IN607D 2021/12 awarded to A.B., funded by GAIN-Agencia Gallega de Innovación, Consellería de Economía, Emprego e Industria. A.R was supported by a predoctoral fellowship from the Instituto de Salud Carlos III (FI24/00178). A.M. was supported by a postdoctoral fellowship from the Instituto de Salud Carlos III (CD23/00057).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Antimicrobial activity of Cefiderocol against the Carbapenemase-producing Enterobacter cloacae complex and characterization of reduced susceptibility associated with Metallo-β-Lactamase VIM-1

  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Alonso-García, Isaac
  • Álvarez-Fraga, Laura
  • Outeda-García, Michelle
  • Martínez Guitián, Marta
  • Peña-Escolano, Andrea
  • Maceira, Romina
  • Lence, Emilio
  • González-Bello, Concepción
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Emergence of cefiderocol resistance among carbapenemase-producing Enterobacterales, particularly those in the Enterobacter cloacae complex (ECC), is becoming of alarming concern; however, the mechanistic basis of this phenomenon remains poorly understood. We describe the acquisition of VIM-1-mediated reduced cefiderocol susceptibility (MICs 0.5 to 4 mg/L) in a collection of 54 carbapenemase-producing isolates belonging to the ECC. MICs were determined by reference methodologies. Antimicrobial resistance genomic analysis was performed through hybrid WGS. The impact of VIM-1 production on cefiderocol resistance in the ECC background was examined at microbiological, molecular, biochemical, and atomic levels. Antimicrobial susceptibility testing yielded 83.3% susceptible isolates and MIC50/90 values of 1/4 mg/L. Decreased susceptibility to cefiderocol was mainly associated with isolates producing VIM-1, with cefiderocol MICs 2- to 4-fold higher than for isolates carrying other types of carbapenemases. E. cloacae and Escherichia coli VIM-1 transformants displayed significantly enhanced cefiderocol MICs. Biochemical assays with purified VIM-1 protein revealed low but detectable cefiderocol hydrolysis. Simulation studies revealed how cefiderocol is anchored to the VIM-1 active site. Additional molecular assays and WGS data analysis highlighted the implication of SHV-12 coproduction and suggested the inactivation of the FcuA-like siderophore receptor as further contributors to the higher cefiderocol MICs. Our findings warn of the potential of the VIM-1 carbapenemase to at least partly limit the activity of cefiderocol in the ECC. This effect is probably enhanced due to combination with additional mechanisms, such as ESBL production and siderophore inactivation, and indicates the need for active surveillance to extend the life span of this promising cephalosporin., This research was supported by Projects PI17/01482 and PI20/01212 awarded to AB, PI22/01212 to JAS and PI18/00501 to GB, within in the National Plan for Scientific Research, Development and Technological Innovation 2017 to 2020 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINFEC (CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III). The study was also funded by project IN607A 2020/05 (GAIN-Agencia Gallega de Innovación-Consellería de Economía, Emprego e Industria) awarded to GB and project IN607D 2021/12 awarded to AB. It was also supported by Planes Nacionales de I+D+i2017 to 2020 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth2014 to 2020. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026), J.C.V.-U. was financially supported by IN606B-2022/009 Grant (Xunta de Galicia), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and PGS was financially supported by IN606A 2021/021 Grant (Xunta de Galicia). M.O. was financially supported by IN607D 2021/12 (Xunta de Galicia). I.A.-G. was financially supported by the Rio Hortega program (ISCIII, CM21/00076). C.G.-B. acknowledges financial support from the Spanish Ministry of Science and Innovation (PID2019-105512RB-I00), the Xunta de Galicia (ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation2019 to 2022 [ED431G 2019/03]), and the European Regional Development Fund (ERDF)., Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A-2019/029, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Marine Organisms from the Yucatan Peninsula (Mexico) as a Potential Natural Source of Antibacterial Compounds

  • Pech-Puch, Dawrin
  • Pérez Povedano, Mar Anabel
  • Gómez, Patricia
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Vázquez-Ucha, Juan Carlos
  • Novoa Olmedo, María Lourdes
  • Guillén-Hernández, Sergio
  • Villegas-Hernández, Harold
  • Bou, Germán
  • Rodríguez, Jaime
  • Beceiro Casas, Alejandro
  • Jiménez, Carlos
[Abstract] A total of 51 sponges (Porifera) and 13 ascidians (Chordata) were collected on the coast of the Yucatan Peninsula (Mexico) and extracted with organic solvents. The resulting extracts were screened for antibacterial activity against four multidrug-resistant (MDR) bacterial pathogens: the Gram-negative Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa and the Gram-positive Staphylococcus aureus. The minimum inhibitory concentrations (MICs) of the organic extracts of each marine organism were determined using a broth microdilution assay. Extracts of eight of the species, in particular the Agelas citrina and Haliclona (Rhizoniera) curacaoensis, displayed activity against some of the pathogens tested. Some of the extracts showed similar MIC values to known antibiotics such as penicillins and aminoglycosides. This study is the first to carry out antimicrobial screening of extracts of marine sponges and ascidians collected from the Yucatan Peninsula. Bioassay-guided fractionation of the active extracts from the sponges Amphimedon compressa and A. citrina displayed, as a preliminary result, that an inseparable mixture of halitoxins and amphitoxins and (-)-agelasine B, respectively, are the major compounds responsible for their corresponding antibacterial activities. This is the first report of the antimicrobial activity of halitoxins and amphitoxins against major multidrug-resistant human pathogens. The promising antibacterial activities detected in this study indicate the coast of Yucatan Peninsula as a potential source of a great variety of marine organisms worthy of further research., This work was supported by Grants RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, co-funded by the FEDER Programme from the European Union, by projects PI15/00860 and PI18/00501 to GB and PI14/00059 and PI17/01482 to AB (Instituto de Salud Carlos III) and BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). The study was also funded by projects IN607A 2016/22 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) and GRC2018/039 and Agrupación Estratégica CICA-INIBIC ED431E 2018/03 (Consellería de Educación, Universidades e Formación Profesional) from the Xunta de Galicia (autonomous government of the region). Support was also provided by Planes Nacionales de I+D+i 2013-2016 and ISCIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund "A way to achieve Europe" and the operative program Intelligent Growth 2014-2020. J.C.V.U. was financially supported by the pFIS Programme (FI18/00315), M.M.G. was financially supported by a Clara Roy grant (SEIMC) and C.L.M. by IN606A-2019/029. D.P.P. received a fellowship from the program National Council of Science and Technology (CONACYT) of Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan (Mexico), Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; GRC2018/039, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Kpi, a Chaperone-Usher Pili System Associated with the Worldwide-Disseminated High-Risk Clone Klebsiella Pneumoniae ST-15

  • Gato, Eva
  • Vázquez-Ucha, Juan Carlos
  • Rumbo-Feal, Soraya
  • Álvarez-Fraga, Laura
  • Vallejo, J. A.
  • Martínez Guitián, Marta
  • Beceiro Casas, Alejandro
  • Ramos Vivas, Jose
  • Sola-Campoy, Pedro Juan
  • Pérez-Vázquez, María
  • Oteo, Jesús
  • Rodiño-Janeiro, Bruno Kotska
  • Romero, A.
  • Poza, Margarita
  • Bou, Germán
  • Pérez Gómez, Astrid
[Abstract] Control of infections caused by carbapenem-resistant Klebsiella pneumoniae continues to be challenging. The success of this pathogen is favored by its ability to acquire antimicrobial resistance and to spread and persist in both the environment and in humans. The emergence of clinically important clones, such as sequence types 11, 15, 101, and 258, has been reported worldwide. However, the mechanisms promoting the dissemination of such high-risk clones are unknown. Unraveling the factors that play a role in the pathobiology and epidemicity of K. pneumoniae is therefore important for managing infections. To address this issue, we studied a carbapenem-resistant ST-15 K. pneumoniae isolate (Kp3380) that displayed a remarkable adherent phenotype with abundant pilus-like structures. Genome sequencing enabled us to identify a chaperone-usher pili system (Kpi) in Kp3380. Analysis of a large K. pneumoniae population from 32 European countries showed that the Kpi system is associated with the ST-15 clone. Phylogenetic analysis of the operon revealed that Kpi belongs to the little-characterized γ2-fimbrial clade. We demonstrate that Kpi contributes positively to the ability of K. pneumoniae to form biofilms and adhere to different host tissues. Moreover, the in vivo intestinal colonizing capacity of the Kpi-defective mutant was significantly reduced, as was its ability to infect Galleria mellonella. The findings provide information about the pathobiology and epidemicity of Kpi+ K. pneumoniae and indicate that the presence of Kpi may explain the success of the ST-15 clone. Disrupting bacterial adherence to the intestinal surface could potentially target gastrointestinal colonization., This research was supported by Projects p-01216A and IJCI-2016-29524 (to A.P.), funded by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Minestry of Economy and Competetiveness (MINECO), respectively. It was also supported by Projects PI11/01034 (to M.P.), PI14/00059 and PI17/1482 (to M.P. and A.B.), and PI18/00501 (to G.B.), included in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the Instituto de Salud Carlos III (ISCIII) and Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014-2020. Grant BFU2016-77835-R of the MINECO (to A.R.) also supported this research. E.G. was financially supported by the SEIMC project. J.C.V.-U. was financially supported by the PFIS (Contratos Predoctorales de Formación en Investigación en Salud) program (F18/00315); J.A.V. was financially supported by IN607A 2016/22; M.M.-G. was financially supported by a Clara Roy grant (SEIMC); A.B. was financially supported by the Miguel Servet program (ISCIII, Spain); B.K.R.-J. was financially supported by Marie S. Curie Action SaPhaDe project (MSCA-IF-GF-836754); and A.P. was financially supported by the Juan de la Cierva program (MINECO, IJCI-2016-29524), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; p-01216A, Xunta de Galicia; IN607A 2016/22
RUC. Repositorio da Universidade da Coruña
Publication Tesis doctoral (DoctoralThesis)

Detección rápida de resistencia bacteriana a antibióticos mediante microscopía de fluorescencia

  • López Baltar, Isidoro
[Resumo] A resistencia bacteriana aos antibióticos é un grave problema de saúde mundial. En situacións críticas, a prescrición rápida do antibiótico axeitado é esencial. Polo tanto, sería de grande interese dispor de procedementos de detección de resistencia que sexan máis rápidos que os antibiogramas estándar, que dependen da avaliación do crecemento bacteriano. Esta tese continúa a liña de exploración, deseño e validación de posibles características fenotípicas-morfolóxicas simples, visibles mediante microscopía de fluorescencia, que permitan a detección rápida e fiable da resistencia a diferentes antibióticos en patóxenos con alto impacto clínico. No caso do cotrimoxazol, en Escherichia coli e Klebsiella pneumoniae, avaliouse a prevención ou non de alongamento celular inducido por mitomicina C. A prevención ou non da actividade da DNase nos nucleoides bacterianos foi eficaz na caracterización de diferentes antibióticos inhibidores da síntese de proteínas en Staphyloccocus aureus. Finalmente, para a mestura combinada de ciprofloxacino (quinolona) e ampicilina (betalactámico) en E. coli, a sensibilidade/resistencia a cada antibiótico determinouse simultaneamente estimando a condensación ou non do nucleoide (ciprofloxacino) e a presenza ou non de fragmentos de ADN intercelular (ampicilina). Os resultados foron consistentes cos do antibiograma estándar e obtivéronse nun prazo de 60 a 270 minutos., [Resumen] La resistencia bacteriana a los antibióticos es un grave problema sanitario a nivel mundial. En situaciones críticas es importante la prescripción rápida del antibiótico idóneo. Para ello sería de gran interés disponer de procedimientos de detección de resistencias, más rápidos que los antibiogramas estándar, dependientes de la evaluación del crecimiento bacteriano. En esta tesis se continúa la línea de exploración, diseño y validación, de posibles características fenotípicas-morfológicas simples, visibles mediante microscopía de fluorescencia, que permitan la detección rápida y fiable de resistencia a diferentes antibióticos en patógenos de gran impacto clínico. En el caso del cotrimoxazol, en Escherichia coli y Klebsiella pneumoniae, se evaluó la prevención o no del alargamiento celular inducido por mitomicina C. La afectación o no de la actividad ADNasa sobre los nucleoides bacterianos, fue efectiva para caracterizar diferentes antibióticos inhibidores de la síntesis de proteínas, en Staphyloccocus aureus. Finalmente, para la mezcla conjunta de ciprofloxacino (quinolona) y ampicilina (betalactámico) en E. coli, se logró discriminar simultáneamente la sensibilidad/resistencia a cada antibiótico, estimando la condensación o no del nucleoide (ciprofloxacino) y la presencia o no de fragmentos de ADN intercelular (ampicilina). Los resultados concordaron con los del antibiograma estándar, obteniéndose en tiempos entre 60 y 270 minutos., [Abstract] Bacterial resistance to antibiotics is a serious global health problem. In critical situations, the rapid prescription of the appropriate antibiotic is essential. Therefore, it would be of great interest to have available resistance detection procedures that are faster than standard antibiograms, which depend on the evaluation of bacterial growth. This thesis continues the line of exploration, design, and validation of possible simple phenotypic-morphological characteristics, visible using fluorescence microscopy, that allow for the rapid and reliable detection of resistance to different antibiotics in pathogens with high clinical impact. In the case of cotrimoxazole, in Escherichia coli and Klebsiella pneumoniae, the prevention or not of mitomycin C-induced cell elongation, was evaluated. The prevention or not of DNase activity on bacterial nucleoids was effective in characterizing different protein synthesis-inhibiting antibiotics in Staphyloccocus aureus. Finally, for the combined mixture of ciprofloxacin (quinolone) and ampicillin (beta-lactam) in E. coli, sensitivity/resistance to each antibiotic was simultaneously determined by estimating the condensation or not of the nucleoid (ciprofloxacin) and the presence or not of intercellular DNA fragments (ampicillin). The results were consistent with those of the standard antibiogram, and were obtained within 60 to 270 minutes., Los trabajos que han dado lugar a esta tesis han sido financiados por los proyectos que se señalan a continuación: - PI14/01346. “Desarrollo y validación de un procedimiento sim-ple para la determinación rápida de la resistencia bacteriana a antibióticos inhibidores de la síntesis de proteínas”. Fondo de Investigaciones Sanitarias (FIS). (187.852,50 euros). Años 2015-2017. Prorrogado hasta marzo de 2019. - RD16/0016/0006. “Red temática de investigaciones coopera-tiva: Red española de investigación en patología infecciosa”. Años 2013-2016 y 2017-2022. - PI20/01263. “Desarrollo de un nuevo procedimiento simple y rápido para determinar la sensibilidad/resistencia bacteriana a quinolonas y sus combinaciones con beta-lactámicos, de modo simultáneo e independiente. Fondo de Investigaciones Sanita-rias (FIS). (99.220 euros). Años 2021-2023. Prorrogado hasta 2024. - CB21/13/00055. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas Instituto de Salud Carlos III (ISCIII) 01/01/2021 60.000 €.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

(p)ppGpp and its role in bacterial persistence: new challenges

  • Pacios Santamaría, Olga
  • Blasco, Lucía
  • Bleriot Rial, Inés
  • Fernández-García, Laura
  • Ambroa, Antón
  • Zamora López, María José
  • Bou, Germán
  • Cantón, Rafael
  • García-Contreras, Rodolfo
  • Wood, Thomas K.
  • Tomás, María
Review, [Abstract] Antibiotic failure not only is due to the development of resistance by pathogens but can also often be explained by persistence and tolerance. Persistence and tolerance can be included in the "persistent phenotype," with high relevance for clinics. Two of the most important molecular mechanisms involved in tolerance and persistence are toxin-antitoxin (TA) modules and signaling via guanosine pentaphosphate/tetraphosphate [(p)ppGpp], also known as "magic spot." (p)ppGpp is a very important stress alarmone which orchestrates the stringent response in bacteria; hence, (p)ppGpp is produced during amino acid or fatty acid starvation by proteins belonging to the RelA/SpoT homolog family (RSH). However, (p)ppGpp levels can also accumulate in response to a wide range of signals, including oxygen variation, pH downshift, osmotic shock, temperature shift, or even exposure to darkness. Furthermore, the stringent response is not only involved in responses to environmental stresses (starvation for carbon sources, fatty acids, and phosphates or heat shock), but it is also used in bacterial pathogenesis, host invasion, and antibiotic tolerance and persistence. Given the exhaustive and contradictory literature surrounding the role of (p)ppGpp in bacterial persistence, and with the aim of summarizing what is known so far about the magic spot in this bacterial stage, this review provides new insights into the link between the stringent response and persistence. Moreover, we review some of the innovative treatments that have (p)ppGpp as a target, which are in the spotlight of the scientific community as candidates for effective antipersistence agents., This study was funded by grant PI16/01163 and PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research–European Regional Development Fund, A way of Making Europe, Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0006 and RD16/0016/0011), and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Program (SERGAS and ISCIII). L. Fernández-García was supported by postdoctoral fellowship from the Diputation A Coruña (Xunta Galicia). T.J.K. is supported by a National Health and Medical Research Council Early Career Fellowship (GNT1088448).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial

  • Pérez Gómez, Astrid
  • Gato, Eva
  • Pérez-Llarena, Francisco J.
  • Fernández-Cuenca, Felipe
  • Gude, María José
  • Oviaño, Marina
  • Pachón, María Eugenia
  • Garnacho-Montero, José
  • González-Galán, Verónica
  • Pascual, Álvaro
  • Cisneros, José Miguel
  • Bou, Germán
[Abstract] Objectives: To characterize the antimicrobial susceptibility, molecular epidemiology and carbapenem resistance mechanisms in Pseudomonas aeruginosa isolates recovered from respiratory tract samples from patients with ventilator-associated pneumonia enrolled in the MagicBullet clinical trial. Methods: Isolates were collected from 53 patients from 12 hospitals in Spain, Italy and Greece. Susceptibility was determined using broth microdilution and Etest. MALDI-TOF MS was used to detect carbapenemase activity and carbapenemases were identified by PCR and sequencing. Molecular epidemiology was investigated using PFGE and MLST. Results: Of the 53 isolates, 2 (3.8%) were considered pandrug resistant (PDR), 19 (35.8%) were XDR and 16 (30.2%) were MDR. Most (88.9%) of the isolates from Greece were MDR, XDR or PDR, whereas fewer of the isolates from Spain (33.3%) and Italy (43.5%) showed antibiotic resistance. Three Greek isolates were resistant to colistin. Overall, the rates of resistance of P. aeruginosa isolates to imipenem, ciprofloxacin, ceftolozane/tazobactam and ceftazidime/avibactam were 64.1%, 54.7%, 22.6% and 24.5%, respectively. All isolates resistant to ceftolozane/tazobactam and ceftazidime/avibactam (Greece, n = 10; and Italy, n = 2) carried blaVIM-2. Spanish isolates were susceptible to the new drug combinations. Forty-eight restriction patterns and 27 STs were documented. Sixty percent of isolates belonged to six STs, including the high-risk clones ST-111, ST-175 and ST-235. Conclusions: MDR/XDR isolates were highly prevalent, particularly in Greece. The most effective antibiotic against P. aeruginosa was colistin, followed by ceftolozane/tazobactam and ceftazidime/avibactam. blaVIM-2 is associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam, and related to highly resistant phenotypes. ST-111 was the most frequent and disseminated clone and the clonal diversity was lower in XDR and PDR strains., This work was supported by the MagicBullet study. The European Union Directorate-General funded MagicBullet for Research and Innovation through the Seventh Framework Program for Research and Development (grant agreement 278232). Funding was also provided by the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion, Spanish Network for Research in Infectious Diseases (RD16/0016/0006) – co-financed by European Development Regional Fund ‘A way to achieve Europe'. This work was supported by the Fondo de Investigación Sanitaria (grant PI15/00860 to G. B.), integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII). A. P. was supported by grant IJCI-2016-29524.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

In vitro and in vivo activities of -lactams in combination with the novel -lactam enhancers zidebactam and WCK 5153 against multidrug-resistant metallo-lactamase-producing klebsiella pneumoniae

  • Moya, Bartolomé
  • Barceló, Isabel M.
  • Cabot, Gabriel
  • Torrens Ribot, Gabriel
  • Palwe, Snehal
  • Joshi, Prashant
  • Umarkar, Kushal
  • Takalkar, Swapna
  • Periasamy, Hariharan
  • Bhagwat, Sachin
  • Patel, Mahesh
  • Bou, Germán
  • Oliver, Antonio
[Abstract] Zidebactam and WCK 5153 are novel bicyclo-acyl hydrazide (BCH) agents that have previously been shown to act as β-lactam enhancer (BLE) antibiotics in Pseudomonas aeruginosa and Acinetobacter baumannii The objectives of this work were to identify the molecular targets of these BCHs in Klebsiella pneumoniae and to investigate their potential BLE activity for cefepime and aztreonam against metallo-β-lactamase (MBL)-producing strains in vitro and in vivo Penicillin binding protein (PBP) binding profiles were determined by Bocillin FL assay, and 50% inhibitory concentrations (IC50s) were determined using ImageQuant TL software. MICs and kill kinetics for zidebactam, WCK 5153, and cefepime or aztreonam, alone and in combination, were determined against clinical K. pneumoniae isolates producing MBLs VIM-1 or NDM-1 (plus ESBLs and class C β-lactamases) to assess the in vitro enhancer effect of BCH compounds in conjunction with β-lactams. Additionally, murine systemic and thigh infection studies were conducted to evaluate BLE effects in vivo Zidebactam and WCK 5153 showed specific, high PBP2 affinity in K. pneumoniae The MICs of BLEs were >64 μg/ml for all MBL-producing strains. Time-kill studies showed that a combination of these BLEs with either cefepime or aztreonam provided 1 to >3 log10 kill against MBL-producing K. pneumoniae strains. Furthermore, the bactericidal synergy observed for these BLE-β-lactam combinations translated well into in vivo efficacy even in the absence of MBL inhibition by BLEs, a characteristic feature of the β-lactam enhancer mechanism of action. Zidebactam and WCK 5153 are potent PBP2 inhibitors and display in vitro and in vivo BLE effects against multidrug-resistant (MDR) K. pneumoniae clinical isolates producing MBLs., This work was supported by Wockhardt Bio AG, Switzerland, and by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund A Way to Achieve Europe ERDF through the Spanish Network for Research in Infectious Diseases (grants number RD12/0015 and RD16/0016).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies

  • González de Aledo, Manuel
  • González-Bardanca, Mónica
  • Blasco, Lucía
  • Pacios Santamaría, Olga
  • Bleriot Rial, Inés
  • Fernández-García, Laura
  • Fernández-Quejo, Melisa
  • López Díaz, María
  • Bou, Germán
  • Tomás, María
This article belongs to the Special Issue Non-antimicrobial Agents as Adjuvants against Bacterial Infections, [Abstract] One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) due to their profile of drug resistance and virulence. Therefore, innovative lines of treatment must be developed for these bacteria. In this review, we summarize the different strategies for the treatment and study of molecular mechanisms of AMR in the ESKAPE pathogens based on the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins’ technologies: loss of plasmid or cellular viability, random mutation or gene deletion as well directed mutations that lead to a gene’s loss of function., This study was funded by grants PI16/01163 and PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research-European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0006) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/, Accessed on 21 June 2021). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López was financially supported by a grant IN606A-2020/035 and IN606B-2018/008, respectively, (GAIN, Xunta de Galicia), and M. Gonzalez-Bardanca was financially supported by the Rio Hortega program (ISCIII, CM20/00198), Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2018/008
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Pneumonia infection in mice reveals the involvement of the feoA gene in the pathogenesis of Acinetobacter baumannii

  • Poza, Margarita
  • Álvarez-Fraga, Laura
  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Vallejo, J. A.
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Acinetobacter baumannii has emerged in the last decade as an important nosocomial pathogen. To identify genes involved in the course of a pneumonia infection, gene expression profiles were obtained from A. baumannii ATCC 17978 grown in mouse infected lungs and in culture medium. Gene expression analysis allowed us to determine a gene, the A1S_0242 gene (feoA), over-expressed during the pneumonia infection. In the present work, we evaluate the role of this gene, involved in iron uptake. The inactivation of the A1S_0242 gene resulted in an increase susceptibility to oxidative stress and a decrease in biofilm formation, in adherence to A549 cells and in fitness. In addition, infection of G. mellonella and pneumonia in mice showed that the virulence of the Δ0242 mutant was significantly attenuated. Data presented in this work indicated that the A1S_0242 gene from A. baumannii ATCC 17978 strain plays a role in fitness, adhesion, biofilm formation, growth, and, definitively, in virulence. Taken together, these observations show the implication of the feoA gene plays in the pathogenesis of A. baumannii and highlight its value as a potential therapeutic target., This work has been funded by Projects PI15/00860 to GB, CP13/00226 to AB, PI11/01034 to MP and P14/00059 and PI17/01482 to MP and AB, all integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe”. The study was also funded by the project IN607A 2016/22 (Consellería de Cultura, Educación e Ordenación Universitaria) to G.B. Also supported by Planes Nacionales de I+D+i 2008–2011 / 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014 and REIPI RD16/0016/006) co-financed by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. J. A. Vallejo was financially supported by the Sara Borrell Programme (ISCIII, Spain CD13/00373), J.C. Vázquez-Ucha was financially supported by the Miguel Servet Programme (ISCIII, Spain CP13/00226) and M. Martínez-Guitián was financially supported by the grant Clara Roy (Spanish Society of Clinical Microbiology and Infectious Diseases). We thank M. I. Voskuil (Dept. of Immunology and Microbiology, University of Colorado Medical School, CO, USA) for providing pMo130., Xunta de Galicia. Consellería de Cultura, Educación e Ordenación Universitaria; IN607A 2016/22
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Characterization of Extended-Spectrum β-Lactamase-Producing Shigella sonnei in Spain: Expanding the Geographic Distribution of Sequence Type 152/CTX-M-27 Clone

  • López-Cerero, Lorena
  • Stolz, Emilio
  • Pulido, Marina R.
  • Pascual, Álvaro
We describe the first occurrence in Spain of community cases of CTX-M-27-producing Shigella sonnei sequence type 152 (ST152), resistant to quinolones and azithromycin. The cases included adult males and also one pediatric case. The isolates were clustered together with an Australian isolate and differed from other outbreak-causing strains in England by more than 50 alleles. They carried the blaCTX-M-27 gene on an 83-Kb F2:A-:B- plasmid, similar to that found in a British isolate., This work was supported by the Plan Nacional de I+D+i 2013 to 2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI; RD16/0016/0001), cofinanced by the European Development Regional Fund “A Way to Achieve Europe,” operative program Intelligent Growth 2014 to 2020. M. R. Pulido is supported by a VIPPI-US fellowship from the University of Seville., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project

  • Mussa, Marco
  • Martínez Pérez-Crespo, Pedro María
  • López-Cortés, Luis Eduardo
  • Retamar Gentil, Pilar
  • Sousa, Adrián
  • Goikoetxea-Aguirre, Josune
  • Reguera Iglesias, José María
  • León Jiménez, Eva
  • Fernández-Natal, Isabel
  • Armiñanzas Castillo, Carlos
  • Boix-Palop, Lucía
  • Cuquet Pedragosa, Jordi
  • Morán Rodríguez, Miguel Ángel
  • Fernández Suárez, Jonathan
  • Arco-Jiménez, Alfonso del
  • Jover-Sáenz, Alfredo
  • Bahamonde-Carrasco, Alberto
  • Galán-Sánchez, Fátima
  • Sánchez Calvo, Juan Manuel
  • Smithson Amat, Alejandro
  • Vinuesa García, David
  • Sánchez-Porto, Antonio
  • López-Hernández, Inmaculada
  • Rodríguez-Baño, Jesús
Biliary-tract bloodstream infections (BT-BSI) caused by Enterococcus faecalis and E. faecium are associated with inappropriate empirical treatment and worse outcomes compared to other etiologies. The objective of this study was to investigate the risk factors for enterococcal BT-BSI. Patients with BT-BSI from the PROBAC cohort, including consecutive patients with BSI in 26 Spanish hospitals between October 2016 and March 2017, were selected; episodes caused by E. faecalis or E. faecium and other causes were compared. Independent predictors for enterococci were identified by logistic regression, and a predictive score was developed. Eight hundred fifty episodes of BT-BSI were included; 73 (8.5%) were due to target Enterococcus spp. (48 [66%] were E. faecium and 25 [34%] E. faecalis). By multivariate analysis, the variables independently associated with Enterococcus spp. were (OR; 95% confidence interval): cholangiocarcinoma (4.48;1.32 to 15.25), hospital acquisition (3.58;2.11 to 6.07), use of carbapenems in the previous month (3.35;1.45 to 7.78), biliary prosthesis (2.19;1.24 to 3.90), and moderate or severe chronic kidney disease (1.55;1.07 to 2.26). The AUC of the model was 0.74 [95% CI0.67 to 0.80]. A score was developed, with 7, 6, 5, 4, and 2 points for these variables, respectively, with a negative predictive value of 95% for a score ≤ 6. A model, including cholangiocarcinoma, biliary prosthesis, hospital acquisition, previous carbapenems, and chronic kidney disease showed moderate prediction ability for enterococcal BT-BSI. Although the score will need to be validated, this information may be useful for deciding empirical therapy in biliary tract infections when bacteremia is suspected. IMPORTANCE Biliary tract infections are frequent, and a significant cause of morbidity and mortality. Bacteremia is common in these infections, particularly in the elderly and patients with cancer. Inappropriate empirical treatment has been associated with increased risk of mortality in bacteremic cholangitis, and the probability of receiving inactive empirical treatment is higher in episodes caused by enterococci. This is because many of the antimicrobial agents recommended in guidelines for biliary tract infections lack activity against these organisms. To the best of our knowledge, this is the first study analyzing the predictive factors for enterococcal BT-BSI and deriving a predictive score., This work was financed by Plan Nacional de I+D+i 2013‐2016, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades, through grants PI16/01432 and Spanish Network for Research in Infectious Diseases (REIPI) [RD16/0016/0001; RD16/0016/0007; and RD16/0016/0012]; co‐financed by European Development Regional Fund “A Way to Achieve Europe,” Operative program Intelligent Growth 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Risk of cardiac device-related infection in patients with late-onset bloodstream infection. Analysis on a National Cohort

  • Boix-Palop, Lucía
  • Dietl, Beatriz
  • Calbo, Esther
  • Di Marco, Andrea
  • Xercavins, Mariona
  • Martínez Pérez-Crespo, Pedro María
  • Sousa, Adrián
  • Montejo, Miguel
  • Rodríguez-Baño, Jesús
  • López-Cortés, Luis Eduardo
[Objectives] To determine the incidence of cardiac device-related infection (CDRI) among patients with cardiac device (CD) during late-onset bloodstream infection (BSI) and to identify the risk factors associated with CDRI., [Methods] Patients with a CD (cardiac implantable electronic devices -CIED- and/or prosthetic heart valve -PHV-) and late-onset-BSI (>1 year after the CD implantation/last manipulation) were selected from the PROBAC project, a prospective, observational cohort study including adult patients with bacteraemia consecutively admitted to 26 Spanish hospitals from October 2016 to March 2017. Multivariate analyses using logistic regression were performed to identify the risk factors associated with CDRI., [Results] 317 BSI from patients carrying a CD were registered, 187 (56.2%) were late-onset-BSI. A total of 40 (21.4%) CDRI were identified during late-onset-BSI. The CDRI cumulative incidence in Gram-positive-BSI was 41.8% (38/91), with S. aureus, Enterococcus spp. and viridans streptococci showing the greatest percentages: 40% (12/30), 42% (11/26) and 75% (6/8), respectively. Independent predictors of CDRI were an unknown source of infection (OR: 2.88 [CI 95%:1.18–7.06], p = 0.02), Gram-positive-aetiology (23.1 [5.23–102.1], p < 0.001) and persistent bacteraemia (4.81 [1.21–19], p = 0.03). In an exploratory analysis, S. aureus (3.99 [1.37–11.65], p = 0.011), Enterococcus spp. (5.21 [1.76–15.4], p = 0.003) and viridans streptococci (28.7 [4.71–173.5], p < 0.001) aetiology were also found to be risk factors for CDRI., [Conclusions] CDRI during late-onset-BSI is a frequent phenomenon. Risk of CDRI differs among species, happening in almost half of the Gram-positive-BSI. An unknown source of the primary infection, Gram-positive-aetiology -especially S. aureus, Enterococcus spp. and viridans streptococci-, and persistent bacteraemia were identified as risk factors for CDRI., This study was funded by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, through the following grants: Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; RD16/0016/0007; RD16/0016/0008; RD16/0016/0012), co-financed by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligent Growth 2014–2020, and PI16/01432., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Role of inorganic phosphate concentrations in in vitro activity of fosfomycin

  • Ortiz-Padilla, Miriam
  • Portillo-Calderón, Inés
  • Maldonado, Natalia
  • Rodríguez-Martínez, José-Manuel
  • Gregorio-Iaria, Belén de
  • Merino-Bohórquez, Vicente
  • Rodríguez-Baño, Jesús
  • Pascual, Álvaro
  • Docobo-Pérez, Fernando
[Objectives] The objective of this study was to evaluate the in vitro activity of fosfomycin under different physiological concentrations of inorganic phosphate (Pi)., [Methods] The wild-type BW25113 strain, four isogenic mutants (ΔglpT, ΔuhpT, ΔglpT-uhpT, and ΔphoB) and six clinical isolates of Escherichia coli with different fosfomycin susceptibilities were used. EUCAST breakpoints were used. Susceptibility was evaluated by agar dilution using standard Mueller–Hinton agar (Pi concentration of 1 mM similar to human plasma concentration) and supplemented with Pi (13 and 42 mM, minimum and maximum urinary Pi concentrations) and/or glucose-6-phosphate (25 mg/L). Fosfomycin transporter promoter activity was assayed using PglpT::gfpmut2 or PuhpT::gfpmut2 promoter fusions in standard Mueller–Hinton Broth (MHB), supplemented with Pi (13 or 42 mM) ± glucose-6-phosphate. Fosfomycin activity was quantified, estimating fosfomycin EC50 under different Pi concentrations (1, 13 and 42 mM + glucose-6-phosphate) and in time–kill assays using fosfomycin concentrations of 307 (maximum plasma concentration (Cmax)), 1053 and 4415 mg/L (urine Cmax range), using MHB with 28 mM Pi (mean urine Pi concentration) + 25 mg/L glucose-6-phosphate., [Results] All the strains showed decreased susceptibility to fosfomycin linked to increased Pi concentrations: 1–4 log2 dilution differences from 1 to 13 mM, and 1–8 log2 dilution differences at 42 mM Pi. Changes in phosphate concentration did not affect the expression of fosfomycin transporters. By increasing Pi concentrations higher fosfomycin EC50 bacterial viability was observed, except against ΔglpT-uhpT. The increase in Pi reduced the bactericidal effect of fosfomycin., [Discussion] Pi variations in physiological fluids may reduce fosfomycin activity against E. coli. Elevated Pi concentrations in urine may explain oral fosfomycin failure in non-wild-type but fosfomycin-susceptible E. coli strains., This study has been funded by Instituto de Salud Carlos III through the projects PI16/01824, PI19/01645 and REIPI RD16/0016/0001 (co-funded by European Regional Development Fund “A way to make Europe”). Miriam Ortiz-Padilla is supported by a PFIS grant from the Instituto de Salud Carlos III (FI17/00235). Inés Portillo-Calderón is supported by a Rio Hortega grant from the Instituto de Salud Carlos III (CM20/0092). (Co-funded by European Social Fund “Investing in your future”)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impact of SARS-CoV-2 RNAemia and other risk factors on long-COVID: A prospective observational multicentre cohort study

  • Rombauts, Alexander
  • Infante, Carmen
  • Álamo Martínez de Lagos, Mikel del
  • Alba, Jorge
  • Valiente, Adoración
  • Donado-Mazarrón, Carla
  • Carretero-Ledesma, Marta
  • Rodríguez-Álvarez, Regino José
  • Omatos, Sonia
  • Palacios-Baena, Zaira Raquel
  • Abelenda, Gabriela
  • Silva-Sánchez, María del Mar
  • Goikoetxea-Aguirre, Josune
  • Oteo, José Antonio
  • Rodríguez-Baño, Jesús
  • Cordero, Elisa
  • Gudiol, Carlota
  • Sánchez-Céspedes, Javier
  • Carratalà, Jordi
As the COVID-19 pandemic has progressed, long-COVID has emerged as a major problem that poses a significant challenge for attending physicians and health care policy makers. Therefore, we read with much interest the recently published unicentre study in the Journal of Infection by Righi et al.,1 carried out on 465 adult COVID-19 patients (235 [50.5%] hospital-admitted) followed-up during nine months, concluding that those with advanced age, intensive care unit (ICU) admission, and multiple symptoms at onset were more likely to have long-term COVID-19 symptoms, with negative impact on physical and mental wellbeing. Other studies have found that female gender, age, longer hospital stay, pre-existing hypertension, cardiovascular disease, diabetes, chronic obstructive pulmonary disease, smoking, obesity, and chronic alcoholism increase the likelihood of long-COVID.2,3 It is known that SARS-CoV-2 RNAemia is a predictor of COVID-19 severity and in-hospital complications.4,5 However, to the best of our knowledge, only two studies have assessed, up to one or three months after the acute COVID-19 onset, whether SARS-CoV-2 RNAemia may have an impact on long-COVID,6,7 both finding that RNAemia at presentation might predict the persistence of symptoms. However, these studies did not provide information regarding long-COVID symptoms nor the association with SARS-CoV-2 RNAemia beyond three months, and could not differentiate between “true” long-COVID and the convalescence phase of the SARS-CoV-2 infection., A.R. has received a predoctoral research grant from the Instituto de Salud Carlos III, Spanish Ministry of Science, Innovation and Universities, (PFIS grant FI18/00183). G.A.A. reports a predoctoral research grant from the 201808-10 project, funded by La Marató de TV3. This study was supported by the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, the Spanish Network for Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0005, RD16/0016/0009, RD16/0016/0013)-co-financed by the European Development Regional Fund, A way to achieve Europe, Operative program Intelligent Growth 2014-2020, and the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) [CB21/13/00009; CB21/13/00006], Madrid, Spain. J.S.C. and E.C. received grants from the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Proyectos de Investigación sobre el SARS-CoV-2 y la enfermedad COVID-19 (COV20/00580; COV20/00370). J.S.C. is a researcher belonging to the program “Nicolás Monardes” (C-0059–2018), Servicio Andaluz de Salud, Junta de Andalucía, Spain. Samples and data from patients included in this study from the Hospital Universitario Cruces (Bizkaia, Spain) were provided by the Basque Biobank (www.biobancovasco.org) and were processed following standard operation procedures with appropriate approval of the Ethical and Scientific Committees., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CRISPR-Cas13a-Based Assay for Accurate Detection of OXA-48 and GES Carbapenemases

  • Ortiz-Cartagena, Concha
  • Pablo-Marcos, Daniel
  • Fernández-García, Laura
  • Blasco, Lucía
  • Pacios, Olga
  • Bleriot, Inés
  • Siller, María
  • López, María
  • Fernández, Javier
  • Aracil, Belén
  • Fraile-Ribot, Pablo Arturo
  • García-Fernández, Sergio
  • Fernández-Cuenca, Felipe
  • Hernández-García, Marta
  • Cantón, Rafael
  • Calvo-Montes, Jorge
  • Tomás, María
© 2023 Ortiz-Cartagena et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license., Carbapenem-resistant pathogens have been recognized as a health concern as they are both difficult to treat and detect in clinical microbiology laboratories. Researchers are making great efforts to develop highly specific, sensitive, accurate, and rapid diagnostic techniques, required to prevent the spread of these microorganisms and improve the prognosis of patients. In this context, CRISPR-Cas systems are proposed as promising tools for the development of diagnostic methods due to their high specificity; the Cas13a endonuclease can discriminate single nucleotide changes and displays collateral cleavage activity against single-stranded RNA molecules when activated. This technology is usually combined with isothermal pre-amplification reactions in order to increase its sensitivity. We have developed a new LAMP-CRISPR-Cas13a-based assay for the detection of OXA-48 and GES carbapenemases in clinical samples without the need for nucleic acid purification and concentration. To evaluate the assay, we used 68 OXA-48-like-producing Klebsiella pneumoniae clinical isolates as well as 64 Enterobacter cloacae complex GES-6, 14 Pseudomonas aeruginosa GES-5, 9 Serratia marcescens GES-6, 5 P. aeruginosa GES-6, and 3 P. aeruginosa (GES-15, GES-27, and GES-40) and 1 K. pneumoniae GES-2 isolates. The assay, which takes less than 2 h and costs approximately 10 € per reaction, exhibited 100% specificity and sensitivity (99% confidence interval [CI]) for both OXA-48 and all GES carbapenemases. IMPORTANCE Carbapenems are one of the last-resort antibiotics for defense against multidrug-resistant pathogens. Multiple nucleic acid amplification methods, including multiplex PCR, multiplex loop-mediated isothermal amplification (LAMP) and multiplex RPAs, can achieve rapid, accurate, and simultaneous detection of several resistance genes to carbapenems in a single reaction. However, these assays need thermal cycling steps and specialized instruments, giving them limited application in the field. In this work, we adapted with high specificity and sensitivity values, a new LAMP CRISPR-Cas13a-based assay for the detection of OXA-48 and GES carbapenemases in clinical samples without the need for RNA extraction., This study was funded by grants PI19/00878 and PI22/00323 awarded to M. Tomás, within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research - European Regional Development Fund “A Way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0006 and CIBER CB21/13/00012, CB21/13/00084 and CB21/13/00095), Instituto de Salud Carlos III FEDER. The research was also funded by grant IN607D 2021/10 within the GAIN (Agencia Gallega de Innovación) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/), and finally an ESCMID grant (European Society of Clinical Microbiology and Infectious Diseases) awarded to L. Fernández-García. O. Pacios, L. Fernández-García, and M. López were financially supported by the grants IN606A-2020/035, IN606B-2021/013 and IN606C-2022/002, respectively (GAIN, Xunta de Galicia). D. Pablo-Marcos was financially supported by a López Albo grant. I. Bleriot was financially supported by pFIS pro- 511 g (ISCIII, FI20/00302)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa, Evaluación de 3 métodos comerciales de determinación de sensibilidad de ceftolozano/tazobactam frente a Pseudomonas aeruginosa resistente a las carbapenemas

  • López-Cerero, Lorena
  • Ballesta, Sofía
  • Elías-López, Cristina
  • Sánchez-Yebra, Waldo
  • Rojo-Martín, María Dolores
  • Pascual, Álvaro
[EN] Introduction: Ceftolozane/tazobactam has shown excellent activity against Pseudomonas aeruginosa, but this drug is not always included in commercial panels. The aim of the study was to evaluate the performance of 2 gradient strips (BioMérieux and Liofilchem) and a commercial microdilution panel (Sensititre, EURGNCOL panel) using this combination against carbapenem-resistant P. aeruginosa isolates. Methods: Three commercial methods were tested with 41 metallo-beta-lactamase-producing and 59 non-carbapenemase-producing P. aeruginosa isolates. Broth microdilution was used as reference. Results: All carbapenemase-producing isolates and only one non-producing isolate were resistant to this antibiotic. Both essential agreement and bias were outside the acceptance intervals since MIC values were higher than reference values for all three methods. The Kappa index indicated poor or weak agreement. Changes in clinical categories were observed in 3 isolates. Conclusions: The three methods yielded poor agreement with the reference. Despite the differences in MIC values, fewer than 3% involved category changes., [ES] Introducción: La combinación ceftolozano/tazobactam ha mostrado una actividad excelente frente a Pseudomonas aeruginosa, pero este fármaco no siempre se incluye en los paneles comerciales. El objetivo de este estudio es evaluar el rendimiento de 2 tiras de gradiente (BioMérieux® y Liofilchem®) y un panel de microdilución comercial (Sensititre®, panel EURGNCOL) utilizando esta combinación frente a aislados de P. aeruginosa resistente a los carbapenémicos. Métodos: Se probaron 3 métodos comerciales con 41 aislados productores de metalobetalactamasas y 59 aislados no productores de carbapenemasas de P. aeruginosa. La microdilución de caldo se utilizó como referencia. Resultados: Todos los aislados productores de carbapenemasas y solo un aislado no productor fueron resistentes a este antibiótico. Tanto la concordancia esencial como el sesgo se encontraron fuera de los intervalos de aceptación, dado que los valores CMI eran superiores que los valores de referencia para los 3 métodos. El índice de Kappa indicó una concordancia pobre o débil. Se observaron cambios en las categorías clínicas en 3 aislados. Conclusiones: Los 3 métodos presentaron una baja concordancia con la microdilución de referencia. A pesar de las diferencias en los valores MIC, menos del 3% implicaron cambios de categoría., This study has been funded by Instituto de Salud Carlos III, Spanish Network for Research in Infectious Diseases (RD16/0016/0001)-co-financed by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014-2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impact of adherence to individual quality-of-care indicators on the prognosis of bloodstream infection due to Staphylococcus aureus: a prospective observational multicentre cohort

  • Escrihuela-Vidal, Francesc
  • Kaasch, Achim J.
  • Cube, Maja Von
  • Rieg, Siegbert
  • Kern, Winfried V.
  • Seifert, Harald
  • Song, Kyoung-Ho
  • Liao, Chun-Hsing
  • Tilley, Robert
  • Gott, Hannah
  • Scarborough, Matt
  • Gordon, Claire
  • Llewelyn, Martin J.
  • Kuehl, Richard
  • Morata, Laura
  • Soriano, Álex
  • Edgeworth, Jonathan
  • Ruiz-de-Gopegui, Enrique
  • Nsutebu, Emmanuel
  • Cisneros, José Miguel
  • Fowler, Vance G.
  • Thwaites, Guy
  • López-Contreras, Joaquín
  • Barlow, Gavin
  • Ternavasio-de la Vega, Hugo-Guillermo
  • Rodríguez-Baño, Jesús
  • López-Cortés, Luis Eduardo
  • International Staphylococcus Aureus Collaboration Study Group, The European Society of Clinical Microbiology and Infectious Diseases Study Group For Bloodstream Infections, Endocarditis And Sepsis
© 2022 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Objectives] To analyse the adherence and impact of quality-of-care indicators (QCIs) in the management of Staphylococcus aureus bloodstream infection in a prospective and multicentre cohort., [Methods] Analysis of the prospective, multicentre international S. Aureus Collaboration cohort of S. Aureus bloodstream infection cases observed between January 2013 and April 2015. Multivariable analysis was performed to evaluate the impact of adherence to QCIs on 90-day mortality., [Results] A total of 1784 cases were included. Overall, 90-day mortality was 29.9% and mean follow-up period was 118 days. Adherence was 67% (n = 1180/1762) for follow-up blood cultures, 31% (n = 416/1342) for early focus control, 77.6% (n = 546/704) for performance of echocardiography, 75.5% (n = 1348/1784) for adequacy of targeted antimicrobial therapy, 88.6% (n = 851/960) for adequacy of treatment duration in non-complicated bloodstream infections and 61.2% (n = 366/598) in complicated bloodstream infections. Full bundle adherence was 18.4% (n = 328/1784). After controlling for immortal time bias and potential confounders, focus control (adjusted hazard ratio = 0.76; 95% CI, 0.59–0.99; p 0.038) and adequate targeted antimicrobial therapy (adjusted hazard ratio = 0.75; 95% CI, 0.61–0.91; p 0.004) were associated with low 90-day mortality., [Discussion] Adherence to QCIs in S. Aureus bloodstream infection did not reach expected rates. Apart from the benefits of application as a bundle, focus control and adequate targeted therapy were independently associated with low mortality., The ISAC-01 study did not receive dedicated funding. Funding for data acquisition of patients who were also enrolled in the ARREST study was provided by the United Kingdom National Institute for Health Research Health Technology Assessment. The funding organizations had no influence on the design of the study, the collection, analysis and interpretation of the data as well as the decision to approve publication of the finished manuscript. A.S.W. is supported by the National Institutes of Health Research Biomedical Research Centre, Oxford. L.E.L.C. and J.R.B. are supported by Plan Nacional de I + D + I 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (RD16/0016/0001)-co-financed by European Development Regional Fund ‘A way to achieve Europe, Operative program Intelligent Growth 2014-2020’. G.T. is supported by the Wellcome trust., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals: the COMBACTE-NET ARTHR-IS multi-centre study

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad
  • Mur, Isabel
  • Tedeschi, Sara
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa
  • Murillo, Óscar
  • Soldevila-Boixader, Laura
  • Scarborough, Mathew
  • Scarborough, Claire
  • Kluytmans, Jan
  • Ferrari, Matteo Carlo
  • Pletz, Mathias W.
  • Mcnamara, Iain
  • Escudero-Sánchez, Rosa
  • Arvieux, Cédric
  • Batailler, Cecile
  • Dauchy, Frédéric-Antoine
  • Liu, Wai-Yan
  • Lora-Tamayo, Jaime
  • Praena-Segovia, Julia
  • Ustianowski, Andrew
  • Cinconze, Elisa
  • Pellegrini, Michele
  • Bagnoli, Fabio
  • Rodríguez-Baño, Jesús
  • Toro, María Dolores del
© 2023 The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Background] The aim of this study was to estimate the incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infections (SA-PJI) after primary hip and knee arthroplasty in European centres., [Methods] This study was conducted in patients who underwent primary hip and knee arthroplasty in 19 European hospitals between 2014 and 2016. The global incidence of PJI and SA-PJI was calculated. The associated disease burden was measured indirectly as infection-related mortality plus loss of function. For healthcare utilization, number and duration of hospitalizations, number and type of surgical procedures, duration of antibiotic treatments, and number of outpatient visits were collected. Subgroup and regression analyses were used to evaluate the impact of SA-PJI on healthcare utilization, controlling for confounding variables., [Results] The incidence of PJI caused by any micro-organism was 1.41%, and 0.40% for SA-PJI. Among SA-PJI, 20.7% were due to MRSA with substantial regional differences, and were more frequent in partial hip arthroplasty (PHA). Related deaths and loss of function occurred in 7.0% and 10.2% of SA-PJI cases, respectively, and were higher in patients with PHA. Compared with patients without PJI, patients with SA-PJI had a mean of 1.4 more readmissions, 25.1 more days of hospitalization, underwent 1.8 more surgical procedures, and had 5.4 more outpatient visits, controlling for confounding variables. Healthcare utilization was higher in patients who failed surgical treatment of SA-PJI., [Conclusions] This study confirmed that the SA-PJI burden is high, especially in PHA, and provided a solid basis for planning interventions to prevent SA-PJI., This work was supported by the Innovative Medicines Initiative Joint Undertaking (grant agreement No. 115523), COMBACTE-NET consortium (European Union FP7/2007–2013 and GlaxoSmithKline Biologicals SA, as EFPIA partner). R.E., L.S, O.M., R.E.-S., J.L.-T., J.P., J.R.-B. and M.D.del T. are members of the Spanish Network for Research in Infectious Diseases (REIPI), supported by the Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0005; 0009; 0011; 0015), co-financed by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligence Growth 2014–2020. M.W.P. was partly supported by the German Research Foundation (GRK 2723, project number 444711651)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae

  • López-Argüello, Silvia
  • Montaner, Maria
  • Mármol-Salvador, Amanda
  • Velázquez-Escudero, Ana
  • Docobo-Pérez, Fernando
  • Oliver, Antonio
  • Moyà, Bartolomé
© 2023 López-Argüello et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license., The lack of effective first-line antibiotic treatments against Neisseria gonorrhoeae, and the worldwide dissemination of resistant strains, are the main drivers of a worsening global health crisis. β-lactam antibiotics have been the backbone of therapeutic armamentarium against gonococci. However, we are lacking critical insights to design rationally optimized therapies. In the present work, we generated the first PBP-binding data set on 18 currently available and clinically relevant β-lactams and 4 β-lactamase inhibitors in two N. gonorrhoeae ATCC type collection strains, 19424 and 49226 (PBP2 type XXII and A39T change in mtrR). PBP binding (IC50) was determined via the Bocillin FL binding assay in isolated membrane preparations. Three clusters of differential PBP IC50s were identified and were mostly consistent across both strains, but with quantitative differences. Carbapenems were coselective for PBP2 and PBP3 (0.01 to 0.03 mg/L). Third- and fourth-generation cephalosporins cefixime, cefotaxime, ceftazidime, cefepime, and ceftriaxone showed the lowest IC50 values for PBP2 (0.01 mg/L), whereas cefoxitin, ceftaroline, and ceftolozane required higher concentrations (0.04 to >2 mg/L). Aztreonam was selective for PBP2 in both strains (0.03 to 0.07 mg/L); amdinocillin bound this PBP at higher concentrations (1.33 to 2.94 mg/L). Penicillins specifically targeted PBP2 in strain ATCC 19424 (0.02 to 0.19 mg/L) and showed limited inhibition in strain ATCC 49226 (0.01 to >2 mg/L). Preferential PBP2 binding was observed by β-lactam-based β-lactamase inhibitors sulbactam and tazobactam (1.07 to 6.02 mg/L); meanwhile, diazabicyclooctane inhibitors relebactam and avibactam were selective for PBP3 (1.27 to 5.40 mg/L). This data set will set the bar for future studies that will help the rational use and translational development of antibiotics against multidrug-resistant (MDR) N. gonorrhoeae., B.M. received funds from a RADIX17/3-1 fellowship and RADIX17/3-2 grant, programs within the FUTURMed project IdISBa Research Institute of Health Sciences of the Balearic Islands, Hospital Universitario Son Espases, Palma, Spain. Call funded by the 2017 annual plan of the sustainable tourism tax. Govern de les Illes Balears, by the Miguel Servet Research Contract Program CP20/00138 from the National Institutes of Health Carlos III (ISCIII) and by the Agencia Estatal de Investigación (AEI - State Research Agency), Spain, through the Plan Estatal de Investigación Científica PROYECTOS DE I+D+i PID2020-112654RB-I00 / AEI / 10.13039/501100011033. The assay development part of this work was supported by the award R01AI136803 to B.M. from the National Institute of Allergy and Infectious Diseases (NIAID). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health (NIH). A.O. received funds from the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, cofinanced by European Regional Development Fund “A Way to Achieve Europe” ERDF, through the Spanish Network for the Research in Infectious Diseases (RD16/0016). A.O. has received fees as speaker and/or research grants from MSD, Pfizer, and Wockhardt., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Research data Set de datos (Dataset)

Supplementary data for López-Argüello et al; Penicillin-binding protein occupancy dataset for 18 β-lactams and 4 β-lactamase inhibitors in Neisseria gonorrhoeae

  • López-Argüello, Silvia
  • Montaner, Maria
  • Mármol-Salvador, Amanda
  • Velázquez-Escudero, Ana
  • Docobo-Pérez, Fernando
  • Oliver, Antonio
  • Moyà, Bartolomé
Contains: Figures S1-S2 and Table S1., The lack of effective first-line antibiotic treatments against Neisseria gonorrhoeae, and the worldwide dissemination of resistant strains, are the main drivers of a worsening global health crisis. β-lactam antibiotics have been the backbone of therapeutic armamentarium against gonococci. However, we are lacking critical insights to design rationally optimized therapies. In the present work, we generated the first PBP-binding data set on 18 currently available and clinically relevant β-lactams and 4 β-lactamase inhibitors in two N. gonorrhoeae ATCC type collection strains, 19424 and 49226 (PBP2 type XXII and A39T change in mtrR). PBP binding (IC50) was determined via the Bocillin FL binding assay in isolated membrane preparations. Three clusters of differential PBP IC50s were identified and were mostly consistent across both strains, but with quantitative differences. Carbapenems were coselective for PBP2 and PBP3 (0.01 to 0.03 mg/L). Third- and fourth-generation cephalosporins cefixime, cefotaxime, ceftazidime, cefepime, and ceftriaxone showed the lowest IC50 values for PBP2 (0.01 mg/L), whereas cefoxitin, ceftaroline, and ceftolozane required higher concentrations (0.04 to >2 mg/L). Aztreonam was selective for PBP2 in both strains (0.03 to 0.07 mg/L); amdinocillin bound this PBP at higher concentrations (1.33 to 2.94 mg/L). Penicillins specifically targeted PBP2 in strain ATCC 19424 (0.02 to 0.19 mg/L) and showed limited inhibition in strain ATCC 49226 (0.01 to >2 mg/L). Preferential PBP2 binding was observed by β-lactam-based β-lactamase inhibitors sulbactam and tazobactam (1.07 to 6.02 mg/L); meanwhile, diazabicyclooctane inhibitors relebactam and avibactam were selective for PBP3 (1.27 to 5.40 mg/L). This data set will set the bar for future studies that will help the rational use and translational development of antibiotics against multidrug-resistant (MDR) N. gonorrhoeae., B.M. received funds from a RADIX17/3-1 fellowship and RADIX17/3-2 grant, programs within the FUTURMed project IdISBa Research Institute of Health Sciences of the Balearic Islands, Hospital Universitario Son Espases, Palma, Spain. Call funded by the 2017 annual plan of the sustainable tourism tax. Govern de les Illes Balears, by the Miguel Servet Research Contract Program CP20/00138 from the National Institutes of Health Carlos III (ISCIII) and by the Agencia Estatal de Investigación (AEI - State Research Agency), Spain, through the Plan Estatal de Investigación Científica PROYECTOS DE I+D+i PID2020-112654RB-I00 / AEI / 10.13039/501100011033. The assay development part of this work was supported by the award R01AI136803 to B.M. from the National Institute of Allergy and Infectious Diseases (NIAID). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health (NIH). A.O. received funds from the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, cofinanced by European Regional Development Fund “A Way to Achieve Europe” ERDF, through the Spanish Network for the Research in Infectious Diseases (RD16/0016). A.O. has received fees as speaker and/or research grants from MSD, Pfizer, and Wockhardt., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prepandemic viral community-acquired pneumonia: Diagnostic sensitivity and specificity of nasopharyngeal swabs and performance of clinical severity scores

  • Berastegui-Cabrera, Judith
  • Aguilar Guisado, Manuela
  • Crespo-Rivas, Juan Carlos
  • López-Verdugo, Macarena
  • Merino Díaz, Laura
  • Escoresca-Ortega, Ana
  • Calero-Acuña, Carmen
  • Carrasco Hernández, Laura
  • Toral-Marín, Javier Ignacio
  • Abad Arranz, María
  • Ramírez-Duque, Nieves
  • Barón Franco, Bosco
  • Pachón, Jerónimo
  • Álvarez-Marín, Rocío
  • Sánchez-Céspedes, Javier
© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., The objectives of this work were to assess the diagnostic sensitivity and specificity of nasopharyngeal (NP) swabs for viral community-acquired pneumonia (CAP) and the performance of pneumonia severity index (PSI) and CURB-65 severity scores in the viral CAP in adults. A prospective observational cohort study of consecutive 341 hospitalized adults with CAP was performed between January 2018 and March 2020. Demographics, comorbidities, symptoms/signs, analytical data, severity scores, antimicrobials, and outcomes were recorded. Blood, NP swabs, sputum, and urine samples were collected at admission and assayed by multiplex real time-PCR, bacterial cultures, and Streptococcus pneumoniae and Legionella pneumophila antigens detection, to determine the etiologies and quantify the viral load. The etiology was identified in 174 (51.0%) patients, and in 85 (24.9%) it was viral, the most frequent rhinovirus and influenza virus. The sensitivity of viral detection in sputum (50.7%) was higher than in NP swabs (20.9%). Compared with sputum, the positive predictive value and specificity of NP swabs for viral diagnosis were 95.8% and 96.9%, respectively. Performance of PSI and CURB-65 scores in all CAP with etiologic diagnosis were as expected, with mortality associated with higher values, but they were not associated with mortality in patients with viral pneumonia. NP swabs have lower sensitivity but high specificity for the diagnosis of viral CAP in adults compared with sputum, reinforcing the use NP swabs for the diagnostic etiology work-up. The PSI and CURB-65 scores did not predict mortality in the viral CAP, suggesting that they need to be updated scores based on the identification of the etiological agent., This work was supported by National Plan R + D + I 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministry of Economy, Industry, and Competitiveness, Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0009]; cofinanced by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020; and supported by the grant PI17/01055 from the Instituto de Salud Carlos III. MAG, RAM and JSC [grant number CB21/13/00006] also received support from the CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, cofinanced by the European Development Regional Fund. J.S.C. is a researcher belonging to the program “Nicolás Monardes” (C-0059-2018), Servicio Andaluz de Salud, Junta de Andalucía, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Proteomic Study of the Interactions between Phages and the Bacterial Host Klebsiella pneumoniae

  • Bleriot, Inés
  • Blasco, Lucía
  • Pacios, Olga
  • Fernández-García, Laura
  • López, María
  • Ortiz-Cartagena, Concha
  • Barrio-Pujante, Antonio
  • Fernández-C
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Oteo-Iglesias, Jesús
  • Tomás, María
© 2023 Bleriot et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license., Phages and bacteria have acquired resistance mechanisms for protection. In this context, the aims of the present study were to analyze the proteins isolated from 21 novel lytic phages of Klebsiella pneumoniae in search of defense mechanisms against bacteria and also to determine the infective capacity of the phages. A proteomic study was also conducted to investigate the defense mechanisms of two clinical isolates of K. pneumoniae infected by phages. For this purpose, the 21 lytic phages were sequenced and de novo assembled. The host range was determined in a collection of 47 clinical isolates of K. pneumoniae, revealing the variable infective capacity of the phages. Genome sequencing showed that all of the phages were lytic phages belonging to the order Caudovirales. Phage sequence analysis revealed that the proteins were organized in functional modules within the genome. Although most of the proteins have unknown functions, multiple proteins were associated with defense mechanisms against bacteria, including the restriction-modification system, the toxin-antitoxin system, evasion of DNA degradation, blocking of host restriction and modification, the orphan CRISPR-Cas system, and the anti-CRISPR system. Proteomic study of the phage-host interactions (i.e., between isolates K3574 and K3320, which have intact CRISPR-Cas systems, and phages vB_KpnS-VAC35 and vB_KpnM-VAC36, respectively) revealed the presence of several defense mechanisms against phage infection (prophage, defense/virulence/resistance, oxidative stress and plasmid proteins) in the bacteria, and of the Acr candidate (anti-CRISPR protein) in the phages., This study was funded by grant PI19/00878 and PI22/00323 awarded to M.T. within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development, and Innovation 2008-2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research/European Regional Development Fund “A Way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI; RD16/0016/0006 and RD16/0016/0008), CIBERINFEC (CIBER21/13/00012, CB21/13/00049, CIBER21/13/00084, and CIBER21/13/00095), and Personalized Medicine Project (MePRAM; PMP/00092) and also by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC; http://www.seimc.org/). M.T. was financially supported by the Miguel Servet Research Program (SERGAS and ISCIII). I.B. was financially supported by pFIS program (ISCIII, FI20/00302). O.P., L.F.-G., and M.L. were financially supported by grants IN606A-2020/035, IN606B-2021/013, and IN606C-2022/002, respectively (GAIN; Xunta de Galicia)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RecA inactivation as a strategy to reverse the heteroresistance phenomenon in clinical isolates of Escherichia coli

  • Díaz-Díaz, Sara
  • Yerbes, Pilar
  • Recacha, Esther
  • Gregorio-Iaria, Belén de
  • Pulido, Marina R.
  • Romero-Muñoz, María
  • Docobo-Pérez, Fernando
  • Pascual, Álvaro
  • Rodríguez-Martínez, José-Manuel
RecA inhibition could be an important strategy to combat antimicrobial resistance because of its key role in the SOS response, DNA repair and homologous recombination contributing to bacterial survival. This study evaluated the impact of RecA inactivation on heteroresistance in clinical isolates of Escherichia coli and their corresponding recA-deficient isogenic strains to multiple classes of antimicrobial agents. A high frequency (>30%) of heteroresistance was observed in this collection of clinical isolates. Deletion of the recA gene led to a marked reduction in heteroresistant subpopulations, especially against quinolones or β-lactams. The molecular basis of heteroresistance was associated with an increase in copy number of plasmid-borne resistance genes (blaTEM-1B) or tandem gene amplifications (qnrA1). Of note, in the absence of the recA gene, the increase in copy number of resistance genes was suppressed. This makes the recA gene a promising target for combating heteroresistance., This work was supported by the Plan Nacional de I+D+i 2013–2016 and the Instituto de Salud Carlos III [projects PI17/01501 and PI20/00239], Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI) [RD16/0016/0001 and RD16/0016/0009]—co‐financed by European Development Regional Fund ‘A way to achieve Europe’, Operative program Intelligent Growth 2014–2020. SD-D is supported by a PFIS grant from the Instituto de Salud Carlos III [FI18/00086], co-funded by ESF ‘Investing in your future’. ER is supported by a Juan Rodés Grant from the Instituto de Salud Carlos III [JR21/00030], co-funded by ESF ‘Investing in your future’. MRP is supported by a VIPPI-US fellowship from the University of Seville. MR-M is supported by the Fondo Social Europeo [EJ5-91, Programa Iniciativa de Empleo Juvenil]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inhibition of adenovirus transport from the endosome to the cell nucleus by rotenone

  • Balsera-Manzanero, María
  • Ghirga, Francesca
  • Ruiz-Molina, Ana
  • Mori, Mattia
  • Pachón, Jerónimo
  • Botta, Bruno
  • Cordero-Matía, Elisa
  • Quaglio, Deborah
  • Sánchez-Céspedes, Javier
© 2024 Balsera-Manzanero, Ghirga, Ruiz-Molina, Mori, Pachón, Botta, Cordero, Quaglio and Sánchez-Céspedes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms., Regardless of the clinical impact of human adenovirus (HAdV) infections in the healthy population and its high morbidity in immunosuppressed patients, a specific treatment is still not yet available. In this study, we screened the CM1407 COST Action’s chemical library, comprising 1,233 natural products to identify compounds that restrict HAdV infection. Among them, we identified rotenolone, a compound that significantly inhibited HAdV infection. Next, we selected four isoflavonoid-type compounds (e.g., rotenone, deguelin, millettone, and tephrosin), namely rotenoids, structurally related to rotenolone in order to evaluate and characterized in vitro their antiviral activities against HAdV and human cytomegalovirus (HCMV). Their IC50 values for HAdV ranged from 0.0039 µM for rotenone to 0.07 µM for tephrosin, with selective indices ranging from 164.1 for rotenone to 2,429.3 for deguelin. In addition, the inhibition of HCMV replication ranged from 50% to 92.1% at twice the IC50 concentrations obtained in the plaque assay for each compound against HAdV. Our results indicated that the mechanisms of action of rotenolone, deguelin, and tephrosin involve the late stages of the HAdV replication cycle. However, the antiviral mechanism of action of rotenone appears to involve the alteration of the microtubular polymerization, which prevents HAdV particles from reaching the nuclear membrane of the cell. These isoflavonoid-type compounds exert high antiviral activity against HAdV at nanomolar concentrations, and can be considered strong hit candidates for the development of a new class of broad-spectrum antiviral drugs., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was partially supported by EU funding within the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT). This work was partially supported by the Plan Nacional de I + D + i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009), cofinanced by the European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 20142020, the Instituto de Salud Carlos III, Proyectos de Investigación en Salud (PI18/01191), and Proyectos de Desarrollo Tecnológico en Salud (DTS20/00010). JS-C and EC (CB21/13/00006) also were supported by CIBERINFEC—Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea–NextGenerationEU. JS-C is a researcher belonging to the program “Nicolás Monardes” (C-0059-2018), Servicio Andaluz de Salud, Junta de Andalucía, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Rapid Phenotypic Convergence towards Collateral Sensitivity in Clinical Isolates of Pseudomonas aeruginosa Presenting Different Genomic Backgrounds

  • Hernando-Amado, Sara
  • López-Causapé, Carla
  • Laborda, Pablo
  • Sanz-García, Fernando
  • Oliver, Antonio
  • Martínez Menéndez, José Luis
Collateral sensitivity (CS) is an evolutionary trade-off by which acquisition of resistance to an antibiotic leads to increased susceptibility to another. This Achilles' heel of antibiotic resistance could be exploited to design evolution-based strategies for treating bacterial infections. To date, most studies in the field have focused on the identification of CS patterns in model strains. However, one of the main requirements for the clinical application of this trade-off is that it must be robust and has to emerge in different genomic backgrounds, including preexisting drug-resistant isolates, since infections are frequently caused by pathogens already resistant to antibiotics. Here, we report the first analysis of CS robustness in clinical strains of Pseudomonas aeruginosa presenting different ab initio mutational resistomes. We identified a robust CS pattern associated with short-term evolution in the presence of ciprofloxacin of clinical P. aeruginosa isolates, including representatives of high-risk epidemic clones belonging to sequence type (ST) 111, ST175, and ST244. We observed the acquisition of different ciprofloxacin resistance mutations in strains presenting varied STs and different preexisting mutational resistomes. Importantly, despite these genetic differences, the use of ciprofloxacin led to a robust CS to aztreonam and tobramycin. In addition, we describe the possible application of this evolutionary trade-off to drive P. aeruginosa infections to extinction by using the combination of ciprofloxacin-tobramycin or ciprofloxacin-aztreonam. Our results support the notion that the identification of robust patterns of CS may establish the basis for developing evolution-informed treatment strategies to tackle bacterial infections, including those due to antibiotic-resistant pathogens. IMPORTANCE Collateral sensitivity (CS) is a trade-off of antibiotic resistance evolution that could be exploited to design strategies for treating bacterial infections. Clinical application of CS requires it to robustly emerge in different genomic backgrounds. In this study, we performed an analysis to identify robust patterns of CS associated with the use of ciprofloxacin in clinical isolates of P. aeruginosa presenting different mutational resistomes and including high-risk epidemic clones (ST111, ST175, and ST244). We demonstrate the robustness of CS to tobramycin and aztreonam and the potential application of this evolutionary observation to drive P. aeruginosa infections to extinction. Our results support the notion that the identification of robust CS patterns may establish the basis for developing evolutionary strategies to tackle bacterial infections, including those due to antibiotic-resistant pathogens., This work was supported by Instituto de Salud Carlos III (grants RD16/0016/0011 and RD16/0016/0004)—cofinanced by the European Development Regional Fund “A Way to Achieve Europe,” by grant S2017/BMD-3691 InGEMICS-CM, funded by Comunidad de Madrid (Spain) and European Structural and Investment Funds, and by MCIN/AEI/10.13039/ 501100011033—grants PID2020-113521RB-I00 and “Severo Ochoa” Program for Centers of Excellence in R&D (SEV-2017-0712). P.L. is the recipient of an FPU fellowship from MINECO. C.L.-C. is the recipient of a Juan Rodes fellowship from Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Drivers of extended-spectrum β-lactamase (ESBL)- producing Enterobacterales colonization among residents of long-term care facilities: a European multicentre prospective cohort study

  • Göpel, Siri
  • Guther, Julia
  • Gladstone, Beryl Primrose
  • Conzelmann, Nadine
  • Bunk, Stefanie
  • Terzer, Tobias
  • Verschuuren, T. D.
  • Martak, Daniel
  • Salamanca, Elena
  • Autenrieth, I. B.
  • Peter, Silke
  • Kluytmans, Jan
  • Hocquet, Didier
  • Rodríguez-Baño, Jesús
  • Tacconelli, Evelina
The preliminary results of this study were presented online at the 30th European Congress of Clinical Microbiology and Infectious Diseases in Paris, France in April 2020 (Abstract # 6724)., MODERN WP1 Study Group (in addition to the authors listed above) Tübingen: Simone Eisenbeis, Florian Hölzl. Seville: Alvaro Pascual, Rocío Medina. Utrecht: Ad Fluit. All the authors stated above meet the required criteria of the International Committee of Medical Journal Editors., Background: Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-PE) are highly prevalent in long-term care (LTCF) settings. In order to estimate the acquisition rate of ESBL-producing Escherichia coli and Klebsiella pneumoniae in LTCF settings, and identify clinical and environmental risk factors, a multi-centre, prospective cohort study was conducted in six LTCFs in Germany, France, Spain and the Netherlands., Methods: Longitudinal screening of residents was performed over 32 weeks, collecting epidemiological and clinical data and environmental samples. The primary outcome was the rate of new acquisition of ESBL-PE among LTCF residents. Molecular epidemiology was studied using whole genome sequencing, and risk factor analysis was undertaken using logistic and Poisson regression models., Results: In total, 299 residents provided 1958 samples during follow-up. The prevalence of ESBL-PE colonization at baseline was 16.4%, and the incidence of acquisition was 0.79 per 1000 resident-days, both with high variability between LTCFs. Age ≥80 years, vascular disease and antibiotic consumption within the preceding year were risk factors for baseline colonization. Lack of hand sanitizers and a low nurse:resident ratio were associated with colonization. The presence of medical devices was associated with risk of acquisition. Vascular disease, hemiplegia, antibiotic consumption, and non-availability of private bathrooms were associated with carriage of multiple sequence types (STs). The prevalence of ESBL-PE among environmental samples was 2%, exclusively in LTCFs with high prevalence among residents. Genetic analysis showed a high prevalence of ST10 E. coli and ST405 K. pneumoniae at two study sites., Conclusion: Infection prevention interventions, including availability of hand sanitizers, the number of nurses per resident, and antimicrobial stewardship, constitute important measures to control ESBL-PE in LTCFs. Genome-based surveillance could guide targeted interventions., This study was part of a Joint Programming Initiative on Antimicrobial Resistance collaborative research project, under the 2016 Joint Call Framework (Transnational Research Projects on the Transmission Dynamics of Antibacterial Resistance). It received funding from the following national research agencies: Spain: Instituto de Salud Carlos III (grant no. AC16/00076), Netherlands: Netherlands Organization for Health Research and Development (grant no. AC681055), France: Agence Nationale de la Recherche (grant no. ANR-16-JPEC-0007-03) and Germany: German Federal Ministry of Education and Research (grant no. 01KI1701). As part of a separate research project, ES, MD-V and JR-B received support for research from the Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001), co- financed by the European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligence Growth 2014-2020. BPG is funded by the German Centre for Infection Research Clinical Research Unit (DZIF-CRU) at Tübingen. The funders played no role in the study design, collection, analysis and interpretation of data, writing and submission for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial

  • Rando, Emanuele
  • Delgado-Valverde, Mercedes
  • Goikoetxea-Aguirre, Josune
  • Guio Carrión, Laura
  • Blanco-Vidal, María José
  • Barrios Andrés, José Luis
  • Pérez-Rodríguez, María Teresa
  • Martínez-Lamas, Lucía
  • Arnaiz de Las Revillas, Francisco
  • Armiñanzas, Carlos
  • Ruiz de Alegría, Carlos
  • Jiménez-Aguilar, Patricia
  • Martínez-Rubio, María del Carmen
  • Sáez-Béjar, Carmen
  • Cuevas, Carmen de las
  • Martín-Aspas, Andrés
  • Galán, Fátima
  • Yuste, José Ramón
  • Leiva-León, José
  • Bou, Germán
  • Capón González, Patricia
  • Boix-Palop, Lucía
  • Xercavins-Valls, Mariona
  • Goenaga Sánchez, Miguel Ángel
  • Anza, Diego Vicente
  • Castón, Juan José
  • Recio Rufián, Manuel
  • Merino, Esperanza
  • Rodríguez, Juan Carlos
  • Loeches, Belén
  • Rosso-Fernández, Clara
  • Bravo-Ferrer, José María
  • Retamar-Gentil, Pilar
  • Rodríguez-Baño, Jesús
  • López-Cortés, Luis Eduardo
[Objectives] We investigated the effectiveness of early oral switch for treating Enterobacterales bloodstream infection (BSI) by performing a post hoc emulation trial of the SIMPLIFY trial., [Methods] We conducted a post hoc analysis of a randomized controlled trial. We specified the target trial characteristics selecting patients who achieved clinical stability on day 5. We categorized patients into those who switched on day 5 and those who continued intravenously. The primary outcome was clinical cure at the test of cure. We set a propensity score for being switched on day 5 to reduce confounding. We ran simple, not-propensity-adjusted, and propensity-adjusted logistic regression models to ascertain the association of switch on day 5 with clinical cure., [Results] Among 303 patients who achieved clinical stability on day 5, 110 (36.3%) were switched orally on day 5, and 193 (63.7%) were kept intravenously. We detected no difference in clinical cure between those switched on day 5 and those continued intravenously (risk ratios 1.04, 95% confidence intervals [CI] 0.98-1.10). Propensity-adjusted analysis did not show an association between day 5 switch and clinical cure (OR 2.10, 95% CI 0.96-7.41)., [Conclusion] Oral step-down therapy on day 5 was not associated with worse clinical cure for Enterobacterales BSI., The study was funded by the Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0003; 0005; 0007; 0008; 0009; 0011; 0012; 0015); Spanish Clinical Research and Clinical Trials Platform, (SCReN, PT13/0002/0010 and PT17/0017/0012, and PI15/00439), co‐financed by European Union; European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligence Growth 2014‐2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fosfomycin in bacteraemic urinary tract infection due to multidrug-resistant Escherichia coli: insights of post hoc DOOR analysis of the FOREST trial

  • Sojo-Dorado, Jesús
  • López-Hernández, Inmaculada
  • Gutiérrez-Gutiérrez, Belén
  • Rosa-Riestra, Sandra de la
  • Docobo-Pérez, Fernando
  • Hernánez-Torres, Alicia
  • Pascual, Álvaro
  • Rodríguez-Baño, Jesús
[Purpose] A post hoc analysis of data from a previously published clinical trial was conducted using the desirability of outcome ranking (DOOR) methodology with the aim provide additional information on the use of fosfomycin for the treatment of bacteraemic urinary tract infection (BUTI) caused by multi-drug-resistant (MDR) E. coli., [Methods] Three DOOR systems with five, six and seven categories, respectively were developed. Safety and efficacy were prioritised in all rankings, but step down to oral therapy and exposure to antibiotics with lower ecological impact were also considered in DOOR-6 and DOOR-7. The probability that a patients assigned to fosfomycin was classified into a more desirable outcome category was calculated for the three DOOR definitions. Subgroups analyses and an ordinal logistic regression model were also performed., [Results] Data from 143 participants were analysed. The probability of having a more desirable outcome after treatment with fosfomycin versus the comparators was 0.44 (95% CI 0.36 − 0.52) for DOOR-5; 0.50 (95% IC 0.42 − 0.58) using DOOR-6 and 0.61 (95% CI 0.53–0.69) with DOOR-7. In subgroups, the highest probability of having a better DOOR with fosfomycin was seen in the clinically evaluable population and among patients without chronic heart disease or renal insufficiency for the DOOR-7 definition., [Conclusions] DOOR analysis could be applied to the FOREST trial data; the results were somehow different for the different DOOR systems used. Overall, fosfomycin was favoured when oral step-down treatment and use of antibiotics with lower ecological impact were included., The study was funded by grants RD16/0016/0001, 0002, 0003, 0005, 0007, 0008, 0009, 0011, 0012, and 0015 from Plan Nacional de Investigación, Desarrollo e Innovación (I + D + i) 2013 to 2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI); PT13/0002/0010 and PT17/0017/0012 from the Spanish Clinical Research and Clinical Trials Platform (SCReN); and PI 13/01282 co-financed by the European Development Regional Fund “A Way to Achieve Europe” and Operative Program Intelligence Growth 2014 to 2020. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Spectral attenuation of brain and retina tissues in the near-infrared range measured using a fiber-based supercontinuum device

  • Saldaña-Díaz, José Eduardo
  • Jarabo, Sebastián
  • Salgado-Remacha, Francisco Javier
  • Perdices, Lorena
  • Pinilla, Isabel
  • Sanchez-Cano, Ana
A novel setup for the efficient constant optical measurements of biological tissues in the near infrared is presented. The system combines the use of a fiber-based supercontinuum source with a simple optics fiber collimator. This configuration allows a wide spectral range of measurement and, at the same time, can efficiently filter the straightforward transmitted light while avoiding scattered light. As a performance example, the optical characterization of rat brain and retina tissues are shown. The attenuation coefficient for both tissues in the near infrared region is also obtained. This technique could be applied in clinical research as a noninvasive method with several potential practical applications.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Development of optokinetic tracking software for objective evaluation of visual function in rodents

  • Segura, Francisco
  • Arines, Justo
  • Sánchez-Cano, Ana
  • Perdices, Lorena
  • Orduna-Hospital, Elvira
  • Fuentes-Broto, Lorena
  • Pinilla, Isabel
The aim of this study was to develop software that performs the optokinetic tracking assessment without the involvement of experimenters to increase the objectivity of the test. To check the effectiveness of the software, several videos were analyzed and the results were compared to those produced by two experimenters. Videos consisted of visual acuity and contrast sensitivity tests on normal animals and pigmented P23H rats (animal model of retinitis pigmentosa). Our software showed a reasonably high success rate: in approximately 78% of the cases, both the software program and the experimenters were in agreement, including the direction of rotation. The software detected 7% false positive cases, 10% false negative cases, and it was wrong in 5% of the cases. Decrease in visual function with age in pigmented P23H rats was observed from the first time interval, although minimum thresholds were found in visual parameters at advanced ages. We developed simple software based on current functions included in the Matlab image processing toolbox that was able to recognize, with a reasonably high percentage of success, the subtle head movements of the rodent produced when visual perception of the optokinetic optotype occurs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Meropenem heteroresistance in clinical isolates of OXA-48–producing Klebsiella pneumoniae

  • López-Camacho, E.
  • Paño-Pardo, J.R.
  • Sotillo, A.
  • Elías-López, C.
  • Martínez-Martínez, L.
  • Gómez-Gil, R.
  • Mingorance, J.
OXA-48–producing Klebsiella pneumoniae isolates often show growth of colonies within inhibition zones in carbapenem diffusion assays. The nature of these colonies was investigated in a series of clinical isolates of OXA-48–producing K. pneumoniae obtained in the context of a hospital outbreak, and they were found to be persistent colonies that reproduced again the same phenotype when they were collected and tested in diffusion assays again. The frequency of mutations conferring resistance to meropenem (8 µg/mL) was determined for the same isolates. The average mutation frequency was 5.47·10-6 (range: 2.59·10-8–5.87·10-5), and the analysis of several resistant mutants showed that all of them had mutations in the ompK36 porin gene. Heteroresistance was investigated using population analysis profiling. The profiles were compatible with mutation frequency assays, and all the colonies analyzed were resistant mutants. In OXA-48–producing K. pneumoniae, the growth of persisters seems to be specific of diffusion assays.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey

  • Del Barrio-Tofiño, Ester
  • Sánchez-Diener, Irina
  • Zamorano, Laura
  • Cortes-Lara, Sara
  • López-Causapé, Carla
  • Cabot, Gabriel
  • Bou, Germán
  • Martínez-Martínez, Luis
  • Oliver, Antonio
  • on behalf of the GEMARA-SEIMC/REIPI Pseudomonas study group
  • Castillo-García, Francisco Javier
  • Seral, Cristina
Objectives: To evaluate the correlation of O-antigen serotypes with resistance profiles and high-risk clones in a Spanish nationwide survey. Methods: Up to 30 consecutive healthcare-associated Pseudomonas aeruginosa isolates were collected during October 2017 from each of 51 hospitals (covering all Spanish regions) with a total of 1445 isolates studied. MICs of 13 antipseudomonal agents and MDR/XDR profiles had been previously determined, as well as whole-genome sequences of 185 representative XDR isolates. O-antigen serotypes (O1–O16) were determined by agglutination using serotype-specific antisera (BioRad). The Pseudomonas aeruginosa serotyper (PAst) program was used for in silico serotyping. Results: The most frequent serotypes were O6 (17.8%), O1 (15.4%) and O11 (13.3%). In contrast, the most frequent serotype among XDR isolates (17.3%) was O4 (34.1%), distantly followed by O11 (15.9%). Within serotypes, XDR phenotypes were more frequent for O12 (60.0%) and O4 (57.3%). The most frequent clone among the XDR isolates was ST175 (40.9%), followed by CC235 (10.7%), ST308 (5.2%) and CC111 (3.6%). Up to 81.6%of XDR ST175 isolates typed O4, whereas 18.4% were non-typeable. O4 genotype was detected in all sequenced (n=55) ST175 isolates. On the other hand, CC235 and ST308 were associated with O11, whereas CC111 was linked to serotype O12. Conclusions: O4 serotype is linked to the MDR/XDR profile of widespread ST175 (typically only susceptible to colistin, amikacin and the novel combinations ceftolozane/tazobactam and ceftazidime/avibactam) and therefore, after local validation, its detection in the microbiology laboratory might be useful for guiding semi-empirical antipseudomonal therapies and infection control measures in Spanish hospitals.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Invasive fusariosis in nonneutropenic patients, Spain, 2000-2015

  • Pérez-Nadales, E.
  • Alastruey-Izquierdo, A.
  • Linares-Sicilia, M.J.
  • Soto-Debrán, J.C.
  • Abdala, E.
  • García-Rodríguez, J.
  • Montejo, M.
  • Muñoz, P.
  • Lletí, M.S.
  • Rezusta, A.
  • de Pipaón, M.R.P.
  • Yáñez, L.
  • Merino, E.
  • Campos-Herrero, M.I.
  • Costa-Mateo, J.M.
  • Fortún, J.
  • García-Lozano, T.
  • Garcia-Vidal, C.
  • Fernández-Ruiz, M.
  • Sánchez-Reus, F.
  • Castro-Méndez, C.
  • Guerrero-Lozano, I.
  • Soler-Palacín, P.
  • Aguado, J.M.
  • Martínez-Martínez, L.
  • Torre-Cisneros, J.
  • Nucci, M.
In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page 339.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Photodynamic Therapy Combined with Antibiotics or Antifungals against Microorganisms That Cause Skin and Soft Tissue Infections: A Planktonic and Biofilm Approach to Overcome Resistances

  • Perez-Laguna, V
  • Garcia-Luque, I
  • Ballesta, S
  • Rezusta López, A
  • Gilaberte Calzada, Y
The present review covers combination approaches of antimicrobial photodynamic therapy (aPDT) plus antibiotics or antifungals to attack bacteria and fungi in vitro (both planktonic and biofilm forms) focused on those microorganisms that cause infections in skin and soft tissues. The combination can prevent failure in the fight against these microorganisms: antimicrobial drugs can increase the susceptibility of microorganisms to aPDT and prevent the possibility of regrowth of those that were not inactivated during the irradiation; meanwhile, aPDT is effective regardless of the resistance pattern of the strain and their use does not contribute to the selection of antimicrobial resistance. Additive or synergistic antimicrobial effects in vitro are evaluated and the best combinations are presented. The use of combined treatment of aPDT with antimicrobials could help overcome the difficulty of fighting high level of resistance microorganisms and, as it is a multi-target approach, it could make the selection of resistant microorganisms more difficult.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

  • Gómez-Zorrilla, Silvia
  • Becerra-Aparicio, Federico
  • López Montesinos, Inmaculada
  • Ruiz de Gopegui, Enrique
  • Grau, Inmaculada
  • Pintado, Vicente
  • Padilla, Belén
  • Benito, Natividad
  • Boix-Palop, Lucía
  • Fariñas, Maria Carmen
  • Peñaranda, María
  • Gamallo, Maria Rocío
  • Martinez, Jose Antonio
  • Morte-Romea, Elena
  • Del Pozo, Jose Luis
  • Durán-Jordá, Xavier
  • Díaz-Regañón, Jazmin
  • López-Mendoza, Diego
  • Cantón, Rafael
  • Oliver, Antonio
  • Ruiz-Garbajosa, Patricia
  • Horcajada, Juan Pablo
  • Siverio, Ana
  • Gijón, Desiré
  • Merino, Irene
  • López-Causapé, Carla
  • Sabé, Nuria
  • Shaw, Evelyn
  • Berbel, Dámaris
  • Tubau Quintano, Fe
  • Sánchez Carrillo, Carlos
  • Cercenado, Emilia
  • Sendra, Elena
  • Rubio, Verónica
  • Rivera, Alba
  • Calvo, Esther
  • Badía, Cristina
  • Xercavins, Mariona
  • de Malet, Ana
  • Canoura-Fernández, Luis
  • Salvo, Soledad
  • Paño-Pardo, Jose Ramón
  • Carmona-Torre, Francisco
Introduction: Healthcare-associated (HCA) infections represent a growing public health problem. The aim of this study was to compare community-onset healthcare associated (CO-HCA) bacteremic urinary tract infections (BUTI) and hospital-acquired (HA)-BUTI with special focus on multidrug resistances (MDR) and outcomes. Methods: ITUBRAS-project is a prospective multicenter cohort study of patients with HCA-BUTI. All consecutive hospitalized adult patients with CO-HCA-BUTI or HA-BUTI episode were included in the study. Exclusion criteria were: patients < 18 years old, non-hospitalized patients, bacteremia from another source or primary bacteremia, non-healthcare-related infections and infections caused by unusual pathogens of the urinary tract. The main outcome variable was 30-day all-cause mortality with day 1 as the first day of positive blood culture. Logistic regression was used to analyze factors associated with clinical cure at hospital discharge and with receiving inappropriate initial antibiotic treatment. Cox regression was used to evaluate 30-day all-cause mortality. Results: Four hundred forty-three episodes were included, 223 CO-HCA-BUTI. Patients with CO-HCA-BUTI were older (p < 0.001) and had more underlying diseases (p = 0.029) than those with HA-BUTI. The severity of the acute illness (Pitt score) was also higher in CO-HCA-BUTI (p = 0.026). Overall, a very high rate of MDR profiles (271/443, 61.2%) was observed, with no statistical differences between groups. In multivariable analysis, inadequate empirical treatment was associated with MDR profile (aOR 3.35; 95% CI 1.77–6.35), Pseudomonas aeruginosa (aOR 2.86; 95% CI 1.27–6.44) and Charlson index (aOR 1.11; 95% CI 1.01–1.23). Mortality was not associated with the site of acquisition of the infection or the presence of MDR profile. However, in the logistic regression analyses patients with CO-HCA-BUTI (aOR 0.61; 95% CI 0.40–0.93) were less likely to present clinical cure. Conclusion: The rate of MDR infections was worryingly high in our study. No differences in MDR rates were found between CO-HCA-BUTI and HA-BUTI, in the probability of receiving inappropriate empirical treatment or in 30-day mortality. However, CO-HCA-BUTIs were associated with worse clinical cure. © 2021, The Author(s).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Wildlife and Antibiotic Resistance

  • Laborda, P.
  • Sanz-García, F.
  • Ochoa-Sánchez, L. E.
  • Gil-Gil, T.
  • Hernando-Amado, S.
  • Martínez, J. L.
Antibiotic resistance is a major human health problem. While health care facilities are main contributors to the emergence, evolution and spread of antibiotic resistance, other ecosystems are involved in such dissemination. Wastewater, farm animals and pets have been considered important contributors to the development of antibiotic resistance. Herein, we review the impact of wildlife in such problem. Current evidence supports that the presence of antibiotic resistance genes and/or antibiotic resistant bacteria in wild animals is a sign of anthropic pollution more than of selection of resistance. However, once antibiotic resistance is present in the wild, wildlife can contribute to its transmission across different ecosystems. Further, the finding that antibiotic resistance genes, currently causing problems at hospitals, might spread through horizontal gene transfer among the bacteria present in the microbiomes of ubiquitous animals as cockroaches, fleas or rats, supports the possibility that these organisms might be bioreactors for the horizontal transfer of antibiotic resistance genes among human pathogens. The contribution of wildlife in the spread of antibiotic resistance among different hosts and ecosystems occurs at two levels. Firstly, in the case of non-migrating animals, the transfer will take place locally; a One Health problem. Paradigmatic examples are the above mentioned animals that cohabit with humans and can be reservoirs and vehicles for antibiotic resistance dissemination. Secondly, migrating animals, such as gulls, fishes or turtles may participate in the dissemination of antibiotic resistance across different geographic areas, even between different continents, which constitutes a Global Health issue. Copyright © 2022 Laborda, Sanz-García, Ochoa-Sánchez, Gil-Gil, Hernando-Amado and Martínez.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Low Ciprofloxacin concentrations select Multidrug-Resistant Mutants overproducing efflux pumps in clinical isolates of Pseudomonas Aeruginosa

  • Sanz García, Fernando
  • Hernando Amado, Sara
  • López Causapé, Carla
  • Oliver, Antonio
  • Martínez, José Luis
Low antibiotic concentrations present in natural environments are a severe and often neglected threat to public health. Even if they are present below their MICs, they may select for antibiotic-resistant pathogens. Notably, the minimal subinhibitory concentrations that select resistant bacteria, and define the respective sub-MIC selective windows, differ between antibiotics. The establishment of these selective concentrations is needed for risk-assessment studies regarding the presence of antibiotics in different habitats. Using short-term evolution experiments in a set of 12 Pseudomonas aeruginosa clinical isolates (including high-risk clones with ubiquitous distribution), we have determined that ciprofloxacin sub-MIC selective windows are strain specific and resistome dependent. Nonetheless, in all cases, clinically relevant multidrug-resistant (MDR) mutants emerged upon exposure to low ciprofloxacin concentrations, with these concentrations being below the levels reported in ciprofloxacin-polluted natural habitats where P. aeruginosa can be present. This feature expands the conditions and habitats where clinically relevant quinolone-resistant mutants can emerge. In addition, we established the lowest concentration threshold beyond which P. aeruginosa, regardless of the strain, becomes resistant to ciprofloxacin. Three days of exposure under this sub-MIC "risk concentration" led to the selection of MDR mutants that displayed resistance mechanisms usually ascribed to high selective pressures, i.e., the overproduction of the efflux pumps MexCD-OprJ and MexEF-OprN. From a One-Health viewpoint, these data stress the transcendent role of low drug concentrations, which can be encountered in natural ecosystems, in aggravating the antibiotic resistance problem, especially when it comes to pathogens of environmental origin. IMPORTANCE It has been established that antibiotic concentrations below MICs can select antibiotic-resistant pathogens, a feature of relevance for analyzing the role of nonclinical ecosystems in antibiotic resistance evolution. The range of concentrations where this selection occurs defines the sub-MIC selective window, whose width depends on the antibiotic. Herein, we have determined the ciprofloxacin sub-MIC selective windows of a set of Pseudomonas aeruginosa clinical isolates (including high-risk clones with worldwide distribution) and established the lowest concentration threshold, notably an amount reported to be present in natural ecosystems, beyond which this pathogen acquires resistance. Importantly, our results show that this ciprofloxacin sub-MIC selects for multidrug-resistant mutants overproducing clinically relevant efflux pumps. From a One-Health angle, this information supports that low antimicrobial concentrations, present in natural environments, may have a relevant role in worsening the antibiotic resistance crisis, particularly regarding pathogens with environmental niches, such as P. aeruginosa. It has been established that antibiotic concentrations below MICs can select antibiotic-resistant pathogens, a feature of relevance for analyzing the role of nonclinical ecosystems in antibiotic resistance evolution. The range of concentrations where this selection occurs defines the sub-MIC selective window, whose width depends on the antibiotic.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Rapid phenotypic convergence towards collateral sensitivity in clinical isolates of Pseudomonas aeruginosa presenting different genomic backgrounds

  • Hernando-Amado, S.
  • López-Causapé, C.
  • Laborda, P.
  • Sanz-García, F.
  • Oliver, A.
  • Martínez, J. L.
Collateral sensitivity (CS) is an evolutionary trade-off by which acquisition of resistance to an antibiotic leads to increased susceptibility to another. This Achilles’ heel of antibiotic resistance could be exploited to design evolution-based strategies for treating bacterial infections. To date, most studies in the field have focused on the identification of CS patterns in model strains. However, one of the main requirements for the clinical application of this trade-off is that it must be robust and has to emerge in different genomic backgrounds, including preexisting drug-resistant isolates, since infections are frequently caused by pathogens already resistant to antibiotics. Here, we report the first analysis of CS robustness in clinical strains of Pseudomonas aeruginosa presenting different ab initio mutational resistomes. We identified a robust CS pattern associated with short-term evolution in the presence of ciprofloxacin of clinical P. aeruginosa isolates, including representatives of high-risk epidemic clones belonging to sequence type (ST) 111, ST175, and ST244. We observed the acquisition of different ciprofloxacin resistance mutations in strains presenting varied STs and different preexisting mutational resistomes. Importantly, despite these genetic differences, the use of ciprofloxacin led to a robust CS to aztreonam and tobramycin. In addition, we describe the possible application of this evolutionary trade-off to drive P. aeruginosa infections to extinction by using the combination of ciprofloxacin-tobramycin or ciprofloxacin-aztreonam. Our results support the notion that the identification of robust patterns of CS may establish the basis for developing evolution-informed treatment strategies to tackle bacterial infections, including those due to antibiotic-resistant pathogens. IMPORTANCE Collateral sensitivity (CS) is a trade-off of antibiotic resistance evolution that could be exploited to design strategies for treating bacterial infections. Clinical application of CS requires it to robustly emerge in different genomic backgrounds. In this study, we performed an analysis to identify robust patterns of CS associated with the use of ciprofloxacin in clinical isolates of P. aeruginosa presenting different mutational resistomes and including high-risk epidemic clones (ST111, ST175, and ST244). We demonstrate the robustness of CS to tobramycin and aztreonam and the potential application of this evolutionary observation to drive P. aeruginosa infections to extinction. Our results support the notion that the identification of robust CS patterns may establish the basis for developing evolutionary strategies to tackle bacterial infections, including those due to antibiotic-resistant pathogens.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Insights into immune evasion of human metapneumovirus: novel 180- and 111-nucleotide duplications within viral G gene throughout 2014-2017 seasons in Barcelona, Spain

  • Piñana, M.
  • Vila, J.
  • Maldonado, C.
  • Galano-Frutos, J.J.
  • Valls, M.
  • Sancho, J.
  • Nuvials, F.X.
  • Andrés, C.
  • Martín-Gómez, M.T.
  • Esperalba, J.
  • Codina, M.G.
  • Pumarola, T.
  • Antón, A.
Background: Human metapneumovirus (HMPV) is an important aetiologic agent of respiratory tract infection (RTI). This study aimed to describe its genetic diversity and clinical impact in patients attended at a tertiary university hospital in Barcelona from the 2014-2015 to the 2016-2017 seasons, focusing on the emerging duplications in G gene and their structural properties. Methods: Laboratory-confirmed HMPV were characterised based on partial-coding F and G gene sequences with MEGA.v6.0. Computational analysis of disorder propensity, aggregation propensity and glycosylation sites in viral G predicted protein sequence were carried out. Clinical data was retrospectively reviewed and further associated to virological features. Results: HMPV prevalence was 3%. The 180- and 111-nucleotide duplications occurred in A2c lineage G protein increased in prevalence throughout the study, in addition to short genetic changes observed in other HMPV lineages. The A2c G protein without duplications was calculated to protrude over F protein in 23% of cases and increased to a 39% and a 46% with the 111- and 180-nucleotide duplications, respectively. Children did not seem to be more affected by these mutant viruses, but there was a strong association of these variants to LRTI in adults. Discussion: HMPV presents a high genetic diversity in all lineages. Novel variants carrying duplications might present an evolutionary advantage due to an improved steric shielding, which would have been responsible for the reported increasing prevalence and the association to LRTI in adults.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Risk factors and clinical impact of multi drug resistance in healthcare-associated bacteremic urinary tract infections: a post-hoc analysis of a multi center prospective cohort in Spain

  • Gómez Zorrilla, S.
  • Becerra Aparicio, F.
  • Sendra, E.
  • Zamorano, L.
  • Grau, I.
  • Pintado, V.
  • Padilla, B.
  • Benito, N.
  • Boix Palop, L
  • Fariñas, M.C.
  • Peñaranda, M.
  • Gamallo, M.R.
  • Martínez, J.A.
  • Morte Romea, E.
  • Del Pozo, J.L.
  • López Montesinos, I.
  • Durán Jordá, X.
  • Ponz, R.
  • Cotarelo, M.
  • Cantón, R.
  • Oliver, A.
  • Ruiz Garbajosa, P.
  • Horcajada, J.P.
Background: The global burden associated with antimicrobial resistance is of increasing concern. Aim: To evaluate risk factors associated with multidrug-resistant (MDR) infection and its clinical impact in a cohort of patients with healthcare-associated bacteraemic urinary tract infections (BUTIs). Methods: This was a prospective, multicentre, post-hoc analysis of patients with healthcare-associated-BUTI (ITUBRAS-2). The primary outcome was MDR profile. Secondary outcomes were clinical response (at 48–72 h and at hospital discharge) and length of hospital stay from onset of BUTI. Logistic regression was used to evaluate variables associated with MDR profile and clinical response. Length of hospital stay was evaluated using multivariate median regression. Findings: In all, 443 episodes were included, of which 271 (61.17%) were classified as expressing an MDR profile. In univariate analysis, MDR profile was associated with E. coli episodes (odds ratio (OR): 3.13; 95% confidence interval (CI): 2.11–4.69, P < 0.001) and the extensively drug-resistant (XDR) pattern with P. aeruginosa aetiology (7.84; 2.37–25.95; P = 0.001). MDR was independently associated with prior use of fluoroquinolones (adjusted OR: 2.43; 95% CI: 1.25–4.69), cephalosporins (2.14; 1.35–3.41), and imipenem or meropenem (2.08; 1.03–4.20) but not with prior ertapenem. In terms of outcomes, MDR profile was not associated with lower frequency of clinical cure, but was associated with longer hospital stay. Conclusion: MDR profile was independently associated with prior use of fluoroquinolones, cephalosporins, imipenem, and meropenem, but not with prior ertapenem. MDR-BUTI episodes were not associated with worse clinical cure, although they were independently associated with longer duration of hospital stay.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Antibiotic use and outcome in patients with negative blood cultures, a new target population for antimicrobial stewardship interventions: a prospective multicentre cohort (NO-BACT)

  • Girón Ortega, J.A.
  • Fernández Guerrero, R.
  • Montes de Oca Arjona, M.
  • Sánchez Galán, F.
  • Pellejero Sagastizábal, G.
  • Morte Romea, E.
  • De Cueto, M.
  • Beltrán García, M.
  • Palacios Baena, Z.
  • Jiménez Jorge, S.
  • Rodríguez Baño, J.
  • Retamar Gentil, P.
Objectives: To evaluate the appropriateness of antimicrobial treatment and the risk factors for mortality in patients with negative blood cultures (BC), in order to evaluate whether this population would be a suitable target for antimicrobial stewardship (AMS) interventions. Methods: A multicentre prospective cohort study of patients with negative BC in three Spanish hospitals between October 2018 and July 2019 was performed. The main endpoints were the appropriateness of antimicrobial treatment (evaluated by two investigators according to local guidelines) and 30-day mortality. Cox-regression was performed to estimate the association between variables and 30-day mortality. Results: Of 1011 patients in whom BC was obtained, these were negative in 803 (79%) and were included; 30-day mortality was 9% (70 patients); antibiotic treatment was considered inappropriate in 299 (40%) of 747 patients evaluated at day 2, and in 266 (46%) of 573 at day 5–7. The variables independently associated with increased risk of 30-day mortality were higher age (HR 1.05; 95% CI 1.03–1.07), neoplasia (HR 2.73; 95% CI 1.64–4.56), antibiotic treatment in the 48 h prior to BC extraction (HR 2.06; 95% CI 1.23–3.43) and insufficient antibiotic coverage at day 2 after BC obtainment (HR 2.35; 95% CI 1.39–4.00). Urinary, catheter and biliary sources of infection were associated with lower risk (HR 0.40; 95% CI 0.20–0.81). Conclusions: Antimicrobial treatment is frequently inappropriate among patients with negative BC; insufficient antibiotic coverage at day 2 was associated with mortality. These results suggest that patients with negative BC are a suitable population for AS interventions. Summary: Antimicrobial treatment in patients with negative blood culture was frequently inappropriate, and inappropriate coverage at day 2 was associated with increased risk of death. These data support the consideration of this population as a potential target for antimicrobial stewardship interventions.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Antimicrobial therapy among hospitalized older adults with suspected infection and negative blood cultures

  • Pellejero-Sagastizabal, Galadriel
  • Morte-Romea, Elena
  • Girón Ortega, José Antonio
  • Paño-Pardo, José Ramón
  • Fernández Guerrero, Raquel
  • Guerrero, Francisca
  • Montes de Oca, Montserrat
  • Jiménez-Jorge, Silvia
  • Palacios-Baena, Zaira R.
  • Rodríguez-Baño, Jesús
  • Retamar-Gentil, Pilar
  • Montes de Oca Arjona, Montserrat
  • Galán Sánchez, Fátima
  • Rodríguez Mateos, María Eugenia
  • Girón-González, José Antonio
  • Martín Aspas, Andrés
  • Sánchez Tembleque, Claudio
  • Guerrero Sánchez, Francisca María
  • Morte-Romea, Elena
  • Pellejero-Sagastizabal, Galadriel
  • Luque Gómez, Pilar
  • Paño-Pardo, José Ramón
  • Sierra, José Luis
  • Letona Gimenez, Santiago
  • Palacián, Pilar
  • Rodriguez, Nora Mariela
  • Arenere Mendoza, Mercedes
  • Allende Bandrés, Maria Ángeles
  • Fresquet Molina, Raquel
  • Navarro Pardo, Irene
  • Girón Ortega, José Antonio
  • Fernández Guerero, Raquel
  • Retamar-Gentil, Pilar
  • Palacios-Baena, Zaira
  • de Cueto, Marina
  • Beltrán García, Margarita
  • Cantón Bulnes, María Luisa
  • Suarti, Lorenzo Roberto
  • Rodríguez-Baño, Jesús
Background Managing infections in older adults is challenging due to their unique characteristics, which often drives empirical antimicrobial use, increasing risks of adverse outcomes and antimicrobial resistance (AMR). Data on antimicrobial adequacy in older patients with suspected infection but negative blood cultures (BC) remain scarce, despite this being a common clinical scenario. Methods In this multicenter prospective cohort study (NO-BACT project) across three Spanish hospitals (2018–2019), we compared antimicrobial therapy adequacy between older adults (≥ 85 years) and younger patients with suspected infections and negative BC. Antimicrobial stewardship (AMS) experts evaluated treatment adequacy at days 2 and 5–7 using standardized guideline-based criteria. We assessed predictors of adequacy using logistic regression and examined clinical outcomes including 30-day mortality and length of hospital stay (LOS). Results Among 799 enrolled patients, 90 (11.3%) were older adults. While initial antimicrobial adequacy was comparable between groups at Day 2 (59.8% vs. 60.1%), older adults were significantly less likely to receive adequate treatment by Days 5–7 (adjusted OR 0.46, 95% CI 0.25–0.82, p = 0.009). The main drivers of inadequacy were excess antimicrobial spectrum (84.2%) and inappropriate route of administration (48.7%). Older adults demonstrated higher 30-day mortality (16.7% vs. 7.8%; p = 0.009) despite shorter LOS (8 vs. 10 days, p = 0.006), though treatment adequacy was not associated with mortality. Conclusions In older patients with negative BC, antimicrobial therapy shows high rates of inadequacy that worsen over time, primarily due to delayed de-escalation and prolonged intravenous therapy. These findings identify a clear target for AMS interventions focusing on timely treatment optimization.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Host-dependent editing of SARS-CoV-2 in COVID-19 patients

  • Piñana Moro, Maria
  • Campos Martinez, Carolina
  • Garcia Cehic, Damir
  • Codina Grau, Gema
  • Esperalba Esquerra, Juliana
  • Sulleiro Igual, Elena
  • Joseph Munné, Joan
  • Saubí Roca, Narcís
  • Colomer Castell, Sergi
  • Martin Perez, Maria Carmen
  • Castillo Oliveda, Carla
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
  • Cortese, Maria Francesca
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
SARS-CoV-2; Mutacions; Quasiespècie, SARS-CoV-2; Mutaciones; Cuasiespecie, SARS-CoV-2; Mutations; Quasispecies, A common trait among RNA viruses is their high capability to acquire genetic variability due to viral and host mechanisms. Next-generation sequencing (NGS) analysis enables the deep study of the viral quasispecies in samples from infected individuals. In this study, the viral quasispecies complexity and single nucleotide polymorphisms of the SARS-CoV-2 spike gene of coronavirus disease 2019 (COVID-19) patients with mild or severe disease were investigated using next-generation sequencing (Illumina platform). SARS-CoV-2 spike variability was higher in patients with long-lasting infection. Most substitutions found were present at frequencies lower than 1%, and had an A → G or T → C pattern, consistent with variants caused by adenosine deaminase acting on RNA-1 (ADAR1). ADAR1 affected a small fraction of replicating genomes, but produced multiple, mainly non-synonymous mutations. ADAR1 editing during replication rather than the RNA-dependent RNA polymerase (nsp12) was the predominant mechanism generating SARS-CoV-2 genetic variability. However, the mutations produced are not fixed in the infected human population, suggesting that ADAR1 may have an antiviral role, whereas nsp12-induced mutations occurring in patients with high viremia and persistent infection are the main source of new SARS-CoV-2 variants., This study was supported by the Direcció General de Recerca i Innovació en Salut (DGRIS) of the Catalan Health Ministry, Generalitat de Catalunya, through the Vall d’Hebron Institut de Recerca (VHIR); the European Regional Development Fund (ERDF) “A way to achieve Europe” by the Spanish Network for Research in Infectious Diseases [grant number REIPI RD16/0016/0003]; Instituto de Salud Carlos III [grant number FIS PI19/00301]; and Centro para el Desarrollo Tecnologico Industrial (CDTI) from the Ministry of Economic Affairs and Digital Transformation [grant number IDI-20200297].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Periprosthetic Joint Infection Prophylaxis in the Elderly after Hip Hemiarthroplasty in Proximal Femur Fractures: Insights and Challenges

  • Escola Verge, Laura
  • Sellares Nadal, Julia
  • Corona Pérez-Cardona, Pablo Salvador
  • Almirante Gragera, Benito
  • Pigrau Serrallach, Carles
  • Rodríguez Pardo, Ma Dolores
Profilaxi antibiòtica; Hemiartroplàstia de maluc; Infecció periprotèsica de l'articulació, Profilaxis antibiótica; Hemiartroplastia de cadera; Infección de la articulación periprotésica, Antibiotic prophylaxis; Hip hemiarthroplasty; Periprosthetic joint infection, We review antibiotic and other prophylactic measures to prevent periprosthetic joint infection (PJI) after hip hemiarthroplasty (HHA) surgery in proximal femoral fractures (PFFs). In the absence of specific guidelines, those applied to these individuals are general prophylaxis guidelines. Cefazolin is the most widely used agent and is replaced by clindamycin or a glycopeptide in beta-lactam allergies. A personalized antibiotic scheme may be considered when colonization by a multidrug-resistant microorganism (MDRO) is suspected. Particularly in methicillin-resistant Staphylococcus aureus (MRSA) colonization or a high prevalence of MRSA-caused PJIs a glycopeptide with cefazolin is recommended. Strategies such as cutaneous decolonization of MDROs, mainly MRSA, or preoperative asymptomatic bacteriuria treatment have also been addressed with debatable results. Some areas of research are early detection protocols in MDRO colonizations by polymerase-chain-reaction (PCR), the use of alternative antimicrobial prophylaxis, and antibiotic-impregnated bone cement in HHA. Given that published evidence addressing PJI prophylactic strategies in PFFs requiring HHA is scarce, PJIs can be reduced by combining different prevention strategies after identifying individuals who will benefit from personalized prophylaxis., This work was supported by the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, through the project PI15/02161 and by the Plan Nacional de I+D+i 2013-016 and ISCIIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)-co-financed by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Bioinformatic Tools for NGS-Based Metagenomics to Improve the Clinical Diagnosis of Emerging, Re-Emerging and New Viruses

  • Colomer Castell, Sergi
  • González Sánchez, Alejandra
  • Campos Martinez, Carolina
  • Garcia Cehic, Damir
  • Piñana Moro, Maria
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Quer Sivila, Josep
  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Diagnostic tools; Metagenomics; Viruses, Herramientas diagnosticas; Metagenómica; Virus, Eines diagnòstiques; Metagenòmica; Virus, Epidemics and pandemics have occurred since the beginning of time, resulting in millions of deaths. Many such disease outbreaks are caused by viruses. Some viruses, particularly RNA viruses, are characterized by their high genetic variability, and this can affect certain phenotypic features: tropism, antigenicity, and susceptibility to antiviral drugs, vaccines, and the host immune response. The best strategy to face the emergence of new infectious genomes is prompt identification. However, currently available diagnostic tests are often limited for detecting new agents. High-throughput next-generation sequencing technologies based on metagenomics may be the solution to detect new infectious genomes and properly diagnose certain diseases. Metagenomic techniques enable the identification and characterization of disease-causing agents, but they require a large amount of genetic material and involve complex bioinformatic analyses. A wide variety of analytical tools can be used in the quality control and pre-processing of metagenomic data, filtering of untargeted sequences, assembly and quality control of reads, and taxonomic profiling of sequences to identify new viruses and ones that have been sequenced and uploaded to dedicated databases. Although there have been huge advances in the field of metagenomics, there is still a lack of consensus about which of the various approaches should be used for specific data analysis tasks. In this review, we provide some background on the study of viral infections, describe the contribution of metagenomics to this field, and place special emphasis on the bioinformatic tools (with their capabilities and limitations) available for use in metagenomic analyses of viral pathogens., This study was partially supported by Pla Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF); Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; grants PI19/00301 and PI22/00258 from Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF); and Gilead’s biomedical research project GLD21/00006. S.C-C is a recipient of a predoctoral fellowship, FPU, from Ministerio de Universidades (FPU21/04150).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain)

  • Piñana Moro, Maria
  • González Sánchez, Alejandra
  • Garcia Cehic, Damir
  • Esperalba Esquerra, Juliana
  • Zules Oña, Ricardo Gabriel
  • Campos Martinez, Carolina
  • Codina Grau, Gema
  • Blanco Grau, Albert
  • Colomer Castell, Sergi
  • Martin Perez, Maria Carmen
  • Castillo Oliveda, Carla
  • García-Comuñas, Karen
  • Vásquez-Mercado, Rodrigo
  • Martins-Martins, Reginald
  • Saubí Roca, Narcís
  • Pumarola Suñé, Tomàs
  • Quer Sivila, Josep
  • Campins Martí, Magda
  • Rando Segura, Ariadna
  • Borras Bermejo, Blanca
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Catalonia; SARS-CoV-2; Molecular epidemiology, Cataluña; SARS-CoV-2; Epidemiología molecular, Catalunya; SARS-CoV-2; Epidemiologia molecular, Herein, we describe the genetic diversity of circulating SARS-CoV-2 viruses by whole-genome sequencing (WGS) in Barcelona city (Catalonia, Spain) throughout the first four pandemic waves. From weeks 11/2020–24/2021, SARS-CoV-2-positive respiratory samples were randomly selected per clinical setting (80% from primary care or 20% from the hospital), age group, and week. WGS was performed following the ARTICv3 protocol on MiSeq or NextSeq2000 Illumina platforms. Nearly complete consensus sequences were used for genetic characterization based on GISAID and PANGOLIN nomenclatures. From 2475 samples, 2166 (87%) were fully sequenced (78% from primary care and 22% from hospital settings). Multiple genetic lineages were co-circulating, but four were predominant at different periods. While B.1.5 (50.68%) and B.1.1 (32.88%) were the major lineages during the first pandemic wave, B.1.177 (66.85%) and B.1.1.7 (83.80%) were predominant during the second, third, and fourth waves, respectively. Almost all (96.4%) were carrying D614G mutation in the S protein, with additional mutations that define lineages or variants. But some mutations of concern, such as E484K from B.1.351 and P.1 lineages are currently under monitoring, together with those observed in the receptor-binding domain or N-terminal domain, such as L452R and T478K from B.1.617.2 lineage. The fact that a predominant lineage was observed in each pandemic wave suggests advantageous properties over other contemporary co-circulating variants. This genetic variability should be monitored, especially when a massive vaccination campaign is ongoing because the potential selection and emergence of novel antigenic SARS-CoV-2 strains related to immunological escapement events., This work was supported by Spanish Network for the Research in Infectious Diseases: [Grant Number REIPI RD16/0016/0003]; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business [Grant Number IDI-20200297]; Direcció General de Recerca i Innovació en Salut (DGRIS); European Development Regional Fund (ERDF) “A way to achieve Europe” by Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0003].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain): A long-term, clinical, epidemiologic and economic study

  • Vila Soler, Jorgina
  • Lera Carballo, Esther
  • Piñana Moro, Maria
  • Rello Saltor, Victoria
  • Tobeña Rue, Marc
  • Balcells Ramirez, Joan
  • Benítez Díaz, Zaira
  • Aller Hernández, Marta Beatriz
  • Muñoz Gallarin, Rosario
  • Vázquez, Ana
  • Rodrigo Gonzalo de Liria, Carlos
  • Soler-palacín, Pere
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Cost of illness; Hospitalization; Viruses, Cost de la malaltia; Hospitalització; Virus, Coste de la enfermedad; Hospitalización; Virus, Background Viral lower respiratory tract infections (LRTI) are the leading cause of hospitalization in children. In Catalonia (Spain), information is scarce about the burden of viral LRTIs in paediatric hospitalizations. The aim of this study is to describe epidemiological, clinical, virological and economic features of paediatric hospitalizations due to viral LRTI. Methods From October 2012 to December 2020, children aged <16 years admitted to a tertiary paediatric hospital in Catalonia (Spain) with confirmed viral LRTI were included in the study. Virus seasonality, prevalence, age and sex distribution, clinical characteristics, hospital costs and bed occupancy rates were determined. Results A total of 3,325 children were included (57.17% male, 9.44% with comorbidities) accounting for 4056 hospitalizations (32.47% ≤ 12 months): 53.87% with wheezing/asthma, 37.85% with bronchiolitis and 8.28% with pneumonia. The most common virus was respiratory syncytial virus (RSV) (52.59%). Influenza A was associated with pneumonia (odds ratio [OR] 7.75) and caused longer hospitalizations (7 ± 31.58 days), while RSV was associated with bronchiolitis (OR 6.62) and was the most frequent reason for admission to the paediatric intensive care unit (PICU) (11.23%) and for respiratory support (78.76%). Male sex, age ≤12 months, chronic conditions and bronchiolitis significantly increased the odds of PICU admission. From October to May, viral LRTIs accounted for 12.36% of overall hospital bed days. The total hospitalization cost during the study period was €16,603,415. Conclusions Viral LRTIs are an important cause of morbidity, hospitalization and PICU admission in children. The clinical burden is associated with significant bed occupancy and health-care costs, especially during seasonal periods., This work was partially supported by the Spanish National R + D + I Plan 2008–2011 and by the Carlos III Health Institute, the Subdirectorate-General of Networks and Cooperative Research Centers, the Spanish Ministry of Economy and Competitiveness, the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), and by the Health Research Fund, the Spanish Ministry of Economy and Competitiveness (grants FIS PI14/01838 and FIS PI18/00685), and the European Regional Development Fund (ERDF). Editorial assistance for revision of the English language and edition of the manuscript was provided by Vanessa Marfil, medical writer from MSC (Spain) and funded by Sanofi.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation

  • Calvo Lozano, Olalla
  • Sierra Montoya, Miquel
  • Soler, Maria
  • Estevez, M. Carmen
  • Chiscano Camon, Luis Silvestre
  • Ruiz Sanmartin, Adolfo
  • Ruiz Rodriguez, Juan Carlos
  • Ferrer Roca, Ricard
  • Gonzalez Lopez, Juan Jose
  • Esperalba Esquerra, Juliana
  • Fernandez Naval, Candela
COVID-19; Biosensor plasmónico; Serología, COVID-19; Biosensor plasmònic; Serologia, COVID-19; Plasmonic biosensor; Serology, Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment., ICN2 and UVE acknowledge financial support from H2020 Research and Innovation Programme of the European Commission (H202-SC1-PHE-Coronavirus-2020, CONVAT Project, No. 101003544). The ICN2 is funded by the CERCA program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). ICN2 group is very grateful to EPI Industries (Barcelona, Spain) for its kind donation supporting our research in COVID-19. O.C.-L. acknowledges the economic support from the Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF) (ref. BES-2017-080527) linked to the TEC 2016-78515-R project Predict. A part of the work was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the EU Horizon 2020 (grant agreement No. 871029). A.T. and L.F.-B. acknowledge financial support from GENCAT-DGRIS COVID. We are indebted to all the patients who accepted to participate contributing to science advancement. We are indebted to the HCB-IDIBAPS Biobank for the human samples and data procurement and to the Fundació Glòria Soler for its support to the COVIDBANK collection. We thank the IDIBAPS Biobank for its valuable contribution to sample processing and storage. The authors acknowledge the EU Horizon 2020 Program under grant agreement no. 644956 (RAIS project) for funding the Hospital Vall d’Hebron Biobank. The VHIR-HUVH is supported by Plan Nacional de I + D + i 2013-2016 and ISCIII-Ministerio de Ciencia e Innovación, and Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)─cofinanced by European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014. Part of the samples and data from patients included in this study were provided by the Vall d’Hebron University Hospital Biobank (PT17/0015/0047), integrated in the Spanish National Biobanks Network, and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The authors kindly appreciate the generous donation of samples and clinical data of the donors of the Sepsis Bank of HUVH Biobank and COVID-19 patients attended at HUVH.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Quantifying In-Host Quasispecies Evolution

  • Quer Sivila, Josep
  • Gregori Font, Josep
  • Ibañez Lligoña, Marta
Mutagenesis; Quasispecies evolution; Viral treatment, Mutagénesis; Evolución de las cuasiespecies; Tratamiento viral, Mutagènesi; Evolució de les quasiespècies; Tractament viral, What takes decades, centuries or millennia to happen with a natural ecosystem, it takes only days, weeks or months with a replicating viral quasispecies in a host, especially when under treatment. Some methods to quantify the evolution of a quasispecies are introduced and discussed, along with simple simulated examples to help in the interpretation and understanding of the results. The proposed methods treat the molecules in a quasispecies as individuals of competing species in an ecosystem, where the haplotypes are the competing species, and the ecosystem is the quasispecies in a host, and the evolution of the system is quantified by monitoring changes in haplotype frequencies. The correlation between the proposed indices is also discussed, and the R code used to generate the simulations, the data and the plots is provided. The virtues of the proposed indices are finally shown on a clinical case., This study was partially supported by Pla Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for the Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF); Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; grant PI19/00301 and PI22/00258 from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF), and Gilead’s biomedical research project GLD21/00006.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Next-Generation Sequencing for Confronting Virus Pandemics

  • Quer Sivila, Josep
  • Colomer Castell, Sergi
  • Campos Martinez, Carolina
  • Piñana Moro, Maria
  • González Sánchez, Alejandra
  • Garcia Cehic, Damir
  • Pumarola Suñé, Tomàs
  • Rodríguez Frias, Francisco
  • Tabernero Caellas, David
  • Ibañez Lligoña, Marta
  • Cortese, Maria Francesca
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
COVID-19; Pandemics; Viruses, COVID-19; Pandemias; Virus, COVID-19; Pandèmies; Virus, Virus pandemics have happened, are happening and will happen again. In recent decades, the rate of zoonotic viral spillover into humans has accelerated, mirroring the expansion of our global footprint and travel network, including the expansion of viral vectors and the destruction of natural spaces, bringing humans closer to wild animals. Once viral cross-species transmission to humans occurs, transmission cannot be stopped by cement walls but by developing barriers based on knowledge that can prevent or reduce the effects of any pandemic. Controlling a local transmission affecting few individuals is more efficient that confronting a community outbreak in which infections cannot be traced. Genetic detection, identification, and characterization of infectious agents using next-generation sequencing (NGS) has been proven to be a powerful tool allowing for the development of fast PCR-based molecular assays, the rapid development of vaccines based on mRNA and DNA, the identification of outbreaks, transmission dynamics and spill-over events, the detection of new variants and treatment of vaccine resistance mutations, the development of direct-acting antiviral drugs, the discovery of relevant minority variants to improve knowledge of the viral life cycle, strengths and weaknesses, the potential for becoming dominant to take appropriate preventive measures, and the discovery of new routes of viral transmission., Pla Estratègic de Recerca i Innovació en Salut (PERIS)—Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for the Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF; Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; grant GLD21_00006; and grant PI19/00301 from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Implant Removal in the Management of Prosthetic Joint Infection by Staphylococcus aureus: Outcome and Predictors of Failure in a Large Retrospective Multicenter Study

  • Gómez-Junyent, Joan
  • Lora-Tamayo, Jaime
  • Baraia-Etxaburu, Josu
  • Sánchez-Somolinos, Mar
  • Iribarren, Jose Antonio
  • Pigrau Serrallach, Carles
  • Rodríguez Pardo, Ma Dolores
Staphylococcus aureus; Implant removal; Prosthetic joint infection, Staphylococcus aureus; Extracción de implantes; Infección de la articulación protésica, Staphylococcus aureus; Eliminació d’implants; Infecció de l'articulació protèsica, Objectives: To compare the characteristics and outcomes of cases with acute prosthetic joint infection (PJI; early post-surgical or hematogenous) by Staphylococcus aureus managed with implant removal (IRm) or debridement and retention (DAIR). To analyze the outcomes of all cases managed with IRm (initially or after DAIR failure). Methods: Retrospective, multicenter, cohort study of PJI by S. aureus (2003–2010). Overall failure included mortality within 60 days since surgery and local failure due to staphylococcal persistence/relapse. Results: 499 cases, 338 initially managed with DAIR, 161 with IRm. Mortality was higher in acute PJI managed initially with IRm compared to DAIR, but not associated with the surgical procedure, after propensity score matching. Underlying conditions, hemiarthroplasty, and methicillin-resistant S. aureus were risk factors for mortality. Finally, 249 cases underwent IRm (88 after DAIR failure); overall failure was 15.6%. Local failure (9.3%) was slightly higher in cases with several comorbidities, but independent of previous DAIR, type of IRm, and rifampin treatment. Conclusions: In a large multicenter study of S. aureus PJI managed with IRm, failure was low, but mortality significant, especially in cases with acute PJI and underlying conditions, but not associated with the IRm itself. Rifampin efficacy was limited in this setting., This study was supported by Plan Nacional I+D+I 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0005), co-financed by the European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2004–2020. J. G-J was supported by a grant from the Spanish Ministry of Education (FPU 14/03124).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

  • Sola-Campoy, Pedro Juan
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • Larrosa Escartin, María Nieves
  • Gonzalez Lopez, Juan Jose
  • Cañada-Garcia, Javier E.
  • Moure Garcia, Zaira
Carbapenemases; High-risk clones; Whole genome sequencing, Carbapenemasas; Clones de alto riesgo; Secuenciación del genoma completo, Carbapenemases; Clons d'alt risc; Seqüenciació del genoma sencer, Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain. Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC > 0.12 mg/L with immunochromatography, colorimetric tests, carbapenem inactivation, or carbapenem hydrolysis with MALDI-TOF). Prevalence and incidence were calculated according to population denominators. Antibiotic susceptibility testing was performed using the microdilution method (EUCAST). All 403 isolates collected were sequenced for high-resolution single-nucleotide polymorphism (SNP) typing, core genome multilocus sequence typing (cgMLST), and resistome analysis. Results: In total, 377 (93.5%) CP-Kpn and 26 (6.5%) CP-Eco isolates were collected from 62 (87.3%) hospitals in 46 (92%) provinces. CP-Kpn was more prevalent in the blood (5.8%, 50/853) than in the urine (1.4%, 201/14,464). The cumulative incidence for both CP-Kpn and CP-Eco was 0.05 per 100 admitted patients. The main carbapenemase genes identified in CP-Kpn were blaOXA–48 (263/377), blaKPC–3 (62/377), blaVIM–1 (28/377), and blaNDM–1 (12/377). All isolates were susceptible to at least two antibiotics. Interregional dissemination of eight high-risk CP-Kpn clones was detected, mainly ST307/OXA-48 (16.4%), ST11/OXA-48 (16.4%), and ST512-ST258/KPC (13.8%). ST512/KPC and ST15/OXA-48 were the most frequent bacteremia-causative clones. The average number of acquired resistance genes was higher in CP-Kpn (7.9) than in CP-Eco (5.5). Conclusion: This study serves as a first step toward WGS integration in the surveillance of carbapenemase-producing Enterobacterales in Spain. We detected important epidemiological changes, including increased CP-Kpn and CP-Eco prevalence and incidence compared to previous studies, wide interregional dissemination, and increased dissemination of high-risk clones, such as ST307/OXA-48 and ST512/KPC-3., This research was supported by grants from the Instituto de Salud Carlos III (numbers PI18CIII/00030 and PI21CIII/00039). It was also supported by Plan Nacional de I + D + i 2013–2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (grants RD16CIII/0004/0002, RD16/0016/0001, RD16/0016/0003, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008, RD16/0016/0010, and RD16/0016/0011). Cofinanced by the European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligent Growth 2014–2020. CIBER – Consorcio Centro de Investigación Biomédica en Red (CB21/13/00095, CB21/13/00012, CB21/13/00049, CB21/13/00054, CB21/13/00055, CB21/13/00068, CB21/13/00081, CB21/13/00084, and CB21/13/00099) (CIBERINFEC) and Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU also supported this work.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020–21: outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri

  • Moreno-Mingorance, Albert
  • Mir Cros, Alba
  • Goterris Bonet, Lidia
  • Rodríguez Garrido, Virginia
  • Sulleiro, Elena
  • Barberà Gracia, Mª Jesús
  • Descalzo Jorro, Vicente
  • Bravo, Albert
  • Roca, Josep
  • González-López, Juan José
  • Pumarola Suñe, Tomàs
  • VIÑADO, BELEN
  • Larrosa, María Nieves
  • Hoyos Mallecot, Yannick
Antimicrobial resistance; Shigella sonnei; Sexually transmitted infection, Resistencia antimicrobiana; Shigella sonnei; Infección de transmisión sexual, Resistència antimicrobiana; Shigella sonnei; Infecció de transmissió sexual, Background Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. Objectives To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. Results From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. Conclusions We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens., This work was partially supported by the ‘Ministerio de Economía y Competitividad’, ‘Instituto de Salud Carlos III’, and co-financed by the European Regional Development Fund (ERDF) ‘A Way to Achieve Europe’ (Spanish Network for Research in Infectious Diseases, grant number RD16/0016/0003) and by the Centro de Investigación Biomédica en Red (CIBER de Enfermedades Infecciosas, grant no. CB21/13/00054). A.M.M. is supported by a grant from the ‘Fondo de Investigación Sanitaria’ (Contratos Predoctorales de Formación en Investigación, grant number FI19/00315).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Population dynamics and antigenic drift of Bordetella pertussis following whole cell vaccine replacement, Barcelona, Spain, 1986–2015

  • Mir Cros, Alba
  • Moreno Mingorance, Albert
  • Martin Gomez, M Teresa
  • Codina Grau, Gema
  • Cornejo Sánchez, Thais
  • Rajadell Guiu, Mireia
  • Rodrigo Gonzalo de Liria, Carlos
  • Pumarola Suñé, Tomàs
  • Fàbrega Santamaría, Anna
  • Gonzalez Lopez, Juan Jose
  • Campins Martí, Magda
MLVA; PFGE; Vacuna contra la tos ferina, MLVA; PFGE, Vacuna contra la tos ferina, MLVA; PFGE; Pertussis vaccine, Among the factors associated with the resurgence of whooping cough, special emphasis has been given to pathogen adaptation after the introduction of the acellular vaccine (ACV). To assess the impact of the vaccine transition strategy from whole-cell vaccine (WCV) to ACV on population dynamics of Bordetella pertussis in Barcelona (Spain), we studied 339 isolates collected from 1986 to 2015 by PFGE and multi-locus variable-number tandem repeat analysis (MLVA). Additionally, allelic variants for the pertussis toxin and its promoter, pertactin, type 3 fimbriae and fimbrial serotyping were assessed to determine its antigenic drift. A shift was observed in the B. pertussis population as well as in its antigenic profile concurrently with the introduction of ACV in Barcelona. Four out of the five most prevalent PFGE profiles were replaced by new profiles following the ACV introduction. MLVA type 27 was the dominant genotype, and its frequency increased from 25% to 79.3% after WCV replacement. Antigen typing demonstrated the emergence of prn2, ptxP3, fim3-2 and a shift from the fimbriae 3 to the fimbriae 2 serotypes after the ACV introduction. Our findings support the presence of population and antigenic dynamic changes in B. pertussis likely driven by the introduction of ACV., This work was supported by the “Ministerio de Economía y Competitividad”, “Instituto de Salud Carlos III”, and cofinanced by the European Regional Development Fun (ERDF) “A Way to Achieve Europe” (Spanish Network for Research in Infectious Diseases [grant number RD16/0016/0003], “Fondo de Investigación Sanitaria [grant number FIS PI18/ 00703]). AMC is supported by the “Agència de Gestió d'Ajuts Universitaris i de Recerca, Generalitat de Catalunya” [grant number 2018FI_B_00855].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The frequency of defective genomes in Omicron differs from that of the Alpha, Beta and Delta variants

  • Campos Martinez, Carolina
  • Saubí Roca, Narcís
  • Rodríguez Frias, Francisco
  • Rando Segura, Ariadna
  • Colomer-Castell, Sergi
  • Garcia-Cehic, Damir
  • Parés-Badell, Oleguer
  • ADOMBI, Caroline Mélanie
  • QUER, JOSEP
  • Piñana, María
  • González-Sánchez, Alejandra
  • Esperalba, Juliana
  • Codina, María Gema
  • Pumarola Suñe, Tomàs
  • Gregori Font, Josep
  • Esteban Mur, Juan Ignacio
  • BORRAS BERMEJO, BLANCA
  • Ibañez Lligoña, Marta
  • Antón Pagarolas, Andrés
  • Andrés Vergés, Cristina
Evolution; Genetics; Molecular biology, Evolució; Genètica; Biologia molecular, Evolución; Genética; Biología molecular, The SARS-CoV-2 Omicron variant emerged showing higher transmissibility and possibly higher resistance to current COVID-19 vaccines than other variants dominating the global pandemic. In March 2020 we performed a study in clinical samples, where we found that a portion of genomes in the SARS-CoV-2 viral population accumulated deletions immediately before the S1/S2 cleavage site (furin-like cleavage site, PRRAR/S) of the spike gene, generating a frameshift and appearance of a premature stop codon. The main aim of this study was to determine the frequency of defective deletions in prevalent variants from the first to sixth pandemic waves in our setting and discuss whether the differences observed might support epidemiological proposals. The complete SARS-CoV-2 spike gene was deeply studied by next-generation sequencing using the MiSeq platform. More than 90 million reads were obtained from respiratory swab specimens of 78 COVID-19 patients with mild infection caused by the predominant variants circulating in the Barcelona city area during the six pandemic waves: B.1.5, B.1.1, B.1.177, Alpha, Beta, Delta, and Omicron. The frequency of defective genomes found in variants dominating the first and second waves was similar to that seen in Omicron, but differed from the frequencies seen in the Alpha, Beta and Delta variants. The changing pattern of mutations seen in the various SARS-CoV-2 variants driving the pandemic waves over time can affect viral transmission and immune escape. Here we discuss the putative biological effects of defective deletions naturally occurring before the S1/S2 cleavage site during adaption of the virus to human infection., This study was partially supported by Pla Estratègic de Recerca i Innovació en Salut (PERIS) – Direcció General de Recerca i Innovació en Salut (DGRIS), Catalan Health Ministry, Generalitat de Catalunya; the Spanish Network for the Research in Infectious Diseases (REIPI RD16/0016/0003) from the European Regional Development Fund (ERDF); Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PI19/00301 from Instituto de Salud Carlos III cofinanced by the European Regional Development Fund (ERDF), and Gilead’s biomedical research project GLD21/00006. We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiCov Database on which this research is based.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study), Study protocol of a retrospective multicentre international study

  • Albasanz-Puig, Adaia|||0000-0001-9852-5574
  • Gudiol, Carlota|||0000-0003-3095-4422
  • Parody Porras, Rocío
  • Tebé, Cristian|||0000-0003-2320-1385
  • Akova, Murat|||0000-0002-6904-9473
  • Araos, Rafael|||0000-0001-8075-0626
  • Bote, Alex
  • Brunel, Anne-Sophie|||0000-0001-9437-1977
  • Calik, Sebnem
  • Drgona, Lubos|||0000-0002-5089-3201
  • García, Estefanía
  • Hemmati, Philipp
  • Herrera, Fabián
  • Ibrahim, Karim Yaqub
  • Isler, Burcu
  • Kanj, Souha|||0000-0001-6413-3396
  • Kern, Winfried
  • Maestro-de la Calle, Guillermo
  • Manzur, Adriana
  • Marin, Jorge Iván
  • Márquez-Gómez, Ignacio|||0000-0002-9555-5767
  • Martín-Dávila, Pilar|||0000-0002-7469-897X
  • Mikulska, Malgorzata|||0000-0002-5535-4602
  • Montejo, José Miguel
  • Montero, María Milagro|||0000-0001-5991-6804
  • Morales, Hugo Manuel Paz|||0000-0001-7913-8958
  • Morales Fariña, Inmaculada
  • Novo, Andrés
  • Oltolini, Chiara
  • Peghin, Maddalena|||0000-0002-4640-679X
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Puerta-Alcalde, Pedro|||0000-0003-2490-0217
  • Ruiz-Camps, Isabel|||0000-0003-3743-2379
  • Sipahi, Oguz Resat
  • Tilley, Robert
  • Yáñez, Lucrecia|||0000-0001-9925-3048
  • Gomes, Marisa Z. R.|||0000-0001-6492-1034
  • Carratalà, Jordi|||0000-0003-3209-2563
Introduction Pseudomonas aeruginosa (PA) has historically been one of the major causes of severe sepsis and death among neutropenic cancer patients. There has been a recent increase of multidrug-resistant PA (MDRPA) isolates that may determine a worse prognosis, particularly in immunosuppressed patients. The aim of this study is to establish the impact of antibiotic resistance on the outcome of neutropenic onco-haematological patients with PA bacteraemia, and to identify the risk factors for MDRPA bacteraemia and mortality. Methods and analysis This is a retrospective, observational, multicentre, international study. All episodes of PA bacteraemia occurring in neutropenic onco-haematological patients followed up at the participating centres from 1 January 2006 to 31 May 2018 will be retrospectively reviewed. The primary end point will be overall case-fatality rate within 30 days of onset of PA bacteraemia. The secondary end points will be to describe the following: the incidence and risk factors for multidrug-resistant and extremely drug-resistant PA bacteraemia (by comparing the episodes due to susceptible PA with those produced by MDRPA), the efficacy of ceftolozane/tazobactam, the rates of persistent bacteraemia and bacteraemia relapse and the risk factors for very early (48 hours), early (7 days) and overall (30 days) case-fatality rates. Ethics and dissemination The Clinical Research Ethics Committee of Bellvitge University Hospital approved the protocol of the study at the primary site. To protect personal privacy, identifying information of each patient in the electronic database will be encrypted. The processing of the patients' personal data collected in the study will comply with the Spanish Data Protection Act of 1998 and with the European Directive on the privacy of data. All data collected, stored and processed will be anonymised. Results will be reported at conferences and in peer-reviewed publications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Antibiotic treatment versus no treatment for asymptomatic bacteriuria in kidney transplant recipients, A multicenter randomized trial

  • Sabé, Núria|||0000-0003-1697-4347
  • Oriol, Isabel|||0000-0001-5542-7878
  • Melilli, Edoardo|||0000-0001-6965-3745
  • Manonelles, Anna|||0000-0003-2456-388X
  • Bestard, Oriol|||0000-0001-9468-7920
  • Polo, Carolina
  • Los-Arcos, Ibai|||0000-0001-8835-2702
  • Perelló, Manel|||0000-0003-1859-5279
  • Garcia, Dolors
  • Riera, Lluís
  • Tebé, Cristian|||0000-0003-2320-1385
  • Len, Oscar|||0000-0002-1819-3141
  • Moreso, Francesc.|||0000-0002-7267-3963
  • Cruzado, Josep María
  • Carratalà, Jordi|||0000-0003-3209-2563
Background: Whether antibiotic treatment of asymptomatic bacteriuria (AB) can prevent acute graft pyelonephritis (AGP) in kidney transplant (KT) recipients has not been elucidated. Methods: In this multicenter, open-label, nonblinded, prospective, noninferiority, randomized controlled trial, we compared antibiotic treatment with no treatment for AB in KT recipients in the first year after transplantation when urinary catheters had been removed. The primary endpoint was the occurrence of AGP. Secondary endpoints included bacteremic AGP, cystitis, susceptibility of urine isolates, graft rejection, graft function, graft loss, opportunistic infections, need for hospitalization, and mortality. Results: We enrolled 205 KT recipients between 2013 and 2015. AB occurred in 41 (42.3%) and 46 (50.5%) patients in the treatment and no treatment groups, respectively. There were no differences in the primary endpoint in the intention-to-treat population (12.2% [5 of 41] in the treatment group vs 8.7% [4 of 46] in the no treatment group; risk ratio, 1.40; 95% confidence interval, 0.40-4.87) or the per-protocol population (13.8% [4 of 29] in the treatment group vs 6.7% [3 of 45] in the no treatment group; risk ratio, 2.07, 95% confidence interval, 0.50-8.58). No differences were found in secondary endpoints, except for antibiotic susceptibility. Fosfomycin (P =.030), amoxicillin-clavulanic (P <.001) resistance, and extended-spectrum ß-lactamase production (P =.044) were more common in KT recipients receiving antibiotic treatment for AB. Conclusions: Antibiotic treatment of AB was not useful to prevent AGP in KT recipients and may increase antibiotic resistance. However, our findings should be regarded with caution, due to the small sample size analyzed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rapid and Digital Detection of Inflammatory Biomarkers Enabled by a Novel Portable Nanoplasmonic Imager

  • Belushkin, Alexander|||0000-0003-1928-2223
  • Yesilköy, Filiz|||0000-0001-8483-3285
  • González-López, Juanjo|||0000-0003-2419-5909
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Fàbrega-Santamaria, Anna|||0000-0002-3866-2291
  • Altug, Hatice|||0000-0001-5522-1343
New point-of-care diagnostic devices are urgently needed for rapid and accurate diagnosis, particularly in the management of life-threatening infections and sepsis, where immediate treatment is key. Sepsis is a critical condition caused by systemic response to infection, with chances of survival drastically decreasing every hour. A novel portable biosensor based on nanoparticle-enhanced digital plasmonic imaging is reported for rapid and sensitive detection of two sepsis-related inflammatory biomarkers, procalcitonin (PCT) and C-reactive protein (CRP) directly from blood serum. The device achieves outstanding limit of detection of 21.3 pg mL for PCT and 36 pg mL for CRP, and dynamic range of at least three orders of magnitude. The portable device is deployed at Vall d'Hebron University Hospital in Spain and tested with a wide range of patient samples with sepsis, noninfectious systemic inflammatory response syndrome (SIRS), and healthy subjects. The results are validated against ultimate clinical diagnosis and currently used immunoassays, and show that the device provides accurate and robust performance equivalent to gold-standard laboratory tests. Importantly, the plasmonic imager can enable identification of PCT levels typical of sepsis and SIRS patients in less than 15 min. The compact and low-cost device is a promising solution for assisting rapid and accurate on-site sepsis diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Population dynamics and antigenic drift of Bordetella pertussis following whole cell vaccine replacement, Barcelona, Spain, 1986-2015

  • Mir-Cros, Alba|||0000-0003-4827-9824
  • Moreno Mingorance, Albert|||0000-0002-3073-5046
  • Martin-Gomez, M. Teresa|||0000-0001-8119-8749
  • Codina, María Gema|||0000-0002-5313-5086
  • Cornejo-Sánchez, Thais|||0000-0002-1350-0413
  • Rajadell Guiu, Mireia
  • van Esso, Diego
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Campins Martí, Magda|||0000-0002-8841-6195
  • Jané i Checa, Mireia|||0000-0002-1302-6723
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Fàbrega-Santamaria, Anna|||0000-0002-3866-2291
  • González-López, Juanjo|||0000-0003-2419-5909
Among the factors associated with the resurgence of whooping cough, special emphasis has been given to pathogen adaptation after the introduction of the acellular vaccine (ACV). To assess the impact of the vaccine transition strategy from whole-cell vaccine (WCV) to ACV on population dynamics of Bordetella pertussis in Barcelona (Spain), we studied 339 isolates collected from 1986 to 2015 by PFGE and multi-locus variable-number tandem repeat analysis (MLVA). Additionally, allelic variants for the pertussis toxin and its promoter, pertactin, type 3 fimbriae and fimbrial serotyping were assessed to determine its antigenic drift. A shift was observed in the B. pertussis population as well as in its antigenic profile concurrently with the introduction of ACV in Barcelona. Four out of the five most prevalent PFGE profiles were replaced by new profiles following the ACV introduction. MLVA type 27 was the dominant genotype, and its frequency increased from 25% to 79.3% after WCV replacement. Antigen typing demonstrated the emergence of prn2, ptxP3, fim3-2 and a shift from the fimbriae 3 to the fimbriae 2 serotypes after the ACV introduction. Our findings support the presence of population and antigenic dynamic changes in B. pertussis likely driven by the introduction of ACV.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae

  • Bleriot, Ines
  • Trastoy, Rocío|||0000-0003-4580-7126
  • Blasco, Lucía|||0000-0002-4039-4142
  • Fernández-Cuenca, Felipe
  • Ambroa, Antón|||0000-0002-3525-2553
  • Fernández-García, Laura|||0000-0002-8531-6105
  • Pacios, Olga|||0000-0002-4476-856X
  • Perez-Nadales, Elena
  • Torre-Cisneros, J.|||0000-0003-1529-6302
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Miró, Elisenda|||0000-0003-2781-6926
  • Pascual Hernández, Álvaro|||0000-0002-8672-5891
  • Bou, German|||0000-0001-8837-0062
  • Martínez-Martínez, Luis
  • Tomas, Maria|||0000-0003-4501-0387
Klebsiella pneumoniae is the clinically most important species within the genus and, as a result of the continuous emergence of multi-drug resistant (MDR) strains, the cause of severe nosocomial infections. The decline in the effectiveness of antibiotic treatments for infections caused by MDR bacteria has generated particular interest in the study of bacteriophages. In this study, we characterized a total of 40 temperate bacteriophages (prophages) with a genome range of 11.454-84.199 kb, predicted from 16 carbapenemase-producing clinical strains of belonging to different sequence types, previously identified by multilocus sequence typing. These prophages were grouped into the three families in the order Caudovirales (27 prophages belonging to the family Myoviridae, 10 prophages belonging to the family Siphoviridae and 3 prophages belonging to the family Podoviridae). Genomic comparison of the 40 prophage genomes led to the identification of four prophages isolated from different strains and of genome sizes of around 33.3, 36.1, 39.6 and 42.6 kb. These prophages showed sequence similarities (query cover.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ultrasensitive label-free detection of unamplified multidrug-resistance bacteria genes with a bimodal waveguide interferometric biosensor

  • Maldonado, Jesús
  • González-Guerrero, Ana Belén|||0000-0002-4871-9642
  • Fernandez-Gavela, Adrian|||0000-0002-4562-1308
  • González-López, Juanjo|||0000-0003-2419-5909
  • Lechuga, Laura M.|||0000-0001-5187-5358
Infections by multidrug-resistant bacteria are becoming a major healthcare emergence with millions of reported cases every year and an increasing incidence of deaths. An advanced diagnostic platform able to directly detect and identify antimicrobial resistance in a faster way than conventional techniques could help in the adoption of early and accurate therapeutic interventions, limiting the actual negative impact on patient outcomes. With this objective, we have developed a new biosensor methodology using an ultrasensitive nanophotonic bimodal waveguide interferometer (BiMW), which allows a rapid and direct detection, without amplification, of two prevalent and clinically relevant Gram-negative antimicrobial resistance encoding sequences: the extended-spectrum betalactamase-encoding gene blaCTX-M-15 and the carbapenemase-encoding gene blaNDM-5 We demonstrate the extreme sensitivity and specificity of our biosensor methodology for the detection of both gene sequences. Our results show that the BiMW biosensor can be employed as an ultrasensitive (attomolar level) and specific diagnostic tool for rapidly (less than 30 min) identifying drug resistance. The BiMW nanobiosensor holds great promise as a powerful tool for the control and management of healthcare-associated infections by multidrug-resistant bacteria.
Dipòsit Digital de Documents de la UAB
Publication

Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections, what is the Influence of XDR Phenotype on Outcomes?

  • Montero, María Milagro|||0000-0001-5991-6804
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • Knobel Freud, Hernando|||0000-0003-3186-6416
  • Molas, Ema
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Siverio Pares, Ana Cristina
  • Prim, Núria|||0000-0002-5283-0917
  • Segura, Concepción
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Grau, Santiago|||0000-0002-8428-1836
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
This study aimed to assess the impact of extensively drug-resistant (XDR) phenotype on mortality in Pseudomonas aeruginosa bacteremia. A retrospective cohort study was performed in a tertiary hospital from January 2000 to December 2018. All consecutive prospectively recorded P. aeruginosa bacteremia in adult patients were assessed. In this study, 382 patients were included, of which 122 (31.9%) due to XDR P. aeruginosa. Independent factors associated with 14-day mortality were as follows: high-risk source of bacteremia (hazard ratio (HR) 3.07, 95% confidence interval (CI), 1.73-5.46), septic shock (HR 1.75, 95% CI, 1.12-2.75), and higher Pitt scores (one-point increments; HR 1.25, 95% CI, 1.12-1.38). Otherwise, the appropriateness of definitive antibiotic therapy was a protective factor (HR 0.39, 95% CI, 0.24-0.62). The same variables were also associated with 30-day mortality. XDR phenotype was not associated with 14- or 30-day mortality. In a subanalysis considering only high-risk source cases, combined antimicrobial therapy was independently associated with 14-day favorable outcome (HR 0.56, 95% CI, 0.33-0.93). In conclusion, XDR phenotype was not associated with poor prognosis in patients with P. aeruginosa bacteremia in our cohort. However, source of infection, clinical severity, and inappropriate definitive antibiotic therapy were risk factors for mortality. Combined antimicrobial therapy should be considered for high-risk sources.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID19 patients

  • Andrés, Cristina|||0000-0002-3200-0895
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Piñana, Maria|||0000-0002-4766-2613
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Goterris, Lidia|||0000-0003-1471-4461
  • Codina, María Gema|||0000-0002-5313-5086
  • Quer, Susanna
  • Martín, Maria Carmen
  • Campins Martí, Magda|||0000-0002-8841-6195
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Almirante Gragera, Benito|||0000-0002-1189-2361
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
The SARS-CoV-2 spike (S) protein, the viral mediator for binding and entry into the host cell, has sparked great interest as a target for vaccine development and treatments with neutralizing antibodies. Initial data suggest that the virus has low mutation rates, but its large genome could facilitate recombination, insertions, and deletions, as has been described in other coronaviruses. Here, we deep-sequenced the complete SARS-CoV-2 S gene from 18 patients (10 with mild and 8 with severe COVID-19), and found that the virus accumulates deletions upstream and very close to the S1/S2 cleavage site (PRRAR/S), generating a frameshift with appearance of a stop codon. These deletions were found in a small percentage of the viral quasispecies (2.2%) in samples from all the mild and only half the severe COVID-19 patients. Our results suggest that the virus may generate free S1 protein released to the circulation. We suggest that natural selection has favoured a "Don't burn down the house" strategy, in which free S1 protein may compete with viral particles for the ACE2 receptor, thus reducing the severity of the infection and tissue damage without losing transmission capability.